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Kainate receptors (KARs) are glutamate-gated ion channels that mediate synaptic 
transmission, modulate transmitter release, and mediate excitation in the brain. 
Potentiation in their function predisposes the hippocampus to hyperexcitability and 
seizures. These receptors are widely expressed throughout the central nervous system as 
tetramers composed of various combinations of GluK1-5 subunits. In the hippocampus (a 
brain region commonly associated with seizure initiation), GluK2-, GluK4-, and GluK5-
containing receptors are highly expressed in the CA3 pyramidal cell layer, whereas 
GluK1 is barely detectable. The lack of pharmacological tools hinders identifying the 
functional contribution of each kainate receptor subtype in normal CA3 synaptic 
transmission. To address this critical obstacle, we used whole cell patch clamp 
electrophysiology on HEK-T 293 cells transfected with GluK2 homomers, GluK2/K4 or 
GluK2/K5 heteromers. We found that the drug ACET selectively inhibits GluK5 and 
GluK4 subunits, whereas the drug kynurenate is an antagonist at all kainate subunits but 
was more potent at GluK2 subunits. Furthermore, we were able to discover that binding 
of glutamate to either the two GluK2 subunits or two GluK4/K5 subunits in the 
heteromeric tetramer was sufficient to open the kainate receptor, albeit to a non-
desensitizing current. However, glutamate binding to three or more subunits in the 




potential electrophysiology to stimulate and record KAR-mediated synaptic transmission 
(fEPSPs) at the mossy fiber – CA3 synapse, we found that perfusion of ACET was 
sufficient to entirely block KAR-mediate fEPSPs at the mossy fiber – CA3 synapse. 
These results suggest that 1) drugs ACET and kynurenate can be used as pharmacological 
tools to delineate the functional contribution of specific receptor subtypes, 2) kainate 
receptor activation and desensitization depends on the number of subunits bound to an 
agonist, and 3) KAR-mediated synaptic transmission at the mossy fiber – CA3 is 
conducted through heteromeric GluK4- or GluK5-containing KARs.  
 Metabotropic receptors, such as muscarinic acetylcholine receptors (mAChRs) 
and dopamine receptors (DARs), can also alter the function of glutamate receptors and 
have been implicated in epilepsy. Muscarinic acetylcholine receptors also play a critical 
role in synaptic plasticity and neuronal excitability. There are five types of mAChR, M1-
M5, all of which, except m5 mAChRs, are found at different levels of expression in area 
CA3 of the hippocampus where they are co-expressed with kainate receptors. Muscarinic 
receptors regulated the function of other glutamate receptors, but it is unknown whether 
they can interact with KARs. Dysfunctional interactions between KARs and muscarinic 
acetylcholine receptors (mAChRs) have been implied in neurological diseases, including 
temporal lobe epilepsy. For example, injection of a mAChR agonist (pilocarpine) in 
rodents induces prolonged seizures and epilepsy, which can be blocked by a KAR 
antagonist. Understanding how KARs and mAChRs interact may unlock novel therapies 
for epilepsy. Using field potential electrophysiology, we discovered that mAChR 
activation selectively depresses KAR-mediated fEPSPs at the mossy fiber – CA3 




cannot be totally explained through PKC phosphorylation. Interestingly, M1 mAChR 
depression of KAR fEPSP goes away with aging, suggesting this phenomenon is 
developmentally regulated.  
 Lastly, we investigated whether the dopaminergic system is altered in a chronic 
model of temporal lobe epilepsy. Similarly to mAChRs, DARs, specifically D1-like 
DARs, play a critical role in synaptic plasticity, neuronal excitability, and have been 
associated with seizure propagation. We demonstrated that D5 DARs, but not D1 DARs, 
expression is significantly depressed in the epileptic hippocampus. Furthermore, we 
found that dopamine clearance is reduced, while total dopamine content is unchanged in 
the epileptic brain compared to sham-treated controls.  
Taken together, we demonstrate the first steps toward discovering a novel 
interaction between KARs and mAChRs in the brain. Furthermore, we identified 
compensatory changes that occur in the dopaminergic system as a result of chronic 
temporal lobe epilepsy. These findings will provide potential targets for therapeutic 
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Glutamate receptors mediate fast excitatory transmission in the brain. Particularly, 
in the hippocampus they are required for synaptic plasticity that underlies learning and 
memory. There are three types of ionotropic glutamate receptors: α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate 
receptors. Of these three types, kainate receptors are the least understood, although the 
most interesting of the bunch. Unlike the other receptors, kainate receptors are located at 
both presynaptic and postsynaptic sites, where they mediate synaptic transmission and 
neurotransmitter release through not only the classical ionotropic mechanism but also 
through a metabotropic G-protein mechanism. Additionally, kainate receptors have slow 
excitatory postsynaptic potentials (EPSPs), which allows for temporal summation. 
Furthermore, kainate receptor subtypes have unique pharmacology based upon the 
subunits that compose them, and can undergo posttranslational modification (i.e. 
phosphorylation), which allows kainate receptors to have diverse responses to the same 
ligand. Overactivation of kainate receptions have been linked to neurological diseases, 




 Neurotransmitters, likes acetylcholine and dopamine, can modulate glutamate 
receptor function. In the hippocampus, dysfunctional interactions between these 
neurotransmitters and glutamate receptors have been linked to several neurological 
diseases, including epilepsy. For example, administering a muscarinic acetylcholine 
agonist reliably produces seizures in an animal model that remarkably resembles human 
temporal lobe epilepsy. These seizures no longer occur when animals are pretreated with 
a kainate receptor antagonist. Additionally, administering a dopamine receptor agonist 
can precipitate seizures, which can also be blocked by a kainate receptor antagonist. 
Interestingly, alternative therapies known to improve brain health and learning and 
memory, such as routine physical exercise, have been shown to modulate acetylcholine 
and dopamine content in the brain. This demonstrates a dynamic interaction between the 
glutamatergic system and other monoamines that are required for optional brain health.  
 Our goal is to understand the interaction between the glutamatergic system and 
monoamines in the brain. Furthermore, we want to understand how disruption in these 
interactions could lead to neurological disease, such as in epilepsy, and how alternative 
therapies, such as physical exercise, can counteract this disruption. Several studies have 
observed how AMPA and NMDA ionotropic glutamate receptors are modulated by 
muscarinic and dopamine receptors. However, it is not known whether kainate receptors 
are altered by these metabotropic receptors. In this collection of studies we seek to 1) 
discover a pharmacological tool that will help us identify KAR subunits involved in 
synaptic transmission, 2) determine whether KAR-mediated synaptic transmission is 




diseases, such as epilepsy, can alter monoamine content and infer how these changes can 
impact the hippocampal glutamatergic system. 
 
1.2 THE HIPPOCAMPUS 
 
1.2.1 HIPPOCAMPAL FUNCTION 
The hippocampus is a group of millions of cells buried deep within the medial 
temporal lobe of the human and other mammalian brain. This structure resembles a 
seahorse, and was thus named after the Latin translation “hippocampus” by the 
Bolognese anatomist Giulio Cesare Aranzi (circa 1564). Since its discovery, the 
functional role of the hippocampus remained heavily debated until the late 1950’s when 
scientists William Scoville and Brenda Milner began excising the mesial temporal lobe 
from patients with brain damage. The most notable patient, known as H.M., suffered 
severely from uncontrollable seizures. He underwent surgery to remove the ‘epileptic 
core’, which included removing both hippocampi, in an effort to reduce his seizure 
frequency. The studies and observations of H.M. by William Scoville and Brenda Milner 
in 1957 (Scoville and Milner, 2000) concluded that while the surgery was successful in 
reducing the seizures, the patient was left incapable of developing new memories 
(anterograde amnesia) nor had he retained memory of events that occurred immediately 




Since that initial clinical observation, decades of behavioral research have 
accumulated a large body of evidence confirming the hippocampus’s role in acquiring, 
maintaining, and recalling memories. However, the hippocampus is not involved in every 
type of memory. It is generally accepted that the hippocampus is critical for both 
declarative memory and spatial memory (Burgess et al., 2002). Declarative memory 
refers to memories that can be consciously recalled, such as facts and verbal knowledge. 
These memories can be categorized into two subclasses: sematic memory, which is the 
capacity to remember factual knowledge, and episodic memory, which stores 
observational memories attached to specific personal experiences. In contrast, spatial 
memory is the ability to encode information regarding one’s environment and spatial 
orientation, which is necessary for navigation. The hippocampus achieves this with 
“place cells”. Place cells are neurons located in the hippocampus that activate in 
correspondence to a specific location independent of orientation (O’Keefe, 1976; Wilson 
and McNaughton, 1993; Muller et al., 1994). In addition to acquiring and storing 
memories, the hippocampus is also involved in memory retrieval. Although this 
hippocampal function is still heavily debated due to the complicated nature of 
experimental procedures and interpretation, it is believed that the hippocampus is 
required for retrieval of detailed contextual memories (generally recent memories) 
(Wiltgen et al., 2010). However, memories that lose precision (memories of our distant 
past) can be retrieved independently of the hippocampus (Wiltgen et al., 2010). This 
theory is also corroborates with clinical observations of patient H.M. and others with 




removing their hippocampi, but did not experience deficits in recalling distant memories 
(Squire, 1992; Hodges, 1994; Squire and Alvarez, 1995). 
In accordance to the hippocampus’s central role in learning and memory, aging 
(Scahill et al., 2003; Raz et al., 2004; Rodrigue and Raz, 2004; Du et al., 2006) and 
diseases associated with learning and memory impairment, including Alzheimer’s (Wang 
et al., 2006), epilepsy (Chang and Lowenstein, 2003) and schizophrenia (Heckers, 2001), 
are strongly associated with hippocampal atrophy and sclerosis. Additionally, therapies 
that are known to improve learning and memory performance, such as physical exercise, 
can reverse and/or delay hippocampal atrophy (Erickson et al., 2011). The ability to 
understand diseases that impair learning and memory and develop more effective 
treatments for these diseases likely lies within our understanding of the hippocampus. 
Fortunately, the anatomical structure and circuitry of this region in the healthy brain has 
been well characterized.  
 
1.2.2 HIPPOCAMPAL ANATOMY   
 Humans and other mammals have two hippocampi, one located on either side of 
the brain – deep within the medial temporal lobe. The hippocampus is shaped like a 
curved tube, resembling a cashew nut. The hippocampus is intimately connected and 
function in coordination with other regions (dentate gyrus (DG), subiculum, 
presubiculum, parasubiculum, and entorhinal cortex (EC)), known collectively as the 
hippocampal formation. These accessory regions are required for funneling information 




the hippocampus. Particularly, the hippocampus proper itself consists of three Cornu 
Ammonis fields (CA): CA1, CA2, and CA3. However, throughout this document and 
most commonly in peer reviewed literature, the hippocampus refers to regions CA1, 
CA2, CA3 and the DG.  
 Unlike discovering the function of the hippocampus, early investigations by 
neuroanatomists were remarkably accurate in their depictions of the structure and cellular 
organization of the hippocampus. In fact, illustrations of the hippocampus produced by 
Ramon y Cajal in his book Histologie due Systeme Nerveux (1911) are still widely used 
today. This ease in defining the hippocampal neuroanatomy was probably due to the 
unique laminar organization of the hippocampus. Principal cells are tightly packed into a 
single layer within each hippocampus region. This organization produces a highly 
organized unidirectional flow of information known as the ‘trisynaptic circuit’ (See 
Figure 1.1 for illustration). Briefly, the first synapse (perforant path) consists of axons 
from principal cells in the EC synapsing onto principal cells dendrites in the DG. The 
second synapse (mossy fiber pathway) consists of axons from the principal cells in the 
DG synapsing onto principal cells in CA3. Finally, the third synapse (Schaffer collateral 
path) consists of axons from CA3 principal cells (Schaffer collaterals) synapse onto CA1 
principal cell dendrites. Information received by CA1 principal cells is then exited from 
the hippocampus proper to the subiculum. Although the ‘trisynaptic circuit’ accounts for 
general information flow through principal cells, diversions from this circuit and the 
inclusion of non-principal cells makes the hippocampus circuitry more complex and will 






Figure 1.1 Illustration of the trisynaptic circuit: 1) perforant path axons synapse onto 
dentate granule cell dendrites, 2) dentate granule cell axons (mossy fibers) synapse onto 
CA3 pyramidal cell dendrites, and 3) CA3 pyramidal cell axons synapse onto CA1 











 1.2.3 DENTATE GYRUS ANATOMY AND CIRCUITRY 
 The dentate gyrus (DG) is the first step in the hippocampus structure to receive 
information leading towards the processing and production of memories. The entorhinal 
cortex (EC), which accumulates cortical sensory information, projects unidirectionally 
mainly to the dentate gyrus through axons called the perforant path. The DG does not 
reciprocate axonal projections to the EC.  
 The DG has three distinct layers. The most superficial layer is called the 
molecular layer or stratum moleculare. This layer is relatively cell-free (albeit a small 
number of interneurons) and contains predominately dendrites from DG principal cells, 
called dentate granule cells (DGCs). The other major occupant of the molecular layer are 
the axon fibers projecting from the EC, which make up the perforant path. The layer in 
which the principal DGCs are tightly packed and aligned is called the granule cells layer 
or stratum granulosum. The cell body of interneurons, called pyramidal basket cells, are 
also located on the inner boundary of the granule cells layer and the third layer of the DG, 
called the polymorphic layer. The polymorphic layer, also called the hilus, is the most 
inner layer of the DG. Numerous cell types are located in the hilus, but the most 
prominent are the mossy cells. Mossy cell bodies and dendrites reside in the DG hilus, 
and their axons extend into the inner third of the molecular layer 
(associational/commissural projection) where they synapse onto both granule cells and 
GABAergic interneurons. Additionally, the hilus consists of axons from DGCs, called 





 1.2.4 CA3 ANATOMY AND CIRCUITRY 
 The CA3 region contains the second synapse in the trisynaptic pathway. This 
region can be subdivided into four distinct layers: stratum oriens, stratum pyramidale, 
stratum lucidum, and stratum radiatum. The most superficial region is the stratum oriens. 
This region contains the basal (downward extending) dendrites of CA3 pyramidal 
neurons. Additionally, this region contains axons projecting from CA3 pyramidal neurons 
and synapsing onto adjacent CA3 pyramidal neurons (recurrent collaterals), as well as 
CA3 pyramidal axons (Schaffer collateral) projecting to CA1 pyramidal neurons. Lastly, 
this region contains a plethora of inhibitory interneurons. Just deep of the SO layer, is the 
stratum pyramidale (SP), which contains the very densely packed pyramidal cell bodies. 
The stratum lucidum is located deep to SP and contains mossy fibers originating from the 
DG. Lastly, the stratum radiatum (SR) is the deepest layer and contains CA3 pyramidal 
neuron dendrites, EC axons projecting onto CA3 pyramidal dendrites (perforant path), 
and various interneuron subtypes. 
 
 1.2.5 CA1 & CA2 ANATOMY AND CIRCUITRY  
 The anatomical organization and nomenclature for regions CA1 and CA2 are 
identical. Densely packed pyramidal cells align to form a layer known as the stratum 
pyramidale. Superficial to this layer is the stratum oriens, which similarly to area CA3, 
contains both the apical dendrites of CA1/CA2 pyramidal cells and axons projecting from 
CA1/CA2 pyramidal neurons into mainly the subiculum. Deep to the stratum pyramidale 




Additionally, this layer contains Schaffer collateral fibers synapsing onto CA1/CA2 
pyramidal dendrites. Various types of interneurons are distributing throughout the 
stratum oriens and stratum radiatum and sparsely throughout the stratum pyramidale. 
Unlike the CA3 region, the CA1 contains very few recurrent connections, making it less 
likely to undergo feed-forward bursting.  
 
1.3 SYNAPTIC PLASTICITY 
 
 1.3.1 GLUTAMATE RECEPTORS 
Glutamate is the main excitatory neurotransmitter in the brain. At synapses, 
glutamate is stored in vesicles, where it is released from presynaptic neurons in response 
to nerve impulses. Released glutamate binds to glutamate receptors and produces 
neuronal activation, which is essential for brain function. Glutamate receptors come in 
two subclasses: ionotropic and metabotropic. Ionotropic receptors contain a channel pore 
that opens in response to bound glutamate, allowing the flow of ions and mediating fast 
synaptic transmission. Alternatively, metabotropic glutamate receptors couple to a G-
protein and elicit a second-messenger signaling cascade when bound to glutamate. There 
are three primary categories of ionotropic glutamate receptors: N-methyl-D-aspartate 
receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptor 
(AMPAR), and kainate receptor (KAR). Each receptor subtype was identified based on 




methyl-4-isoxazolepropionic acid (AMPA), kainate (KA) respectively. However, recent 
pharmacology studies have identified promiscuity among ionotropic glutamate receptors 
in their affinity for these agonists. 
Ionotropic glutamate receptors are distributed throughout the hippocampus on 
principal and non-principal neurons, where they mediate the cellular form of learning and 
memory. It is believed that the cellular basis for learning and memory is intimately 
related to the ability of a synapse to strengthen or weaken. This phenomenon is called 
synaptic plasticity. There are several forms of synaptic plasticity that vary based on their 
persistence over time and the mechanisms by which they occur. Generally, synaptic 
plasticity is put into two categories: short-term plasticity, in which change in synaptic 
strength lasts seconds to minutes, and long-term plasticity, in which the change in 
synaptic strength lasts for an hour or more.  
 
1.3.2 LONG-TERM POTENTIATION 
Much experimental work has been performed on long-term plasticity, and 
specifically investigating mechanisms leading to persistent activity-dependent 
enhancement in synaptic strength, long-term potentiation (LTP). Long-term potentiation 
can be induced either by strongly stimulating the presynaptic neuron with a non-
physiological relevant high frequency (100Hz, 1sec) train, stimulating the presynaptic 
neuron with an activation pattern that closely resembles learning in the awake brain (theta 




with pharmaceutical agents mimicking other neurotransmitters. All of these protocols for 
induction of LTP elicit a similar cascade of events.  
Although similar mechanisms of LTP have been identified in several synapses 
throughout the brain, much of the studies have been conducted on Schaffer collaterals 
projecting to CA1 pyramidal neurons. Electrical stimulation of Schaffer collateral axons 
causes a release of stored glutamate from presynaptic vesicle. This released glutamate 
binds to various glutamate receptor subtypes located postsynaptically on CA1 pyramidal 
neurons. Specifically, AMPA receptors open when bound to glutamate allowing a net 
positive flow of Na
+
 ions into the CA1 pyramidal cells. This causes the cell to become 
more depolarized (excitatory postsynaptic potential (EPSP)) and more likely to fire an 
action potential. NMDA receptors are also located on postsynaptic CA1 pyramidal 
neurons, where they can bind glutamate. However, the NMDAR channel pore is blocked 
by Mg
2+
 ions when the cell is near resting membrane potentials. Thus, if the Schaffer 
collaterals are stimulated at low frequencies, the EPSP amplitude will remain constant or 
slightly increase. However, if high frequency stimulation is applied to Schaffer 
collaterals, more glutamate is released from the presynaptic neuron and repeatedly 
activates AMPA receptors. The sustained AMPA receptor activation causes the CA1 
pyramidal neuron to become highly depolarized. The Mg
2+ 
block will then withdraw from 




 into the CA1 pyramidal 
neuron. This increase in Ca
2+
 elicits signaling cascades with downstream effects of PKC 
and PKA phosphorylation of AMPA receptors to facilitate more AMPA receptor 




elicit EPSP amplitudes that are increased and remain elevated for several hours. Thus, the 
CA1 pyramidal neuron is more likely to fire an action potential.  
LTP at the perforant path to dentate gyrus granule cells and Schaffer collaterals to 
CA1 pyramidal neurons are NMDAR dependent. Also, LTP at the perforant path 
projected onto CA3 pyramidal neurons, and recurrent collaterals interconnecting CA3 
pyramidal neurons are also NMDAR dependent. However, the mossy fiber pathway that 
synapses onto CA3 pyramidal neurons is not NMDAR dependent. Interestingly, KARs 
are highly expressed pre- and post-synaptic at this synapse, and is one of few regions in 
the hippocampus where there is a measurable KAR field potential.  
 
1.3.3 MOSSY FIBER LONG-TERM POTENTIATION 
Mossy fiber synapses show an unusual form of LTP. Unlike conventional 
synapses where LTP is NMDAR dependent, mossy fiber LTP can occur and persists even 
when NMDAR function is blocked (Harris and Cotman, 1986; Zalutsky and Nicoll, 
1990). Thus, the mechanism by which the mossy fiber – CA3 synapse undergoes 
plasticity is fundamentally different than those at most synapses. Similar to classical 
(Hebbian) LTP, LTP of the mossy fiber – CA3 synapse can be evoked by various high 
frequency stimulation protocols (Zalutsky and Nicoll, 1990; Hirata et al., 1991; Castillo 
et al., 1994; Nicoll and Schmitz, 2005) or stimulation patterns that mimic natural granule 
cell firing patterns (Mistry et al., 2011). The mechanism contributing to MF-LTP is 
thought to occur predominantly presynaptic, by an increase in presynaptic calcium 




presynaptic KARs and/or an increase release of calcium from internal stores also 
contribute to MF-LTP. However, the involvement of postsynaptic mechanisms cannot be 
ruled out as other studies have demonstrated that a postsynaptic rise in Ca
2+
 (Kapur et al., 
1998; Yeckel et al., 1999; Wang et al., 2004) and ephrin-mediated kinases (Contractor et 
al., 2002; Armstrong et al., 2006) are required for MF-LTP.  
 
1.3.4 LONG TERM DEPRESSION 
Long-term depression (LTD) is a persistent weakening in synaptic strength lasting 
for at least one hour. This form of plasticity ensures that the postsynaptic neuron is less 
likely to fire an action potential (depressed EPSPs). LTD occurs in several brain regions, 
including the hippocampus. The discovery of long-term depression (LTD) occurred much 
later (1980’s) than LTP (1973) (Bliss and Gardner-Medwin, 1973; Bliss and Lomo, 1973; 
Ito and Kano, 1982), which may account for why slightly less is known about the 
mechanism of LTD. However, we do know that LTD can be induced by very low 
frequency stimulation patterns (1 to 5 Hz) given for prolonged periods of time 
(Braunewell and Manahan-Vaughan, 2001). This low stimulation intensity causes only a 
modest increase in NMDAR-mediated postsynaptic calcium concentrations, which 
subsequently activates calcium-dependent phosphatases (as opposed to protein kinases in 
LTP) to remove AMPAR from the postsynaptic cell surface (Lisman, 1989; Mulkey and 
Malenka, 1992; Mulkey et al., 1993, 1994). The threshold for determining whether Ca
2+
 






1.3.5 MOSSY FIBER LONG-TERM DEPRESSION 
Low frequency stimulation of mossy fiber axons evokes long-term depression 
(LTD) at mossy fiber – CA3 synapses. This form of LTD is NMDAR-independent 
(Kobayashi et al., 1996) and involves activation of presynaptic metabotropic glutamate 
receptors (Manzoni et al., 1995; Yoshino et al., 1996), causing a reduction in cAMP and 
subsequent protein kinase A (PKA) activity (Tzounopoulos et al., 1998). The end result is 
a lower glutamate release probability. Interestingly, the mechanism of MF-LTD is age 
and developmentally dependent. Rats 2 – 3 weeks postnatal transiently express calcium-
permeable AMPAR (CP-AMPAR) (Pellegrini-Giampietro et al., 1992; Pickard et al., 
2000). As the name suggests, activation of these receptors allows Ca
2+
 ions to flow into 
the cell. At MF synapses expressing CP-AMPAR, the locus of LTD is postsynaptic, 
involving selective trafficking of CP-AMPAR away from the CA3 pyramidal cell surface 
(Ho et al., 2007). Alternatively, rats older than 3 weeks postnatal express predominantly 
calcium-impermeable AMPAR (CI-AMPAR) postsynaptically at mossy fiber – CA3 
synapses, and do not undergo MF-LTD after low frequency depolarization of mossy fiber 
axons.  
 
1.3.6 SHORT-TERM PLASTICITY 
Changes in synaptic strengthening or weakening that lasts for less than 1 hour is 
considered short-term potentiation or short-term depression, respectively. Short-term 




probability of glutamate from presynaptic terminals. An increase in glutamate release 
probability corresponds to short-term potentiation, whereas a decrease in glutamate 
release probability corresponds to short-term depression. The mechanism by which short-
term potentiation occurs is coined the “residual Ca
2+
 hypothesis”. This theory states that 
enhanced transmitter release (facilitation) during a second stimulus is caused by 
remaining Ca
2+
 in the nerve terminal after the initial stimulus (Katz and Miledi, 1968; 
Rosenthal, 1969; Erulkar and Rahamimoff, 1978; Kretz et al., 1982).  
There are several possible mechanisms for short-term depression. The most 
widespread mechanism is use-dependent depletion of release-ready neurotransmitter 
(glutamate) in the presynaptic terminal (Liley and North, 1953; Betz, 1970). In detail, 
when the presynaptic neuron is depolarized it releases glutamate from vesicles that are 
docked and ready to be released into the synapse. With low frequency stimulation, the 
released glutamate is re-uptaken back into the nerve terminal where it can be recycled 
and/or replaced with other glutamate-containing vesicles waiting “on deck”. However, 
with high frequency stimulation, this release-ready pool is not provided enough time to 
recycle (Simons-Weidenmaier et al., 2006). The result is less glutamate released and 
lower EPSPs recorded from the postsynaptic neuron. Another mechanism for short-term 
depression is the reduction of glutamate release mediated by autoreceptors located 
presynaptically. Each of the ionotropic and metabotropic glutamate receptors have been 
shown to be localized on presynaptic terminals were they regulate glutamate release after 
depolarization of the presynaptic neuron (Kerchner et al., 2001; Lee et al., 2002a; 
Bardoni et al., 2004). Alternatively, short-term depression can also occur through a 




the receptors and can also put some channels into a nonresponsive (desensitized) state. 
Desensitization of glutamate receptors located postsynaptically can make the target 
neuron less sensitive to glutamate (Mennerick and Zorumski, 1996; Larkman et al., 
1997). The end result is transiently lower EPSPs.  
 
1.3.7 SYNAPTIC PLASTICITY IN LEARNING AND MEMORY 
 Virtually every synapse in the brain is dynamically regulated. Mechanisms to 
either enhance or depress synaptic transmission can either be short-lived or long lasting. 
We previously described that the hippocampus is necessary for acquiring, retaining, and 
retrieving new memories. Furthermore, we described how ionotropic glutamate receptors 
are the key players in mediating several forms of synaptic plasticity, both long-term and 
short-term, in the hippocampus. However, the question prevails whether synaptic 
plasticity translates to learning and memory. 
 It is generally accepted that synaptic plasticity, especially LTP, is a cellular model 
for learning and memory. The first studies linking synaptic plasticity with learning and 
memory were correlational. Barnes (1979) and Barnes & McNaughton (1985) found that 
persistent LTP was statistically correlated with the rate of learning and/or memory 
retention (Barnes, 1979; Barnes and McNaughton, 1985). Subsequent studies 
accumulated over 20 years have found similar results. This correlation also occurs in the 
diseased brain. For example, in the murine model of Alzheimer’s disease overexpressing 




statistically correlated with a decline in LTP, both in vivo and in vitro (Chapman et al., 
1999). 
 In addition to correlation studies, pharmacological blockage of NMDA receptors 
impairs hippocampus-dependent learning. As described above, NMDAR are necessary 
for LTP and LTD to occur at most synapses, with the mossy fiber – CA3 synapse being 
an exception. Studies have shown that administering a potent NMDAR antagonist 
prevents LTP, and impairs hippocampal-dependent spatial memory, but not hippocampal-
independent forms of memory (visual discrimination) (Morris et al., 1986). Several 
learning paradigm have been used to replicate these findings (Tonkiss et al., 1988; 
Danysz et al., 1988; Staubli et al., 1989; Tonkiss and Rawlins, 1991; Bolhuis and Reid, 
1992; Shapiro and O’Connor, 1992; Cole et al., 1993; Lyford et al., 1993; Caramanos and 
Shapiro, 1994; Fanselow et al., 1994; Li et al., 1997). The impairment in learning 
performance is dose dependent and occurs at comparable drug concentrations that impair 
LTP in vivo and in vitro (Davis et al., 1992). Interestingly, blocking NDMA receptors 
with an antagonist prevents the development of new memories, but does not affect the 
retention of memories (Morris, 1989; Staubli et al., 1989; Morris et al., 1990). This 
suggests that the ability of a synapse to undergo LTP is necessary for the formation of 
new memories, as opposed to retaining or retrieving older memories. Also, drugs that 
activate ionotropic glutamate receptors can enhance both LTP and memory. One such 
class of drugs are the ampakines, which decrease the speed of AMPAR desensitization 
and activation (Arai et al., 1994, 1996). Interesting, this drug shifts the AMPAR kinetics 
to those mimicking NMDA and KARs. Ampakines increase both the probability of LTP 




 Synaptic plasticity also occurs naturally during learning. Spatial exploration 
causes a short-term modulation in perforant path EPSPs (Moser et al., 1993). This 
increase occurs rapidly at the onset of exploration and gradually declines to baseline over 
time (15 min).  These observations present two interesting points. One, synaptic plasticity 
occurred in the time scale when learning is most likely taking place, and two, short-term 
plasticity also has important implications for learning and memory. Indeed, mice with 
genetically compromised presynaptic proteins (alpha CaMKII, synapsin II, and both 
synapsin I and synapsin II) but normal LTP, demonstrate impaired short-term plasticity 
and profound learning difficulties (Silva et al., 1996). However, there have been studies 
that also demonstrate natural occurring LTP during learning. For example, Ishihara et al. 
(1997) found a positive correlation between CA3 population spikes caused by mossy 
fiber stimulation and learning performance in radial arm maze (Ishihara et al., 1997). 
Furthermore, studies have proven post-hoc that adult animals raised in an enriched 
environment have enhanced perforant path – dentate EPSP compared to adult animals 
raised in normal cages (Green and Greenough, 1986). In conclusion, these results 
demonstrate that both short-term and long-term forms of synaptic plasticity are critical 
for the acquisition of new memories. Thus, any neuromodulator that would impact either 











Glutamate receptors, and consequently synaptic transmission, can be dynamically 
regulated by other neurotransmitters and their metabotropic receptors. One example is 
acetylcholine (ACh). Acetylcholine was the first neurotransmitter to be synthesized. Its 
discovery by Sir Henry Hallett Dole and Otto Loewi awarded them the Noble Prize in 
1936. Its name is derived from its chemical structure, an ester of acetic acid and choline. 
Acetylcholine has many functions throughout the body. In the brain, acetylcholine is used 
as a neurotransmitter and plays important roles in learning and memory, arousal, 
attention, and motivation. Aside from its effects in the brain, ACh is also a primary 
neurotransmitter at the neuromuscular junction where ACh activates muscles and is a 
major neurotransmitter in the autonomic nervous system. 
The hippocampus receives acetylcholine from cholinergic fibers projecting from 
the medial septum of the basal forebrain (Dutar et al., 1995). In fact, the human 
hippocampus contains one of the highest densities of cholinergic fibers (Mesulam et al., 
1992). Acetylcholine is synthesized from choline and acetyl coenzyme A by the enzyme 
choline acetyltransferase and becomes packaged into membrane bound vesicles in the 
axons of cholinergic fibers. After an action potential propagates down the cholinergic 
terminal, acetylcholine is released into the synaptic cleft.  Released acetylcholine can 




is rapidly degraded by acetylcholinesterase into choline and acetate. The choline product 
can be re-uptaken into the presynaptic terminal and recycled into acetylcholine. 
 
1.4.2 ACETYLCHOLINE RECEPTORS 
Like other neurotransmitters ACh exerts its effects by binding to receptors. There 
are two categories of ACh receptors: nicotinic acetylcholine receptor (nAChR) and 
muscarinic acetylcholine receptor (mAChR). Similarly to glutamate, they were identified 
and named after their affinity for the selective agonists: nicotine and muscarine. The 
nicotinic receptors act as ligand-gated ionotropic receptors, meaning they undergo a 







) when ACh is bound. Alternatively, mAChRs are G-protein coupled (metabotropic) 
receptors and have a slower response when activated. mAChRs can have either an 
inhibitory or excitatory effect based upon the mAChR activated and the G-protein in 
which the mAChR couples.   
 
1.4.3 MUSCARINIC RECEPTORS 
As stated earlier, mAChRs are metabotropic receptors that couple to G-proteins 
and elicit a second-messenger signaling cascade. mAChRs have seven transmembrane 
regions. There are five types of mAChRs (M1 – M5), each encoded by the gene with 
corresponding names (m1 – m5). M1, M3, and M5 couple to Gq proteins and stimulate a 




(Caulfield and Birdsall, 1998; Lanzafame et al., 2003). The M2 and M4 mAChRs couple 
Gi/o protein and inhibits cAMP activity by downregulating adenylate cyclase. However, 
mAChRs occasionally vary in the G-protein in which they are bound. 
Each of the mAChRs have distinct subcellular localization in the hippocampus 
(Levey et al., 1995). M1 mAChRs are the most abundantly expressed mAChRs in the 
human and rodent hippocampus (Cortes et al., 1984; Cortés et al., 1986; Rodríguez-
Puertas et al., 1997; Scarr et al., 2007), where it is expressed widely in the cell body and 
dendrites of principal neurons (CA1, CA2 and CA3 pyramidal neuron and dentate 
granule neurons). M2 is expressed predominantly in non-principal neurons and discrete 
bands and puncta surrounding pyramidal neuron soma in CA3 more than CA1, but not 
expressed in the pyramidal neurons (Rouse et al., 1997). M3 is expressed in pyramidal 
neurons, neuropil in stratum lacunosum-moleculare, and the outer third of the molecular 
layer of dentate gyrus. M4 is enriched in non-principal neurons and the inner third of the 
molecular layer. Additionally, a subset of M2 and M4 mAChRs were localized 
presynaptically. In conclusion, only the M1 and M3 receptors are predominantly located 
on postsynaptic principal neurons, where they can modulate synaptic plasticity by 
directly interacting with postsynaptic ionotropic glutamate receptors, while M2 and M4 
mAChRs are predominately located on interneurons. The M5 receptor is the least 
abundant of the muscarinic receptors and is expressed at low levels throughout brain. At 
the mossy fiber – CA3 synapse, mAChRs are located both pre- and postsynpatically 





1.4.3 FUNCTION OF MUSCARINIC RECEPTORS IN THE HIPPOCAMPUS  
The cholinergic system is crucial for learning and memory. Perhaps the best 
behavioral illustration is in Alzheimer’s disease, where degeneration of these cholinergic 
projections in the hippocampus is the hallmark symptom for deficits in learning and 
memory, working memory, and attention (Bartus et al., 1982). Additionally, 
scopolamine, a mAChR antagonist, induces memory deficits (delirium and amnesia) in 
healthy volunteer (Drachman and Leavitt, 1974). Still today, several pharmaceutical 
therapies for AD are aimed at inhibiting cholinesterase activity or enhancing cholinergic 
signaling (Lane et al., 2006). Indeed, enhanced cholinergic signaling has shown to 
improve LTP and memory deficits in vivo and in vitro (Caccamo et al., 2006; Chen et al., 
2006). Furthermore, ablation or inhibition of M1 mAChRs impairs spatial memory 
encoding, demonstrating a critical role for mAChRs in hippocampal-dependent learning.  
Muscarinic acetylcholine receptors are located at both presynaptic and 
postsynaptic sites where they modulate synaptic plasticity. Presynaptic mAChRs on 
principal neurons suppress glutamate release, and thereby reducing hippocampal activity 
(a form of short-term depression) (Valentino and Dingledine, 1981). Meanwhile, 
postsynaptic mAChR inhibit K
+
 conductance, which enhances hippocampus activity (a 
form of short-term potentiation) (Cole and Nicoll, 1983). Thus, the same muscarinic 
agonist can have bidirectional affects on short-term synaptic plasticity. Additionally, 
presynaptic muscarinic receptors have been shown to suppress GABA release onto CA3 
hippocampal pyramidal neurons, which is mediated predominantly through M2 mAChRs 




Cholinergic activity can also facilitate LTP in various brain regions, including the 
hippocampus. Application of a cholinergic agonist (Blitzer et al., 1990; Auerbach and 
Segal, 1996) or stimulation of the medial septum in vivo can induce hippocampal LTP 
(Galey et al., 1994; Markevich et al., 1997). Indeed, when a muscarinic agonist is 
perfused onto a brain slice prior to a high frequency stimulus, it can enhance LTP in CA1 
without affecting baseline EPSPs (Blitzer et al., 1990; Auerbach and Segal, 1994; 
Sokolov and Kleschevnikov, 1995; Adams et al., 2004; Shinoe et al., 2005). This 
phenomenon also occurs in the dentate gyrus and shown to be mediated through M1 
mAChRs at both synapses. A recent study using newly developed M1 mAChR selective 
agonist and congenital knockout mice elegantly corroborates previous literature by 
demonstrating that M1 mAChR activation produces a robust potentiation of 
glutamatergic synaptic transmission onto CA1 pyramidal neurons and NMDA-dependent 
LTP (Dennis et al., 2015). However, M1 mAChRs seem not to be necessary for LTP to 
occur, since congenital M1 knockout mice demonstrates only mild deficits in CA1 LTP. 
Interestingly, these mice did experience significant memory deficits in tasks requiring 
both the cortex and hippocampus to interact (Anagnostaras et al., 2003). In conclusion, 
significant evidence supports that M1 mAChRs activation enhances synaptic plasticity at 
CA1 and the dentate gyrus and facilitates the ability to learn.  
In contrast to its effects on tetanus-induced LTP (LTP induced by a high stimulus 
train), mAChR activation by itself can induce LTP (Auerbach and Segal, 1994, 1996) or 
LTD (McCutchen et al., 2006). Interestingly, the expression mAChR-induced LTP or 
LTD is dependent on the mAChR agonist concentration. A low dose of mAChR agonist 




stimulus train, with postsynaptic increase in intracellular calcium and initiation of protein 
kinases activity is required (Auerbach and Segal, 1994, 1996). Whether mAChR LTP is 
NMDA-dependent is controversial. However, at higher concentrations muscarinic 
agonists can induce synaptic depression and LTD following prolonged exposure 
(Auerbach and Segal, 1996; McCutchen et al., 2006; Dickinson et al., 2009). The 
mechanism by which this effect is thought to occur is predominantly mediated through 
M1 and M3 receptors and involves the loss of surface AMPA receptors (NMDAR 
independent) via a calcium-independent signaling cascade involving dephosphorylation 
by protein tyrosine phosphatases (Dickinson et al., 2009).  
Although significant studies have found that M1 mAChR play a major role in 
synaptic plasticity and learning and memory, M2/M4 mAChRs also have an important 
role in synaptic plasticity and learning and memory. An M2 receptor knockout 
demonstrates significant impairments in working memory, behavioral flexibility, and 
LTP (Seeger et al., 2004). Moreover, an M2/M4 specific antagonist can induce LTP in 
CA1 in vivo, albeit requires coactivation of M1/M3 receptors. These studies suggest that 
presynaptic and postsynaptic mAChRs, including specific mAChR subtypes, work in 
conjunction to modulate learning and synaptic plasticity.  
 
1.4.4 MUSCARINIC MODULATION OF GLUTAMATE RECEPTORS 
NMDA receptors 
 As described in the previous sections, neuronal excitability and synaptic 




systems. The mechanism for this interaction requires crosstalk between the two receptors. 
For example, NMDARs (specifically the NMDARs containing the GluN1 subunit) co-
localize with M1 mAChRs on CA1 pyramidal neurons (Marino et al., 1998). Activation 
of M1 mAChRs elicits a protein kinase C (PKC) signaling cascade, which proceeds to 
phosphorylate PYK2 and in turn phosphorylates and activates Src kinase (Lu et al., 
1999). Phosphorylation of ionotropic glutamate receptors is subunit and amino acid site 
specific. For example, the molecular targets of Src are postulated to be three tyrosines on 
the C-terminus of the NMDA subunit, GluN2A (Zheng et al., 1998). Phosphorylation of 
this subunit by the Src kinase increases NMDAR trafficking to the cell surface and 
thereby increased NMDA responses at CA1 synapses. In contrast to M1 receptor 
activation enhancing NMDAR responses at hippocampal CA1 synapse, M1 receptor 
activation depresses NMDAR responses at the mossy fiber – CA3 synapse (Grishin et al., 
2005). The mechanism proposed involves calmodulin-activated tyrosine phosphatases. 
These findings demonstrate that GPCR, specifically mAChRs, can interact with 
NMDARs through second messenger signaling cascades and that phosphorylation of 
glutamate receptors are subunit and amino acid site specific. 
  AMPA Receptors 
 Muscarinic acetylcholine receptors have also been shown to modulate AMPAR 
activity. Muscarinic receptors (mainly M1) induce long-term depression (LTD) at CA1 in 
the hippocampus and cerebellum mainly through changes in AMPA receptor trafficking 
(Dickinson et al., 2009; Nomura et al., 2012). Interestingly, the mechanism eliciting M1 
facilitation of NMDAR activity and M1 LTD of AMPAR activity require similar 




by PKC activation leading to phosphorylation of the AMPAR specific GluA2 subunit 
(Dickinson et al., 2009). PKC phosphorylation of this subunit causes it to dissociate from 
glutamate receptor-interacting protein 1 (GRIP1), which is a protein involved in the 
regulation of glutamate receptor trafficking. Dissociation from GRIP1 allows the GluA2-
containing AMPAR to diffuse laterally out of the synapse, and undergo endocytosis 
mediated by an AMPAR receptor auxiliary protein. These results show that mAChRs can 
also interact with AMPARs through phosphorylation cascades to alter their function at 
the synapse.  
 Alternatively, a study by Grishin et al. (2005) demonstrated that activation of M1 
mAChRs had no affect on AMPAR current at CA3 pyramidal neurons, but reliably 
depressed NMDA receptor current at the same synapse (Grishin et al., 2005). This 
muscarine-induced depression of NMDA receptors was found to be mediated through a 
signaling cascade involving tyrosine phosphatase. 
  Kainate Receptors 
 While previous studies have demonstrated that mAChRs crosstalk with NMDAR 
and AMPAR, little is known about whether mAChRs can crosstalk with KARs. To date 
there has been one study directly investigating this interaction. Benveniste et al. (2010) 
demonstrated that activation of M1 and M3 mAChRs with pilocarpine potentiated 
GluK2-containing (GluK2/K4 and GluK2/K5) KAR heteromers, but not homomeric 
GluK2 KARs (Benveniste et al., 2010). This suggests that the subunits, GluK4 and 
GluK5, are necessary for mAChR potentiation of KARs. Benveniste et al. (2010) 




induced mossy fiber axon excitability. The mechanism responsible this interaction was 
not investigated.  
 This study presents a successful initial step in identifying that crosstalk between 
the mAChRs and KARs can potentially occur. However, it misses in demonstrating 
physiological relevance for this interaction. First, the experiments demonstrating 
mAChRs potentiating heteromeric KARs were performed in Xenopus oocytes. Although 
this model is ideal in deciphering the pharmacology of ligand-gated and voltage-gated 
ionotropic receptors, the relevance of this model diminishes when used to compare 
intracellular signaling mechanisms in oocytes to those in humans. Additionally, their 
experiments in brain slices that showed pilocarpine, a mAChR agonist, enhanced KAR-
induced mossy fiber excitability were performed measuring antidromic spikes. An 
antidromic spike in an electrical impulse that originates in the axon and travels toward the 
cell body (soma), opposite the conventional action potential direction. Thus, the 
physiological relevance of these results is also left to be determined. More research is 
required to determine whether mAChRs can induce physiological relevant changes to 









1.5 DOPAMINERGIC MODULATION OF GLUTAMATE RECEPTORS 
 
1.5.1 DOPAMINE 
 Dopamine (DA) in the central nervous system acts as a neurotransmitter and 
belongs to the catecholamine family (Carlsson et al., 1962). Its name is derived from its 
chemical structure, an amine formed by removing a carboxyl group from a molecule of 
L-DOPA. Dopamine is produced in several areas in the brain, including the substantia 
nigra and ventral tegmental area. DA neurons project to many areas throughout the brain 
through pathways categorized based upon the territories they innervate: mesolimbic, 
mesocortical, nigrostriatal, and tuberoinfundibular (Vallone et al., 2000). The 
hippocampus receives dopaminergic innervation from the mesolimbic pathway projecting 
from the VTA (Gasbarri et al., 1994a, 1994b, 1997). Some fibers from the substantia 
nigra also innervate the temporal (ventral and caudal) hippocampus. 
 DA neurons synthesize dopamine through a specific metabolic pathway. Briefly, 
phenylalanine is converted into tyrosine by the enzyme phenylalanine hydroxylase. 
Tyrosine is then converted into L-DOPA by the enzyme tyrosine hydroxylase (TH). In 
the final step, L-DOPA is converted into dopamine by the enzyme aromatic L-amino acid 
decarboxylase. Dopamine is then stored in vesicle in DA neurons terminals where it 
awaits release. When an action potential terminates at the axon terminal, dopamine is 
then released from the presynaptic vesicles into the synaptic cleft. Upon release, 
dopamine can either undergo 1) degradation by enzymes, such as catechol-O-methyl 




transporter (DAT), or 3) binding to dopamine receptors (DAR) located on the 
postsynaptic neurons.  
 
1.5.2 DOPAMINE RECEPTORS 
Dopamine released from DA neuron terminals bind to receptors with a high 
affinity for dopamine. Dopamine receptors (DARs) are composed of seven 
transmembrane domains. They are metabotropic in function, meaning that they couple to 
G-proteins and elicit their action through second messenger signaling cascades. However, 
recent studies have demonstrated that dopamine receptors can directly bind (protein-
protein interaction) to several other types of metabotropic and ionotropic receptors and 
alter their function (Liu et al., 2000; Lee et al., 2002b). There are five distinct types of 
dopamine receptors: D1, D2, D3, D4, and D5. D1 and D5 dopamine receptors (D1-like 
dopamine receptors) couple to the Gs protein, which stimulates adenylyl cyclase activity 
and increases cyclic adenosine monophosphate (cAMP) concentration. The D2, D3, and 
D4 dopamine receptors (D2-like dopamine receptors) couple to the Gi protein, which 
inhibits adenylyl cyclase activity and subsequently reduces cAMP production.   
Increasing evidence suggests that dopamine, and specifically D1 and D5 DARs, 
play critical roles in learning and memory in the hippocampus. However, the anatomical 
data demonstrating the localization of specific dopamine subtypes are lacking. This gap 
in knowledge is due to the lack of antibodies that can convincingly distinguish between 
D1 and D5 DARs. In an effort to solve this problem, an elegant study performed by 




fluorescent protein) tagged under the promoter of either DRDI (D1 gene) or DRD2 (D2 
gene) (Gangarossa et al., 2012). D1 dopamine receptors were found scattered on 
interneurons in the CA1 and CA3 regions. In the DG, D1 DARs were highly expressed 
throughout the outer and medial molecular layer. In contrast, D2 DARs were expressed 
almost exclusively in hilar mossy cells (Gangarossa et al., 2012; Etter and Krezel, 2014). 
D5 dopamine mRNA is highly abundant in the rat hippocampus (Tiberi et al., 
1991), where they are located on principal cell (pyramidal and dentate granule cells) 
soma, spines, and apical dendrites (Ciliax et al., 2000; Khan et al., 2000; Medin et al., 
2011, 2013). Interesting, D5 dopamine receptors have a tenfold higher affinity for 
dopamine than the D1 dopamine receptor (Sunahara et al., 1991). Thus, older studies 
using radioligands to investigate D1 DAR expression may have inadvertently detected 
both D1 and D5 dopamine receptors (Boyson et al., 1986; Dawson et al., 1986; Dubois et 
al., 1986; Mansour et al., 1990). In conclusion, D1 and D5 dopamine receptors have 
strikingly different expression patterns in the hippocampus that do not appear to co-
localize.  
 
1.5.3 FUNCTION OF DOPAMINE RECEPTORS IN THE HIPPOCAMPUS 
 DA has many functions in the brain, including regulating memory, mood, 
motivation, and motor activity. Due to its diverse roles in brain function, dysregulation of 
dopamine has been link to several neurological disorders, including Parkinson’s disease 
(Ehringer and Hornykiewicz, 1960), drug addiction (Robinson and Berridge, 1993), 




hyperactivity disorder (Del Campo et al., 2011). Specifically in the hippocampus, DA is 
released after novel (Ljungberg et al., 1992), salient (Ungless, 2004), aversive 
(Bromberg-Martin et al., 2010), or rewarding stimuli (Schultz et al., 1993), suggesting 
that dopamine is necessary for giving context to encoded information (Ihalainen et al., 
1999; Bethus et al., 2010). In contrast to the basal ganglia, there is relatively limited 
DAergic input into the hippocampus. Thus, it is thought that DA’s role in hippocampal 
signaling is more of a tonic nature (Shohamy and Adcock, 2010), although this has yet to 
be verified.  
 Both D1-like dopamine receptors and D2-like dopamine receptors mediate critical 
functions in the brain. However, D1-like dopamine receptors have gained increasing 
attention for their significant role in regulating both hippocampus-dependent memory and 
hippocampus-dependent synaptic plasticity (Huang and Kandel, 1995; Lemon and 
Manahan-Vaughan, 2006; Bethus et al., 2010; Clausen et al., 2011; da Silva et al., 2012). 
In the dentate gyrus, D1-like dopamine receptors are thought to regulate the threshold for 
LTP and consequently determine which encoded information becomes a lasting memory 
(Heinemann et al., 1992; Hamilton et al., 2010). Indeed, in freely moving animals, D1-
like dopamine receptors activate during a “novel” or “rewarding” signal, and 
consequentially increases DG excitability (Hamilton et al., 2010). Furthermore, inhibition 
of D1-like dopamine receptors also inhibits LTP in the DG (Yanagihashi and Ishikawa, 
1992; Kusuki et al., 1997; Swanson-Park et al., 1999). In the CA1 region, D1-like 
dopamine receptors have been shown to facilitate synaptic plasticity. Briefly, LTP at the 
Schaffer collateral – CA1 synapse is enhanced with D1-like receptor activation 




prevents LTP both in vitro (Frey et al., 1991; Huang and Kandel, 1995; Otmakhova and 
Lisman, 1996; Swanson-Park et al., 1999) and in freely behaving rats (Lemon and 
Manahan-Vaughan, 2006). Interestingly, LTD is also facilitated by activation of D1-like 
dopamine receptors in CA1 (Chen et al., 1995; Liu et al., 2009) and hindered by D1-like 
dopamine receptor antagonism (Chen et al., 1995). These results are corroborated by an 
in vivo study (Lemon and Manahan-Vaughan, 2006). 
 Another form of synaptic plasticity in which D1-like dopamine has effects is 
depotentiation. Depotentiation occurs when a low frequency stimulation is delivered soon 
(maximum 30 minutes) after LTP has occurred, resulting in the ablation of LTP (Staubli 
and Lynch, 1990; Kulla et al., 1999). Depotentiation is suggested to be a mechanism for 
forgetting. Activation of D1-like dopamine receptors reduce depotentiation in the DG and 
CA1 (Otmakhova and Lisman, 1998; Kulla and Manahan-Vaughan, 2000), whereas 
antagonizing D1-like dopamine receptors prevented this effect (Kulla and Manahan-
Vaughan, 2000). 
 In contrast to the plethora of research done in the CA1 and DG, relatively few 
studies have investigated the effect of D1-like receptors on synaptic plasticity in the CA3 
region. More so than at any other hippocampal synapse, the mossy fiber – CA3 synapse 
is highly sensitive to intracellular cAMP concentrations (Weisskopf et al., 1994), and 
cAMP-dependent pathways have been implicated in its induction of LTP (Weisskopf et 
al., 1994) and LTD (Tzounopoulos et al., 1998). Also, as stated above, D1-like dopamine 
receptors are expressed on dentate granule cells and CA3 pyramidal neurons. Thus, it is 
conceivable that dopamine receptors, which modulate cAMP concentrations, would 




is reduced in guinea pigs in which dopamine is depleted (Ishihara et al., 1991). Also, 
another study by Kobayashi and Suzuki (2007) demonstrated that application of 
dopamine induced acute synaptic potentiation at the mossy fiber – CA3 synapse, which 
was mediated through a cAMP cascade by presynaptic D1-like receptors (Kobayashi and 
Suzuki, 2007). This potentiation was shown to affect AMPA and NMDA receptors. 
Although KARs play a critical role in synaptic plasticity at this synapse, KAR function 
was not investigated. Thus, more studies are required to elucidate the functional role of 
dopamine, specifically D1-like dopamine receptors, at the mossy fiber – CA3 synapse 
and corresponding KAR function. 
 
1.5.4 DOPAMINERGIC MODULATION OF GLUTAMATE RECEPTORS 
 D1-like dopamine receptors alter synaptic transmission and learning and memory 
by interacting with glutamate receptors. Several studies have investigated the effects of 
D1-like dopamine receptor activation on NMDAR and AMPAR function and trafficking. 
However, no study has investigated whether D1 dopamine receptors can affect KAR 
function or trafficking.  
 D1-like dopamine receptors interact with NMDAR through both phosphorylation 
cascades and direct protein-protein interactions. D1-like dopamine activation enhances 
NMDAR surface expression (Hallett et al., 2006; Paoletti et al., 2008) and localization in 
the synapse through stimulation of the tyrosine kinase Fyn (Dunah et al., 2004; Tang et 
al., 2007). Notably, several studies have demonstrated that D1-like dopamine receptors 




2002b). Interestingly, this physical interaction is dynamic. Activation of D1 dopamine 
receptors reduces formation of this D1-like/NMDA receptor complex (Lee et al., 2002b; 
Luscher and Bellone, 2008). Interfering with the D1-like/NMDA receptor formation 
allows NMDAR to traffic (diffuse laterally) to the synapse, thereby increasing NMDAR 
mediated currents and facilitating long-term potentiation (Argilli et al., 2008; Ladepeche 
et al., 2013). Furthermore, formation of the D1/NMDAR receptor complex stabilizes D1-
like dopamine receptors to the synapse. In conclusion, activation of D1-like dopamine 
receptors predominately enhances NMDAR currents. 
 Surprisingly few studies have investigated whether D1-like receptors can interact 
with AMPARs. However, we do know that D1-like dopamine receptors can also 
modulate AMPAR activity and trafficking. Early studies demonstrated that D1-like 
dopamine receptor activation both increased AMPAR phosphorylation through a PKA 
signaling cascade and potentiated AMPAR current amplitude (Price et al., 1999). Indeed, 
application of a D1-like agonist increases AMPAR surface expression (Snyder et al., 
2000; Gao et al., 2006; Vastagh et al., 2012). These data suggests that D1-like dopamine 
receptors in general work to enhance AMPAR function.  
 No study to date has investigated whether D1 dopamine receptors can interact 
with KARs. Metabotropic receptors, such as muscarinic acetylcholine receptors and 
dopamine receptors have been shown to interact with both NMDA and AMPA receptors. 
However, KARs have been neglected. There are several reasons for why KARs should be 
investigated, including that they are unique to the other ionotropic receptors because not 
only do they mediate fast synaptic transmission, but they also modulate the amount of 





1.6 KAINATE RECEPTORS 
 
Kainate receptors were the last of the three ionotropic glutamate receptors to be 
discovered. Like other ionotropic glutamate receptors, KARs are tetrameric, meaning that 
they are formed by the combination of four distinct subunits, and share a common 
subunit structure. Each subunit contains an extracellular N-terminus domain (NTD), 
followed by four membrane domains (M1, M2, M3, and M4) and a cytoplasmic C-
terminus domain (CTD). M1, M3, and M4 are transmembrane domains, named TMD 1, 
TMD 2 and TMD 3 respectively. The M2 domain is a re-entrant pore loop, which 
penetrates and exits the cell membrane intracellularly. The ligand-binding domain (LBD) 
is composed of a segment of the NTD (deemed S1) and a segment of the extracellular 
loop between TMD2 and TMD3. KARs assemble by two subunits (dimers) binding to an 
identical dimer, which is referred to as ‘dimer of dimers’. There are five kainate receptor 
subtypes: GluK1, GluK2, GluK3, GluK4, and GluK5 (formerly GluR5 – GluR7, KA1 
and KA2). Subunits GluK1, GluK2, and GluK3 can form functional homomers, meaning 
that each of the four subunits in the KAR can be entirely GluK1, GluK2, or GluK3. 
However, GluK4 and GluK5 subunits must combine with GluK1, GluK2, or GluK3 
subunits to form a functional KAR The structural repertoire of KAR subunits is further 
diversified by Q/R editing of the GluK1, GluK2, and GluK3 subunits, which alter the 
KAR permeability to Ca
2+








Determining the subcellular localization of KARs have been particularly elusive 
due to the absence of KAR subunit-specific antibodies. Several in situ hybridization 
studies have revealed tissue specific localization, but this method does not have the 
resolution to distinguish subcellular level localization (Wisden and Seeburg, 1993; 
Bureau et al., 1999). Currently, GluK2/K3 and GluK5 specific antibodies are available, 
although their reliability in immunohistochemistry is debatable. Nevertheless, 
corroborating evidence can be extracted from these results. The GluK2 and GluK5 
subunits are the most robustly expressed subunits (Perrais et al., 2010). The GluK5 
subunit is expressed abundantly throughout the brain on principal cells and interneurons 
(Wisden and Seeburg, 1993). Meanwhile, GluK2 subunits are mostly expressed on 
principal neurons throughout the brain, including pyramidal neurons and dentate granule 
cell in the hippocampus (Paternain et al., 2003). In contrast, GluK1 subunits are 
predominantly expressed on interneurons (Paternain et al., 2003). The GluK3 subunit is 
expressed at few synapses in the brain, including the hippocampal dentate gyrus (Wisden 
and Seeburg, 1993). However, the GluK4 subunit has the most restricted expression, 







Each KAR subunit contains a binding site and contributes to the channel pore. 
The only known KAR agonist that is present in the brain is glutamate. Glutamate 
activates homomeric GluK1 and GluK2 receptors with a 50% effective concentration 
(EC50) value in the 100 and 200 micromole (μM) range (Alt et al., 2004; Fisher and 
Fisher, 2014). However, the EC50 value for GluK3 in in the 5mM range (Schiffer et al., 
1997; Perrais et al., 2009). Although GluK4 and GluK5 subunits are non-functional as 
homomers, when expressed in recombinant HEK-293 cells they bind to glutamate. In 
contrast, the EC50 glutamate concentrations for the GluK4 and GluK5 subunits are in the 
30μM and 10μM range respectively (Fisher and Mott, 2011; Fisher and Fisher, 2014). 
Thus, the GluK4 and GluK5 subunits are given the distinction as being “high-affinity” 
subunits.  
Kainate receptors were identified based upon their high binding affinity to the 
neurotoxin kainate acid, compared to the other ionotropic glutamate receptors (NMDA 
and AMPA receptors). Kainate acid (KA) is a naturally occurring analog of glutamate, 
which was isolated from the seaweed Digenea simplex (Nitta et al., 1958). Injection of 
kainate acid in the brain causes lesions in brain regions with abundant kainate receptors 
expression, such as the CA3 region. Similar to glutamate, KA activates the KARs 
subunits with diverse potency. The GluK1 – GluK3 subunits have a “lower” affinity for 
KA (KDs near 50nM) than the “high-affinity” subunits GluK4 and GluK5 (KDs 5 – 




The heteromeric kainate receptors predominate in the central nervous system. The 
abundant co-expression of the GluK2 and GluK5 subunits throughout the brain suggests 
that the GluK2/K5 heteromeric KARs compose majority of the expressed functional 
KARs. Interestingly, incorporation of the high-affinity subunits into KAR assemblies 
alters the pharmacology of the KAR. GluK2/K5 and GluK2/K4 heteromeric KARs are 
more sensitive to glutamate than GluK2 homomers due to the incorporation of the high-
affinity subunits GluK5 and GluK4 (EC50: GluK2/K5 = 10 μM, GluK2/K4 = 50 μM, 
GluK2 = 200 μM) (Heckmann et al., 1996; Paternain et al., 1998; Barberis et al., 2008; 
Fisher and Mott, 2011, 2013). Additionally, the GluK4 and GluK5 subunits can also bind 
to ligands that the other KAR subunits cannot. For example, agonists AMPA, ATPA, and 
willardiine compounds do not activate GluK2 homomeric receptors, but can bind and 
activate heteromeric GluK2/K5 receptors (Alt et al., 2004).  As expected, these 
compounds also have an affinity for AMPA receptors, making interpretation from earlier 
studies misleading.  
The lack of KAR subunit specific antagonist has been the Achilles heel of the 
KAR field. The development and functional characterization of such compounds is 
essential in understanding the functional contribution of KARs subtypes. Recently, an 
intense effort was made to synthesize and characterize subunit-selective KAR antagonist 
against GluK1 (Dargan et al., 2009). They developed a series of KAR antagonist based 
upon the structure of the willardiine compound, which is thought to be a GluK1 specific 
agonist. Among this series of compounds were UBP310, UBP302, and UBP316 (also 
named ACET). However, recent evidence suggests that these compounds are not as 




current in recombinant cells and inhibits postsynaptic KAR transmission at mossy fiber – 
CA3 synapses where GluK1 and GluK3 expression is limited (Pinheiro et al., 2013).  
Another antagonist distinguished as being subunit selective is kynurenic acid. 
Kynurenic acid is a product of normal metabolism and has neuroprotective properties 
(Chmiel-Perzyńska et al., 2014). Recent studies have shown that kynurenic acid can 
discriminate between homomeric GluK2 and heteromeric GluK2/K5 receptors. 
Kynurenic acid antagonizes the glutamate-induced current through GluK2 homomers at 
low concentrations (IC50 = 0.3mM), but virtually has no effect on GluK2/K5 heteromer 
current at concentrations up to 3mM (Alt et al., 2004; Fisher and Mott, 2011). 
 
1.6.3 ACTIVATION AND DESENSITIZATION 
 When a ligand binds to an ionotropic receptor, it can either elicit a conformation 
change in the receptor that allows the receptor to open its channel pore (activation), or it 
can have no effect. A ligand that binds to the receptor and has an effect is an agonist, and 
a ligand that binds to a receptor but has no effect is called an antagonist. Once the ligand 
leaves the binding site, the receptor will undergo another conformational change to close 
the channel pore (deactivation). Alternatively, some receptors (including KARs) will 
decrease its response to the agonist even while the agonist is still bound (desensitization).  
Each KAR subunit contains a binding site and contributes to the channel pore. 
Thus, there are four possible ligand-binding sites on each functional KAR. Previous 
studies demonstrate that, in heteromeric KARs receptors, glutamate binding to the higher 




desensitizing current. Desensitization occurred when the glutamate concentration 
increased to allow binding to the lower affinity GluK2 subunit (Mott et al., 2010; Fisher 
and Mott, 2011). These papers concluded that the high-affinity subunits had the 
distinguished role in opening the KAR, while the low affinity subunit’s role was to 
desensitize the receptor. However, these papers did not test whether binding to only the 
GluK2 subunit is sufficient to open the receptor, and does subsequent binding to the high 
affinity subunits ensue desensitization. More recent work with subunit-selective agonists 
or antagonist (Swanson et al., 2002; Fisher and Mott, 2011; Pinheiro et al., 2013; Fisher 
and Fisher, 2014) and tethered ligands (Reiner and Isacoff, 2014), suggest that partial 
occupancy of the KAR binding sites is sufficient to activate the receptor, and the onset of 
desensitization in heteromeric receptors is determined more by the number of subunits 
bound to the agonist than by the identity of those subunits.  
 
1.6.4 INTERACTING PROTEINS 
Kainate receptors interact with proteins on the plasma membrane that transiently 
regulate their location and function. For example, KARs can interact with PDZ motif-
containing proteins such as postsynaptic density protein 95(PSD-95), protein interacting 
with C kinase-1 (PICK-1), and glutamate receptor interacting protein (GRIP), which 
regulate trafficking of KARs to the cell surface and stabilizing KARs to the synapse 
(Hirbec et al., 2003). It is important to note that these interacting proteins are not specific 




regulation differs between KARs and AMPARs, as these proteins prevent AMPAR 
internalization, but facilitate KAR internalization (Hirbec et al., 2003). 
Two proteins have been identified as true auxiliary proteins to KARs: neuropilin 
tolloid-like 1 and neuropilin tolloid-like 2 (Neto1 and Neto2) (Zhang et al., 2009; Straub 
et al., 2011a, 2011c; Tang et al., 2011). Neto1 and Neto2 are single transmembrane 
proteins that co-localize and associate with KAR in the brain. Neto1 is predominantly 
located in the hippocampus and is almost completely absent in the cerebellum, whereas 
Neto2 is almost completely absent in the hippocampus, but is abundantly expressed 
throughout the cerebellum (Straub et al., 2011b). Neto1 was initially discovered as an 
auxiliary protein to NMDA (Ng et al., 2009), although it arguably has a more pronounced 
effect on KAR function. Neither Neto1 nor Neto2 appear to associate with AMPA 
receptors. Co-expression of Neto1 or Neto2 with KARs in recombinant cells radically 
alters KAR gating. The most pronounced effect is the reduction in KAR receptor 
deactivation and desensitization, while recovery from desensitization accelerates (Copits 
et al., 2011; Straub et al., 2011a; Fisher and Mott, 2013). Thus, the glutamate-induced 
KAR current persists for longer periods in the presence of Neto. Indeed, this effect is 
conserved for all KAR subtypes (Fisher and Mott, 2013). Most importantly, the discovery 
of the Neto-KAR complex corroborates recombinant cell data with brain slice data 
demonstrating slow deactivation kinetics of KARs. 
Current results are conflicting about whether Neto affects KAR trafficking to the 
synapse (Ng et al., 2009; Zhang et al., 2009; Copits et al., 2011; Straub et al., 2011a; 
Tang et al., 2011, 2012; Wyeth et al., 2014). Neto knockout mice demonstrate 




al., 2011; Wyeth et al., 2014). Indeed, genetic ablation of Neto1 (but not Neto2) has 
effects on KAR EPSCs (Straub et al., 2011a; Tang et al., 2011) by showing faster decay 
and reduced amplitudes. However, KAR EPSCs can still occur. Thus, Neto1 may 
function more as a regulator of KAR kinetic properties in addition to targeting KARs to 
the synapse.  
-  
1.6.5 PHOSPHORYLATION 
Although relatively few studies have investigated whether KARs can be 
modulated by GPCRs mACh and dopamine receptors, several studies have shown that 
KARs can undergo protein kinase C (PKC), CaMKII, and PKA phosphorylation. 
Activation of PKC inhibits KAR currents in recombinant cells (Dildymayfield and 
Harris, 1994) and brain slices (Selak et al., 2009). Also in the perirhinal cortex, PKC and 
PICK1 interacts with KARs to cause KAR-EPSC LTD (Park et al., 2006). These studies 
suggest that the mechanism for this KAR LTD is that activation of KARs causes an 
increase in postsynaptic Ca
2+
, which encourages the uncoupling of the PKC-PICK1-
mediated maintenance of KAR EPSC (Staudinger et al., 1997; Park et al., 2006). In the 
hippocampus, PKC was also shown to induce KAR-EPSC LTD, albeit through a 
interacting with SNAP-25, PICK1, GRIP, and the KAR subunit GluK5 co-localized 
postsynaptically (Selak et al., 2009). Furthermore, blocking SNAP-25 activity causes a 
GluK5-dependent increase in KAR-EPSCs, suggesting a role for SNAP-25 in the PKC-




as other studies demonstrate an PKC-dependent increase in KAR EPSCs (Cho et al., 
2003).  
In contrast to PKC, PKA phosphorylation potentiates kainate-evoked currents in 
recombinant cells (Raymond et al., 1993; Wang et al., 1993; Kornreich et al., 2007). 
Furthermore, the phosphatase calcineurin reverses PKA phosphorylation of GluK2 
receptors (Traynelis and Wahl, 1997; Coussen et al., 2005), and causes an NMDA 
receptor and voltage-sensitive Ca2+ channel-dependent depression of KAR current 
(Ghetti and Heinemann, 2000; Rebola et al., 2007). 
KARs activity can also be modulated by CaMKII phosphorylation. A stimulation 
protocol known to induce AMPAR LTP also induces CaMKII phosphorylation of 
GluK5-containing receptors and depression in KAR-mediated synaptic transmission at 
the mossy fiber – CA3 synapse (Caporale and Dan, 2008; Carta et al., 2013). However, 
instead of internalizing the KAR, CaMKII phosphorylation causes the GluK5-containing 
receptor to uncouple from PSD-95 and laterally diffuse out of the synapse (Carta et al., 
2013). 
 
1.6.6 KAINATE RECEPTOR FUNCTION 
  Postsynaptic  
Unlike NMDA and AMPA receptors, KAR-mediated postsynaptic current is 
found at only few synapses in the hippocampus, including the mossy fiber – CA3 synapse 




hippocampal interneurons (Cossart et al., 1998; Frerking et al., 1998). At these synapses, 
KARs EPSCs are small in amplitude (Castillo et al., 1997) and have slow deactivation 
kinetics when compared to NMDA and AMPA receptors (Frerking and Ohliger-Frerking, 
2002; Pinheiro et al., 2013). The slow deactivation kinetics allows the synaptic response 
to temporally summate and increase spike transmission, thereby facilitating LTP 
induction (Sachidhanandam et al., 2009).  
Also unlike NMDA and AMPA receptors, KARs can influence neuronal 
excitability of postsynaptic neurons through metabotropic signaling by affecting the slow 
hyperpolarization (IsAHP) of postsynaptic neurons (Melyan et al., 2002, 2004). The IsAHP is 





channels open to hyperpolarize the neuron and prevent further bursting. Thus, the IsAHP is 
instrumental in spike timing adaptation. Activation of kainate receptors suppresses the 
IsAHP, thus increasing spike-firing frequency and neuron excitability. Evidence suggests 
that the mechanism for KAR inhibition of the IsAHP is mediated through KARs directly 
coupling the Gi/o protein, activating PKC (Melyan et al., 2002) and probably PKA, and 
downstream activation of MAP kinases (Grabauskas et al., 2007). Interestingly, KARs 
can simultaneously elicit both ionotropic and metabotropic actions at the mossy fiber – 
CA3 synapse (Fisahn et al., 2005; Ruiz et al., 2005).  
Presynaptic  
Kainate receptors are also localized both postsynaptic and presynaptic. Kainate 
receptors can act presynaptically to regulate neurotransmitter release at both inhibitory 




extensively studied at the mossy fiber – CA3 synapse, where they have been implicated 
in the large paired-pulse facilitation characteristic of this synapse (Contractor et al., 2001; 
Lauri et al., 2001; Schmitz et al., 2001; Pinheiro et al., 2007). Indeed, a blocker of Ca
2+
 
permeable KARs reduces this synaptic facilitation at the mossy fiber – CA3 synapse 
(Lauri et al., 2003; Scott et al., 2008). Interestingly, activation of presynaptic kainate 
receptors can have a bidirectional effect on transmitter release, either enhancing or 
inhibiting release, dependent upon the concentration of kainate receptor agonist used. 
Exogenous application of a low concentration of KAR agonist facilitates glutamate 
release (Kamiya and Ozawa, 2000; Schmitz et al., 2000), while a high dose of KAR 
agonist produces a depression in glutamate release at mossy fiber – CA3 synapse and 
Schaffer collateral – C1 pyramidal synapse (Chittajallu et al., 1996; Kamiya and Ozawa, 
1998; Vignes et al., 1998; Frerking et al., 2001). Depression of glutamate release by a 
KAR agonist is sensitive to G proteins blockers, and is thus thought to be through a novel 
metabotropic function (Frerking et al., 2001; Negrete-Díaz et al., 2006; Salmen et al., 
2012). Thus, these data suggest that KAR facilitation of glutamate release is mediated 
through ionotropic actions, whereas KAR depression of glutamate release is mediated 









1.7 IMPLICATIONS FOR EPILEPSY 
 
1.7.1 KAR IN EPILEPSY 
The disease most prominently associated with KARs is epilepsy. Overactivation 
of kainate receptors can cause seizures. In fact, intraperitoneal injection of kainate acid 
has served as a reliable animal model of temporal lobe epilepsy (TLE) that mimics 
several behavior and anatomical changes that occur in human epilepsy. Both human and 
rodent models of temporal lobe epilepsy demonstrate recurrent mossy fiber synapses onto 
dentate granule cells (Artinian et al., 2011). These synapses have aberrant kainate 
receptor EPSCs and thereby alter the activity pattern of dentate granule cells (Epsztein et 
al., 2005). It is thought that this positive feedback loop could be the epicenter for seizure 
generation in TLE patients. Indeed, Human tissue from patients with pharmacoresistant 
TLE demonstrated an upregulation of GluK1 subunit expression, potentially contributed 
by the mossy fiber sprouting (Li et al., 2010). Additionally, genetic ablation of the GluK2 
subunit prevents the development of seizures (Mulle et al., 1998). Conversely, 
overexpressing GluK2-containing KARs exhibit spontaneous seizures (Telfeian et al., 
2000). As a result of the previous data demonstrating an association between KARs and 
epilepsy, significant effort have been attributed to demonstrating the therapeutic benefits 
of GluK1 antagonist to prevent the development of epileptiform bursting in the 






 1.7.2 MUSCARINE AND EPILEPSY 
 Several lines of evidence support a role for mAChRs in epilepsy. For example, 
pirenzepine, a mAChR antagonist, significantly retards the development of kindled 
seizures (Eşkazan et al., 1999). Alternatively, in hippocampal slices, when inhibition is 
removed, the anitcholinesterase, eserine, evokes spontaneous epileptiform discharges that 
are blocked by pirenzepine (Gruslin et al., 1999; Potier and Psarropoulou, 2004). Perhaps 
the strongest evidence for an association between epilepsy and mAChRs is the 
epileptogenic effect of the muscarinic agonist, pilocarpine (Cavalheiro et al., 1991). 
Pilocarpine produces sustained seizures (status epilepticus, SE) by acting on M1 
mAChRs (Maslanski et al., 1994; Hamilton et al., 1997; Bymaster et al., 2003). However, 
the role played by the M1 mAChRs in producing SE in the pilocarpine model, the 
subsequent neurodegeneration and the development of spontaneous seizures, is not 
known.  
 Interestingly, the role played by M1 mAChRs in the induction of SE appears to be 
critical but limited. Thus, the muscarinic antagonist, atropine suppresses the induction of 
lithium-pilocarpine-induced SE in rats if injected before pilocarpine, but will not block 
ongoing lithium-pilocarpine-induced SE (Jope et al., 1986; Morrisett et al., 1987). Given 
the role of KARs in this model, this observation suggests that mAChR activation induced 
a KAR-dependent process required for the induction and maintenance of SE. It is further 
suggested that M1 mAChR activation stimulates KARs by both directly depolarizing 




 Several studies have demonstrated a synergistic effect of subconvulsant doses of 
pilocarpine and kainate on the induction of seizures. For example, Millan et al. (1988) 
reported that a subconvulsant dose of kainate induces motor limbic seizures only when 
injected into the prepiriform cortex after a subconvulsant dose of pilocarpine (Millan et 
al., 1988). Similar results were found by De Sarro et al. (1992) in the lateral habenula and 
pedunculopontine nucleus and by Patel et al. (1988) in the entopeduncular nucleus and 
doral striatum (Patel et al., 1988; De Sarro et al., 1992). These epilepsy models are 
thought to be predictive of partial complex seizures, suggesting that the interaction 
between muscarinic and KARs may contribute to the evolution of seizures of this type. In 
contrast, KARs do not appear to be involved in models of more generalized seizures such 
as picrotoxin or bicuculline, since KAR antagonists do not block epileptiform activity in 
these models. 
 
 1.7.3 DOPAMINE AND EPILEPSY 
The dopaminergic system has been associated with epilepsy and seizures for over 
a century. The basal ganglia (primary source of dopamine in the brain) are significantly 
involved in seizure initiation and determining seizure threshold (Trimble, 1977; Toone, 
1991). Forty years ago, epilepsy was thought to be a disease of dopaminergic 
hypoactivity (Lamprecht, 1977; Starr, 1996). This theory was conceived as a result of 
studies demonstrating that application of a general dopamine receptor agonist reduces 
seizure susceptibility (Lamprecht, 1977; Lal, 1988), whereas blockage of dopamine 




discovered that a class of antipsychotic drugs that were known to precipitate seizures 
were general dopamine receptor antagonist (Seeman, 1981). We now known that there 
are two subtypes of dopamine receptors: D1-like and D2-like. These dopamine receptors 
have opposite effects on seizure susceptibility. D1-like dopamine receptor activation 
precipitates seizures (Starr et al., 1987; al-Tajir et al., 1990a, 1990b), while D2-like 
dopamine receptors reduce seizure susceptibility (al-Tajir et al., 1990a; Al-Tajir and 
Starr, 1991).  
 These studies demonstrate a long withstanding association between the 
dopaminergic system and epilepsy. Although we have now identified two subclasses of 
dopamine receptors and their opposing roles in seizure generation, the mechanism for 
how the interaction occurs is not known, nor is it known how the dopaminergic system is 
altered in chronic models of temporal lobe epilepsy. Further studies are needed to 
elucidate these mechanisms.  
 
1.8 IMPLICATIONS FOR EXERCISE 
 
 1.8.1 EPILEPSY AND PHYSICAL EXERCISE  
 Over the past decade, physical activity has been noted as a powerful tool in the 
battle against cognitive impairment. In healthy adults, physical activity has been shown to 
improve performance on memory test and counterbalance the age-related decline in 




These results are indiscriminant on the type of physical activity, but are predicated on the 
intensity of the exercise, with greater cognitive benefits occurring following acute or 
repetitive (chronic) moderate to vigorous physical activity.  
 Exercise has also been shown to prevent the development and reduce the 
progression of neurological diseases. Several reviews exist outlining the beneficial effects 
of exercise on Alzheimer’s disease and Parkinson’s disease (Paillard et al., 2015). 
However, in this document we will focus our attention on exercise’s benefits on epilepsy. 
 The stigma of exercise being harmful for people with epilepsy was prevalent until 
recent years. It was recommended by the American Medical Association in 1968, that 
people with uncontrolled epilepsy should not be allowed to participate in physical activity 
for the fear of inducing seizure and increased risk of injury for the person with seizures 
and others within the vicinity (American Medical Association Committee on the Medical 
Aspects of Sports, 1968). Due to much controversy, this recommendation was relaxed six 
years later to allow the participation of exercise when it was deemed beneficial for social 
integration (Corbitt et al., 1974). 
 Recent evidence in human and animal models demonstrates that physical activity 
can prevent the development in seizures. In animal models, prior exposure to exercise can 
reduce brain cell loss and neuronal damage secondary to brain insults (Arida et al., 2013). 
One study investigating the effects of physical exercise during post-natal development 
showed that when submitted to daily exercise for forty days, rats presented delayed onset 
and reduced intensity of pilocarpine-induced seizure during midlife (Gomes da Silva et 




chronic physical exercise required more electrical stimulus to the limbic brain region 
(kindling) to provoke seizures than controls (Arida et al., 2008). Although there are 
several studies in animal models demonstrating physical activity can prevent seizures and 
the development of epilepsy, the possible preventative effects of exercise on epilepsy in 
humans are still uncertain. There is only one study that has tested this question directly. 
According to a Swedish population-based cohort of 6,796 individuals examined for 40 
years, participants who presented low cardiovascular fitness at the age of 18 had an 
increased risk of developing epilepsy later in life (Nyberg et al., 2013). Thus, this study 
suggests that engaging in physical activity early in life has protective effects on the 
development of epilepsy later in life. Although more studies in humans are needed to 
answer the question whether physical activity can protect the brain from developing 
epilepsy, the consensus among several animal studies and one human study suggest that 
physical exercise can be used as a powerful tool to protect the brain against the 
development of repetitive seizures.  
 As opposed to the development of epilepsy, more human studies have sought to 
answer the question whether exercise can reduce seizure frequency in individuals who 
have already been diagnosed with epilepsy. People who practice regular physical exercise 
report fewer seizures than inactive individuals (Roth et al., 1994). However, human 
intervention studies have rendered mixed results. One study examining fifteen women 
with pharmacologically intractable epilepsy were administered aerobic activity for fifteen 
weeks and presented a decrease in seizure frequency (Eriksen et al., 1994). However, 
another study including twenty-one patients with uncontrolled epilepsy experienced no 




program (Nakken et al., 1990). Although these studies provide contradictory results about 
whether exercise reduces seizure frequency in people with epilepsy, they both support the 
notion that engaging in physical exercise is not a seizure precipitant. Furthermore, other 
studies examining acute bouts of maximal and sub-maximal physical exercise in people 
diagnosed with epilepsy demonstrated reduced epileptiform discharges after physical 
exertion compared to before the exercise bout (Camilo et al., 2009; Vancini et al., 2010; 
de Lima et al., 2011). Animal studies demonstrate a more definitive role of epilepsy 
reducing seizure frequency. Rats with pilocarpine-induced epilepsy who submitted to a 
physical training program presented a lower frequency of spontaneous seizures than 
controls (Westerberg et al., 1984; Arida et al., 1999, 2004, 2009a, 2013). Other animal 
models of epilepsy have demonstrated similar results (Rambo et al., 2009; Reiss et al., 
2009; Tutkun et al., 2010).  
 Lastly, physical activity can also reduce the comorbid mental disorders associated 
with epilepsy. As stated earlier, people with epilepsy are more like to suffer from other 
mental and psychosocial disorders, such as mood and personality disorders and 
behavioral problems. Depression, deficits in learning and memory, stress and anxiety are 
among the most common. In physically healthy adults, engaging in regular physical 
exercise has shown to consistently improve emotional well-being (Roth et al., 1994). 
Similarly, people with epilepsy who practice physical exercise present lower levels of 
depression independently of other factors like age, gender, seizure frequency or stressful 
life experience (Eriksen et al., 1994; Roth et al., 1994; de Lima et al., 2013). Other 
studies have reported positive effects of physical exercise training on mental state, self-




quality of life (Nakken et al., 1990; Eriksen et al., 1994; McAuley et al., 2001; Arida et 
al., 2009b). Thus, physical exercise can improve overall mental health and emotional 
wellbeing in people with epilepsy. In individuals with managed epilepsy, physical 
activity’s benefits of improving mental health may prove more beneficial than the 
possible reduction of seizure frequency.  
 Mental health disorders in people with epilepsy may result from the complicated 
interactions between the antiepileptic medications, epilepsy surgery, and social 
interventions (such as restricted license to drive and fear of seizure in public). 
Interestingly, epilepsy and mood disorders share dysfunctions in neurotransmitter 
systems (dopamine, acetylcholine, glutamate, GABA, etc.), which might contribute to 
their coexistence and bidirectional relationship (Kanner, 2007; Thapar et al., 2009; Arida 
et al., 2012).  
 Several theories for how exercise mediates benefits on cognition in the healthy 
and diseased brain exist. The most prevalent theory is that an increase in cardiovascular 
blood flow that occurs during physical activity initiates the synthesis of several growth 
neurotrophic factors and neurotransmitters, which ultimately results in increased 
neurogenesis, angiogenesis, and synaptogenesis. The alteration of the human brain 
caused by acute and chronic exercise leads to a change in the fundamental network and 
structure in the brain compared to the sedentary brain. Thus, this new brain is efficient at 
preventing the development of seizure, reducing seizure frequency, and ameliorating 
psychosocial comorbidities associated with epilepsy (such as depression, learning and 





 1.8.2 ACETYLCHOLINE AND EXERCISE  
 The cholinergic system and exercise have a close interconnected relationship. 
First, exercise alters the cholinergic system in the brain. Particularly in the hippocampus, 
acetylcholine release increases 2-fold during moderate intensity walking in young 
(Nakajima et al., 2003) and aged adult rats (Uchida et al., 2006). Because depletion of 
acetylcholine is causal for memory impairment, this increase can be beneficial when 
applied to diseased brains. In addition to an increase in acetylcholine release, exercise can 
also reduce degradation of released acetylcholine. One study demonstrated that 
acetylcholinesterase was inhibited in the whole brain by 30 – 50% 2hr to 5hr post forced 
swimming exercise (Tsakiris et al., 2006). Thus, these studies show that exercise can 
modulate the amount of acetylcholine in the extrasynaptic space by both increasing the 
amount of acetylcholine release and inhibiting the amount of acetylcholine degraded, 
which seems to have beneficial effects in the diseased brain.  
A theoretical mechanism for how exercise mediates its beneficial effects in the 
brain is thought to be triggered by an increase in cerebral blood flow. Several studies 
have shown that acetylcholine is necessary for the exercise-induced increase in cerebral 
blood flow. For example, acetylcholine released in the cerebral cortex and hippocampus 
can increase regional blood flow in the cerebral cortex and hippocampus in anesthetized 
rats (Biesold et al., 1989; Cao et al., 1989; Kurosawa et al., 1989; Adachi et al., 1992; 
Sato and Sato, 1992, 1995; Sato et al., 2004). Thus, independent of periphery stimulation, 




moderate speed can increase cerebral blood flow in the hippocampus and cerebral cortex 
independent of systemic arterial pressure via activation of intracranial cholinergic fibers 
and release of ACh from these nerves. Thus, physical exercise stimulates the central 
cholinergic system to increase cerebral blood flow independent of periphery stimulation. 
Lastly, the cholinergic system is involved in the regulation of adult hippocampus 
neurogenesis. Selective lesioning of the medial septum system negatively affects the 
proliferation of neural stem cells (NSCs) and neuronal progenitor cells (Cooper-Kuhn et 
al., 2004; Mohapel et al., 2005; Van Der Borght et al., 2005), whereas the administration 
of acetylcholine esterase (AChE) inhibitor promotes NSC/neuronal progenitor cell 
proliferation (Mohapel et al., 2005; Narimatsu et al., 2009). Specifically, M1 muscarinic 
receptors are necessary for cholinergic-induced NSCs proliferation. Furthermore, 
exercise-induced promotion of aged NSC proliferation was abolished by specific 
lesioning of the septal cholinergic system, demonstrating the cholinergic system is 
necessary for exercise-induced neurogenesis (Itou et al., 2011). Thus, the cholinergic 
system also mediates exercise-induce increase in neurogenesis.  
 
 1.8.3 DOPAMINE AND EXERCISE 
 The effects of exercise on dopamine levels in the hippocampus have rendered 
mixed results. Some studies find that exercise significantly increases dopaminergic 
content (Chaouloff et al., 1986). For example, De Castro et al. confirmed an increase in 
dopaminergic metabolism in the whole brain of rats sacrificed 48 hours after an 8-week 




training model to examine brain dopamine metabolism and found that the sum of 
DOPAC and homovanillic acid was increased with running and remained elevated 
throughout the first hour of recovery (Chaouloff et al., 1987). Indeed, more recent studies 
have demonstrated increases in dopamine concentration and dopamine receptor binding 
(Greenwood et al., 2011). These results may be a result of increased bursting/activation 
of dopamine neuron in the VTA due to wheel running (Wang and Tsien, 2011). 
Additionally, chronic voluntary and forced wheel running demonstrate increase tyrosine 
hydroxylase and well as dopamine in several brain areas (Dishman et al., 1997; Sutoo and 
Akiyama, 2003; Droste et al., 2006; Foley and Fleshner, 2008; Greenwood et al., 2011). 
Thus, exercise seems to mediate an increase in dopamine production and release in the 
brain. 
 Other studies have found no change or a decrease in dopamine levels after acute 
or chronic physical exercise (Brown and Van Huss, 1973; Lukaszyk et al., 1983; Sudo, 
1983; Acworth et al., 1986). Notably, no study has found a significant decrease in 
dopaminergic content specifically in the hippocampus after an acute or chronic physical 
exercise-training plan, although several studies report a significant increase in dopamine 
content in the hippocampus (Chaouloff et al., 1987; Bailey et al., 1992). Thus, it seems 
that exercise, when it does have an effect, tends toward increasing dopaminergic content 







1.9 SIGNIFICANCE REVISITED 
 
 As discussed above, interplay between the glutamatergic system and 
cholinergic/dopaminergic system in the hippocampus are required for learning and 
memory. Specifically, kainate receptors play an important role in the physiology and 
pathophysiology of synaptic transmission. However, there have been no studies that have 
systematically examined whether mAChRs or D1 DARs in the brain alters kainate 
receptor function. To fill this significant knowledge gap, we first needed to identify 
pharmacological tools that can be used to identify specific kainate receptor subtypes. This 
tool will be useful to differentiate which kainate receptor subtypes are responsible for 
mediating KAR synaptic transmission in the normal hippocampus. After identifying 
which kainate receptor subtypes are responsible for KAR synaptic transmission, we must 
determine whether mAChRs and/or D1-like DARs can alter KAR synaptic transmission 
in the normal hippocampus. Several lines of evidence suggest that interaction between 
KARs and muscarinic/dopaminergic receptor may occur; however, this will be the first 
directly tested proof of concept. Understanding whether this interaction occurs and 
identifying which receptors are responsible, will reveal a novel mechanism by which the 
normal brain undergoes synaptic plasticity. Additionally, it will provide newfound 
mechanisms by which neurological disorders, such as epilepsy, and neurological 
therapies, such as exercise, may illicit their effects. Lastly, we will determine how the 
dopaminergic system is altered in the chronically epileptic brain. Understanding long-




comprehensive view of where the dysfunctional interaction between the glutamatergic 
and dopaminergic system exists. These studies are important, because they can shed light 
on a novel mechanism that occurs in the brain, which are necessary for brain health. 
Furthermore, understanding these mechanisms can unlock targets for therapies for 









2.1 INTRODUCTION TO ELECTROPHYSIOLOGY 
Electrophysiology is the study of the flow of ions through a cell or group of cells, 
and it also refers to the specific techniques required to measure this flow of ion. Every 
thought, every nerve impulse, every movement, and every heartbeat is controlled by 
highly specific and precisely timed flow of ions through cell membranes. Interfering with 
this flow could have a wide range of effects, from beneficial (as in exercise) to fatal (such 
as a prolonged seizure). Thus, having a detailed understanding of the ions and the 
transporters/receptors that mediate their passage through the cell membrane is 
indispensable when deciphering neurological disorders and developing novel therapies to 
remedy them. 
Electrophysiologists use the basic physical laws of electricity to understand the 
electrical activity of cells and the receptors inhabiting them. By far, the most useful law 
of electricity in electrophysiology is Ohm’s law. Ohm’s law states that voltage (V) or 
electrical potential (ΔV) is equal to current (I) multiplied by resistance (R): V=IR. In a 
cell, voltage is a measure the electrical potential difference across the cell membrane, 
which in most cells in negative a rest. The current is a measure of the amount of charged 




measure of the friction or resistance on ion flow, which is primarily a function of 
technical access to the cell. Electrophysiology equipment allows us to measure and 
modify eACh electrical component of the cell, as the experimental procedure sees fit.  
 
2.1.1 ELECTRICAL POTENTIAL  
Ions flow through plasma membranes because there is a difference in electrical 
potential (volts, V or ΔV) between the interior and exterior of cells. The ability of every 
cell to maintain an electrical potential is derived from two main characteristics. First, the 
distribution of ions inside the cell differs from those outside the cell. Most cells have a 
higher concentration of potassium (K
+





) inside the cell than in the extracellular space. Ion specific pumps that 
require energy maintain this ionic gradient. Furthermore, the cell’s interior contains 
negatively changed proteins that are impermeable to the cell membrane. Taken together, 
the interior electrical potential of most cells at rest is negative, compared to the 
extracellular space.  
Secondly, the plasma membrane itself has selective ion permeability. Every cell is 
enveloped by a plasma membrane consisting of lipids and proteins. Lipids are 
hydrophobic (repel water), which causes them to arrange into a phospholipid bilayer that 
is impermeable to ions. Ions are transported through this otherwise impermeable layer 
through specialized proteins, ion channels and transporters. The selective permeability of 
the cell membrane for each ion depends on the amount and states of its varied ion 
channels. During rest, most cells are highly permeably to K
+










. These two properties of the cell, the 
varied distribution of ions and the selective permeability of ions, are necessary for a cell 
to maintain its electrical potential.  
 
 2.1.2 VOLTAGE CLAMP 
Voltage clamp is an experimental paradigm used by electrophysiologists to 
measure ion currents through a cell membrane by holding (“clamping”) the electrical 
potential inside the cell constant. In theory, when ionotropic channels, such as kainate 
receptor, bind to glutamate, they open and allow Na
+
 ions to flow into the cells and K
+
 
ions to flow out of the cell, and thereby mediating an inward current of positive ions. By 
holding voltage constant, a change in current is directly related to the function of the 
receptors and channels expressed on the cell. Thus, we can reliably measure and 
confidently interpret KAR kinetics by measuring the current produced by ions flowing 
across the cell membrane at a given voltage.  
 
2.2 WHOLE CELL PATCH-CLAMP ELECTROPHYSIOLOGY 
In patch clamp electrophysiology, we are measuring the flow of ions across a 
single cell or single channel. This technique was first demonstrated by Erwin Neher and 
Bert Sakmann (Neher and Sakmann, 1976) in 1976, and later won the Nobel Prize in 
Physiology or Medicine in 1991. Changes in current and voltage are sensed by an 




cell recording. To acquire a whole-cell configuration a glass electrode is placed on the 
surface of a cell and mild suction is applied to rupture the membrane, allowing for the 
contents of the cell cytoplasm to diffuse and exchange with the internal solution inside 
the glass pipette. The whole-cell configuration produces a convenient method to directly 
apply substances into the cell in order to study the electrical currents and properties from 
the entire cell, or we may perfuse agonist or antagonist on the extracellular space of the 
cell to measure changes in ions flow (current) through receptors.  
 Whole-cell electrophysiology is used to study the movement of electrically 
charged ions, commonly through voltage-gated or ligand-gated channels. Glutamatergic 




 ions. When these 
receptors open, Na
+
 enters the cell and creates a more positive intracellular environment 
(depolarizes). In an effort to maintain the cell electrical potential at -70mV (in voltage 
clamp), a negative current is applied to the cell. Thus, a KAR response from voltage-
clamped data is negative.  
 
 2.2.1 EXPERIMENTAL PROTOCOL FOR WHOLE-CELL PATCH CLAMP RECORDINGS 
HEK-293T cells (GenHunter, Nashville, TN, USA) were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 
IU ml
-1
 penicillin and 100 µg ml
-1
 streptomycin. Cells were passaged with a 0.025% 
trypsin/0.01% EDTA solution in phosphate-buffered saline (10 mM Na2HPO4, 150 mM 
NaCl, pH 7.3). Full length cDNAs for the GluK or Neto1 subunits in mammalian 




previously described (Mott et al. 2010). Plasmids encoding rat GluK2 (Q), GluK4 or 
GluK5 were provided by S. Heinemann (Salk Institute, San Diego, CA, USA). Human 
Neto1 was provided by S. Tomita (Yale University, New Haven, CN, USA). Plasmids 
were transfected at ratios of 1:3:4 (GluK2: GluK4 – GluK5: Neto1), previously shown to 
optimize formation of heteromeric receptors (Barberis et al. 2008) and Neto1 assembly 
with KARs (Fisher & Mott, 2012). To identify transfected cells, we co-transfected 1 µg 
of a cDNA encoding a single-chain antibody recognizing the hapten 4-ethoxymethylene-
2-phenyl-2-oxazoline-5-one (phOx; Chesnut et al. 1996). Positively transfected cells 
were isolated using phOx-coated beads 18 – 28 hr after transfection and plated onto glass 
coverslips treated with poly-L-lysine and collagen.  
 Whole-cell recordings were performed on isolated HEK-293T cells 40 – 52 h 
after transfection under voltage-clamp conditions. Patch pipettes were pulled from 
borosilicate glass with an internal filament (World Precision Instruments, Sarasota, FL, 
USA) on a two-stage puller (Narishige, Japan) to a resistance of 5 – 10 MΩ and filled 
with a solution containing (in mM): 130 CsGluconate, 5 CsCl, 10 Hepes, 5 CsBAPTA, 2 
MgCl2, 2 MgATP, 0.3 NaGTP (pH 7.3, 290-300 mosmol l
-1
). Cells were continually 
perfused with an external solution containing (in mM): 150 NaCl, 3 KCL, 10 Hepes, 1 
CaCl2, 0.4 MgCl2 (pH 7.4, 295-305 mosmol l
-1
). For whole-cell recordings glutamate and 
antagonists (ACET and kynurenate) were applied to cells using a stepper solution 
changer (SF-77B, Warner Instruments, Hamden, CT, USA). The time course of drug 
application was <50 ms in the whole-cell recording configuration as determined using a 
diluted external solution applied to the electrode. Rise times (10 – 90%) of the junction 




diluted external solution. All antagonists were applied to cells before glutamate per 
sweep. Current recordings were amplified (Axopatch 200B; Molecular Devices, Foster 
City, CA, USA), filtered (1kHz) and digitized at 10 kHz using a Digidata 1320 analog to 
digital board (Molecular Devices) and stored on a computer hard drive for off-line 
analysis.  
 
2.3 FIELD POTENTIAL ELECTROPHYSIOLOGY 
 Field-potential electrophysiology is performed extracellularly, as opposed to 
whole cell record which is recorded intracellularly. Once the tissue is prepared a 
stimulating electrode is placed into the tissue to depolarize a population of neurons. Field 
potential electrophysiology allows electrophysiologists to record activity of a population 
of neurons by placing the recording electrode within a cell body region or within the 
dendrites or axons of the neuronal population. Activation of these neurons results in a 
summation of the extracellular potentials creating either a field inhibitory postsynaptic 
potential (fIPSP) or a field excitatory postsynaptic potential (fEPSP).  
 Because these recordings are extracellular and measures collective cell activity, 
the placement of the recording electrode and stimulation electrode is critical to ensure 
proper interpretation of the data. Relative to the electrode, neuronal activation can create 
what is denoted as an extracellular sink or source. The flow of positively charged ions 
into a cell or dendrite leaves the extracellular space more negative, creating an 
extracellular sink, while a positive waveform (source) is created by the current that leaves 




recordings in the mossy fiber – CA3 synapse are at particular risk for improper electrode 
placement, as the CA3 region contains mossy fibers input as well as the 
associational/commissural fibers. Pure stimulation of the mossy fibers, elicited through 
activation of dentate granule cells, would evoke an extracellular sink in area CA3 stratum 
lucidum. However, if the placement of the recording electrode was not precise an 
extracellular source evoked from the CA3 A/C fibers would contaminant the response. 
The overall response would be a fEPSP comprised of both a downward sink and upward 
source. Thus, in experiments involving the mossy fiber – CA3 synapse, steps are taken to 
ensure pure mossy fiber stimulation and recording. 
 
 2.3.1 EXPERIMENTAL PROTOCOL FOR FIELD POTENTIAL RECORDINGS 
Hippocampal slices were made from postnatal day (P) 21 – P28 and P45 – P60 
Sprague-Dawley rats as described previously (Iyengar and Mott, 2008). Briefly, animals 
were deeply anesthetized with isoflurane and decapitated with a guillotine. The brain was 
removed under ice-cold (4ºC), sucrose-based ‘cutting’ artificial cerebrospinal fluid 
(aCSF) that contained (in mM): 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 248 
sucrose, 0.5 CaCl2, and 5 MgSO4 (350mOsm). The use of this solution during the cutting 
process enhances neuronal survival by limiting excessive excitation. Transverse slices 
were made with a vibratome (Leica VT1000S, Nussloch, Germany) at 500 µM and 
incubated for at least one hour at room temperature in aCSF containing (in mM): 125 




AP-5, and 1 mM kynurenate (305 mOsm; pH=7.4). Both the sucrose-based and standard 
aCSF were oxygenated with 95% O2 / 5% CO2. 
 After 1 hour, individual slices were transferred to a submersion chamber 
maintained at 32 – 34 ºC, held in place by a bent piece of platinum wire resting on the 
surface of the slice, and perfused continuously at 3 – 4 ml/min with recording aCSF 
containing (in mM): 125 NaCl, 2.01 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 2 
CaCl2, 1 MgSO4. Glass electrodes were pulled from borosilicate glass to achieve 2 – 3 
MΩ and filled with recording aCSF. Extracellular dendritic field potentials recording 
were made from the stratum lucidum of the CA3 region of the hippocampus, which was 
visually identified with a light microscope (See Figure 2.1). Synaptic currents were 
evoked with a monopolar platinum-iridium glass electrode positioned in the stratum 
lucidum. For AMPA-fEPSPs recordings, we recorded composite MF-fEPSPs, which 
were primarily composed of AMPA-fEPSPs (~ 93%) (Contractor et al., 2003), with aCSF 
containing 10 µM MK-801, 50 µM picrotoxin, and 1 µM CGP 55845 to block NMDA, 
GABAA, and GABAB receptors, respectively. We defined synaptic currents as MF-
fEPSPs if they showed characteristically large paired-pulse facilitation (Salin et al., 
1996), had a rapid rise time and short latency, and were inhibited by >70% by the group 
II-selective metabotropic glutamate receptor (mGluR) agonist (2S,2’R,3’R)-2-(2’3’-
Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM), which was bath applied at the end of 
some experiments. To isolate KA-fEPSPs recordings, we recorded from CA3 pyramidal 
cells in the presence of the aCSF containing the AMPA antagonist GYKI53655 (50 µM) 
in addition to the GABAA, GABAB and NMDA receptor antagonist cocktail. Once KAR-




monophasic, rectangular constant current pulses) were delivered every 30 sec through 
monopolar, platinum-iridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced 
to the bath ground. KAR-fEPSPs were stable for a minimum of 20 min. prior to 
pilocarpine (300 nM) perfusion onto the slice for 10 – 15 min. to activate predominately 
M1 mAChRs. In experiments were M1 mAChRs or PKC were inhibited, telenzepine 
(100 nM) or chelerythrine (5 µM) respectively were applied concurrently with AMPA, 
GABAA, GABAB, and NMDA antagonists. To resolve small KAR-fEPSPs that were 
obscured by stimulation artifacts, we digitally subtracted a “template” stimulation trace 
that was acquired after application of an AMPA/KAR antagonist (CNQX, 50 µM) at the 
end of the recordings. 
 





2.4 PILOCARPINE MODEL OF SE 
 The use of animal models in investigation potential therapies for epilepsy is 
indispensable. These models, and specifically the pilocarpine model, closely resembles 
distinct anatomical and physiological alterations seen in the human disease, including 
sclerosis and cell loss and mossy fiber sprouting. Additionally, the pilocarpine model 
develops spontaneous seizures, chronic hyperexcitability, appropriate responsiveness to 
AEDs, and develop comorbidities, such as anxiety and learning and memory deficits, that 
are strongly associated with chronically epileptic patients. Without these models would 
not be able to elucidate the mechanism precipitation or preventing seizures. The current 
study will utilize a pilocarpine to initiate status epilepticus followed by a period of 
epileptogenesis (30 days) and eventually the development of spontaneously recurring 
seizures.  
 
 2.4.1 ANIMAL CARE AND USE 
 All animal care and use procedures were carried out in accordance with protocols 
written under the guidance of the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and approved by the institutional Animal Care and Use 
Committee at the University of South Carolina. Male Sprague-Dawley rats were 
purchased from Harlan, and housed at 1 – 3 rats per cage with ab libitum access to food 
and water. Rats were housed in a climate-controlled facility with a light/dark cycle of 





 2.4.2 PILOCARPINE MODEL OF STATUS EPILEPTICUS 
 Adult male Sprague-Dawley rats (42 – 50 days; Harlan, Indianapolis, IN) 
received intraperitoneal (i.p.) injections of scopolamine methyl bromide, to block 
peripheral muscarinic receptors, and terbutaline hemisulfate (2 mg/kg) to activate 
peripheral β2-adrenergic receptors to act as a bronchodilator and prevent respirator 
depression associated with SE. Pilocarpine hydrochloride (390 mg/kg) was 
intraperitoneally injected 30 – 40 minutes after scopolamine and terbutaline injection. 
Following pilocarpine injection, rats were observed continuously for the occurrence of 
behavioral seizures and were scored on the Racine scale (Racine, 1972) (Table 2.1). 
Approximately 70% of rats experienced class V seizures. Animals that did not exhibit SE 
after 45 minutes were given an additional ‘booster’ of pilocarpine (200 – 300 mg/kg). 
Nearly 90% of animals receiving a pilocarpine ‘booster’ experienced sufficient SE. 
Animals that successfully had a stage V seizure were allowed to seize 2 hours (status 
epilepticus) before the seizures were suppressed by intraperitoneally injected diazepam 
(DZP, 25 mg/kg). This group of animals served as the ‘pilo’ group. In order to limit 
physical distress and any peripheral effects of pilocarpine, animals received additional 
doses of the scopolamine/terbutaline cocktail approximately one-hour into SE as well as 
upon termination of SE with DZP. A separate group of animals were treated identically, 
but received saline (390 mg/kg) instead of pilocarpine hydrochloride. This group of 
animals served as the ‘sham’ group. Approximately 1 – 2 hours after seizures were 
terminated, animals received a subcutaneous dose of the scopolamine/terbutaline cocktail 




sweetened in high sucrose water. Animals that did not enter SE were excluded from the 
study.  
 All animals were housed overnight in the animal facility and their health status 
was checked as early as possible on the following day to determine if they successfully 
recovered from treatment. Animals still experiencing side effects from treatment 
(lethargy, immobility) were given additional subcutaneous injections of lactated Ringer’s 
solution and the scopolamine/terbutaline cocktail and placed on a heating pad. For 
animals who endured the first night post-treatment the survival rate was nearly 100%. 
Animals in our “pilo” group were video monitored a minimum of 30 days post-treatment 
to ensure the appearance of spontaneously occurring seizures. This experimental protocol 
was used in Chapter 5 to explore alterations in the dopaminergic system in the epileptic 
brain.  
 
Table 2.1 Racine scale of epileptic seizures 
Score Observed Rat Motor Behavior 
0 Normal behavior (exploring, walking, grooming, etc.) 
1 Immobility, staring ‘curled up’ posture 
2 Automatisms 
(Chewing, head bobbing, twitching, wet-dog shakes) 
3 Forelimb/hindlimb myoclonic jerking, head tremor 
4 Rearing and whole body clonus 
5 Rearing and falling over; loss of posture 
6 Tonic-clonus seizures with tonic forelimb flexion/extension, whole-
body clonus 






2.5 WESTERN BLOT ANALYSIS 
 Western blotting is a widely used tool to detect the presence and measure the 
abundance of specific proteins (MacPhee, 2010). Western blotting begins with successful 
extraction and isolation of a particular lysate. Proteins are then separation by molecular 
weight through electrophoresis onto a polyacrylamide gel. The proteins are then 
transferred onto a membrane and probed with antisera to detect the presence of the 
specific protein. During application of the appropriate primary and secondary antibody, 
the membrane undergoes blocking to prevent non-specific binding between antibody and 
membrane. Blocking usually consists of submerging the membrane in a non-fat milk or 
bovine serum albumin solution. Once the appropriate antisera is bound to the protein, its 
relative expression can be determined through process such as enhanced 
chemiluminescence (ECL). The peroxidase conjugated secondary antisera serves to 
oxidize the luminol substrate within the ECL to emit light. This light is then captured 
onto film and measured using densitometry. The following sections describe in detail the 
western blotting protocol utilized in Chapter 5 to determine differences in dopamine 
D1/D5 receptor, DAT, and COMT protein abundance within specific brain regions in the 
hippocampus following pilocarpine-induces temporal lobe epilepsy.  
 
 2.5.1 MEMBRANE PREPARATION 
 Immunoblot analysis was performed as described in a previous study (Grillo et 
al., 2011). Briefly, the hippocampus was rapidly extracted and processed ‘whole’ or 




homogenization buffer (mM: 2 EDTA, 2 EGTA, 20 HEPES, 0.32M sucrose, 1% 
phosphatase inhibitor, and 1% protease inhibitor). The samples were then homogenized 
and centrifuged for 10 min at 500 x g at 4C to remove nuclear fraction. The supernatant 
containing the total membrane fraction was centrifuged at 31,000 x g for 30 min at 4C. 
The resulting crude plasma membrane fraction was resuspended in phosphate buffered 
saline (PBS) and stored at -80ºC until used for analysis. A Bradford protein assay was 
used as a simple and accurate way to measure protein concentration in the crude plasma 
membrane, and used to ensure equal protein is loaded across all lanes.  
 
 2.5.2 SDS-PAGE AND ANTIBODY DEVELOPMENT 
 Aliquots of 20 μg of crude plasma membrane proteins were denatured by diluting 
them in a 1:1 ratio with BioRad Laemmli Sample Buffer with 5% β-mercaptoethanol. 
Samples were then heated at 95C for 5 min and loaded into pre-cast polyacrylamide gels 
(4 – 15%). Running buffer (in mM: 25 Tris, 240 Glycine, 0.1% SDS) was added to the 
appropriate tank, BioRad mini PROTEAN-Tetra, and ran using the BioRad Power Pack 
HC for at least 30 min at 175 – 200 V. Following sodium dodecyl sulfate polyacrylamide 
gel polyvinylidene fluoride (PVDF) membranes using the BioRad Trans-Blot SD Semi-
Dry Transfer Cell. Protein transfer was completed using the BioRad Power Pack HC for 
30 min at 25V. Transfer buffer contained (in mM): 25 Tris, 192 Glycine, and 20% 
methanol. All equipment was acquired from Bio-Rad Laboratories, Inc. 
 PVDF blocked in TBS plus 5% nonfat dry milk for 60 min. PVDF 




overnight incubation at 4°C, blots were washed with TBS plus 0.05% Tween 20 (TBS-T) 
and incubated with peroxidase labeled species-specific secondary antibodies. PVDF 
membranes were then washed with TBS-T and developed using enhanced 
chemiluminescence reagents (ECL, Amersham) as described by the manufacturer. 
Normalization for protein loading was performed using a mouse monoclonal primary 
antibody selective for actin (Sigma Chemical Company). 
 





D1 Millipore; AB1765P 1:200 
D5 Santa Cruz; sc-1441 1:250 
TH Millipore; AB152 1:1,000 
COMT Millipore AB5873 1:1,500 
DAT Millipore: AB2231 1:2,000 
 
2.6 IMMUNOHISTOCHEMISTRY 
 Immunohistochemistry is a power tool used to visualize the localization and 
distribution of specific protein the fixed tissue. Thus, much care should be taken to 
preserve the original architecture and connectivity in the brain. Immunostaining 
techniques use a combination of immunology and histology. Immunology is used to 
produce protein-specific antibodies from the serum of animals. Antibodies bind to 
corresponding antigens presented on the cell surface. We use an indirect method of 
immunohistochemistry to amplify the labeled signal. Antibodies for the specific protein is 




unbound antibody is washed off (primary). To identify the location of the antibody and 
consequently the location of the antigen, an additional antibody is applied to tissue. This 
antibody was developed in another species to recognize and bind to the species from 
which the primary antibody was developed (secondary). Lastly, another antibody 
conjugated with a peroxidase enzyme will bind to the antibody complex. This peroxidase 
enzyme recognizes peroxide and allows us to visualize the location of the antibodies and 
consequently the location of the antigen.  
 Histology is used because we observe the structure and preservation of tissue. 
Generally, brains are fixed with formaldehyde and can either be sectioned immediately or 
undergo cryoprotecting, which allows longer preservation of the tissue morphology in the 
freezer. In many cases, this fixative can prevent sufficient antibody/antigen binding. 
Thus, a popular detergent, Triton X can be used to improve penetration of the antibody 
and improve labeling. We employed such techniques in this study. The following sections 
describe in detail the immunohistochemistry protocol used in Chapter 5 to determine 
alterations in dopamine D1/D5 receptor expression within the hippocampus following 
pilocarpine-induced chronic temporal lobe epilepsy. 
Free-floating sections were incubated with a mouse anti-glutamic acid 
decarboxylase 67 (GAD-67, 1:1000; Millipore; product No. MAB5406), goat anti-
dopamine D5 receptor (D5, 1:500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA; product No. sc-1441), rat anti-dopamine D1 receptor (D1, 1:100; Sigma, St. Louis, 
MO, USA; product No. D2944), or rabbit anti-tyrosine hydroxylase (TH, 1:2000; 
Millipore; product No. AB152) antibodies for 24 hours at room temperature (RT) or 48 




quantification of GABAergic neurons. These steps were followed by secondary antibody 
incubation with either biotinylated donkey anti-mouse, anti-rabbit, anti-goat, or anti-rat 
(1:400, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; product 
Nos. 715-065-151, 711-065-152, 705-065-003, 712-065-150) for 1.5 hours at RT, and 
horseradish peroxidase conjugated streptavidin (1:1600; Jackson ImmunoResearch 
Laboratories, Inc.; product No. 016-030-084) for 1 hour at RT. Immunoreactivity was 
developed using nickel sulfate-cobalt chloride intensified diaminobenzidine with 
hydrogen peroxide, yielding blue-black immunopositive cells. 
 
 2.6.1 PERFUSION OF TISSUE FIXATION 
 All tissue was processed according to previously described protocols (Stanley et 
al., 2012). Briefly, rats were deeply anesthetized using isoflurance and transcardially 
perfused with phosphate-buffered saline and 4% paraformaldehyde. Briefly, once 
anesthetized, a lateral incision to the lower abdomen was made which extended upwards 
to expose the chest cavity and the heart. A hemostatic clamp was placed on the 
descending vena cava to prevent perfusate flow to the lower extremities. A 20 x ½ gauge 
needle attached to the perfusion pump was inserted through the apex of the left ventricle 
and held firmly in place with a hemostat. Once inserted, the right atrium was clipped to 
allow perfusate flow. Ice cold, oxygenated (95% O2 / 5% CO2) 0.05 M PBS (pH 7.4) 
was perfused at approximately 60 mL/min for 4 – 5 min, followed by the ice cold fixative 




brains were removed and postfixed overnight followed by cryoprotection in 30% sucrose. 
Tissue was coronally sectioned at a 45 µm thickness on a crystat. 
 
 
 2.6.2 IMMUNOPEROXIDASE 
 Free-floating sections were incubated with primary antibodies (Table 2.2) 
antibodies for 24 hours at room temperature (RT) or 48 hours at 4°C. The GAD-67 
antibody was used for cell body labeling as well as quantification of GABAergic neurons. 
These steps were followed by secondary antibody incubation for 1.5 hours at RT, and 
horseradish peroxidase conjugated streptavidin (1:1600; Jackson ImmunoResearch 
Laboratories, Inc.; product No. 016-030-084) for 1 hour at RT. Immunoreactivity was 
developed using nickel sulfate-cobalt chloride intensified diaminobenzidine with 
hydrogen peroxide, yielding blue-black immunopositive cells. 
 





GAD-67 MAB5406 1:1,000 
D5 sc-1441 1:500 
D1 D2944 1:100 






 2.6.3 SLIDE PREPARATION AND ANALYSIS 
 Stained and free floating tissue sections were mounted on slides with a 0.15% 
gelatin solution and allowed to dry overnight. Once dry, tissue were serial dehydration 
step with increasing concentrations of ethanol (50%, 70%, 95%, 100%, 100%; 3 
min/bath) followed by two, 10 min incubations in xylene. Slides were immediately cover-
slipped using cover glass and DPX mounting solution (Sigma, St. Louis, MO) and 
allowed several days to dry prior to analysis and long-term storage. Analysis on 
immunohistochemical data was performed using cell counts.  
  
 2.6.4 CELL COUNTS & PHOTOMICROGRAPHS 
 Immunopositive cells were counted using a Nikon ECLIPSE 80i microscope 
equipped with a CX900 camera (Nikon; Tokyo, Japan) using Neurolucida software (v.10; 
MicroBrightField, Inc.; Williston; VT, USA). Minor adjustments to color, contrast, and 
brightness were made using Adobe Photoshop 7.0 (San Jose, CA, USA).  
 
2.7 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 High performance liquid chromatography (HPLC) is a technique that can be used 
to identify, quantify and purify individual analytes of a given solution. Typically, HPLC 
involves a high pressure pump used to carry analytes suspended in a mobile phase 
through an analytical column. The column contains densely packed silica beads that 




analytes are detected by an electrochemical detector. Retention times can be varied based 
on mobile phase flow rate, composition or pH, as well as ambient temperature in some 
cases. All HPLC products were purchase from BASi.  
Rats were deeply anesthetized with isoflurane. Their hippocampi were rapidly 
extracted and immediately weighted and chilled. Hippcampal tissue was homogenized 
using individual plastic disposable pestles and 1.5mL centrifuge tubes. The tissue was 
homogenized in a 0.1M perchloric acid (HClO4) solution containing 0.02% sodium 
metabisulfite (Na2S2O5) and dihydroxybenzylamine (DHBA, 146.5 ng/mL, as an internal 
standard for monamines) in a proportion of 15 µL solution for each milligram of tissue. 
The homogenized tissue was then centrifuges at 11,000g at 4ºC for 40 min. After 
centrifugation, the sample supernatant was filtered using 0.2 µM nylon disposable 
syringe filters and stored at -80ºC until analyzed. Centrifuged tubes containing the tissue 
pellet was also stored at -80ºC to use as a post hoc control to normalize for protein 
concentration. We analyzed hippocampal tissue homogenates from “control” and 
“epileptic” rats using high performance liquid chromatography (HPLC) with 
electrochemical detection for the analytes dopamine, DOPAC, and norepinephrine (NE). 
Elution times for these monoamines and their metabolites are displaying in Table 2.2 
(Cavalheiro et al., 1994). 
 
Table 2.4 Chromatographic parameters for monoamines and monoamine 
metabolites 
Neurotransmitter Retention time (min) 




4-hydroxy-3-methoxyphenly glycol (MPHG) 4.20 
Norepinephrine (NE) 4.60 
Dihydroxybenzylamine (DHBA) 7.30 
Dihydroxyphenylacetic acid (DOPAC) 8.00 





2.7.1 DOPAMINE CHROMATOGRAPHY 
 Dopamine, DOPAC, and NE were separated by a C18 carbon polymer column 
using a mobile phase (pH 3.4) containing 14.5 mM NaH2PO4. A post-column 
immobilized enzyme reactor containing covalently bound dopamine, DOPAC, and NE 
oxidase generated stoichiometric quantities of hydrogen peroxide, which were detected 
by a “peroxidase wired” glassy carbon electrode (Huang et al., 1995; Fadel et al., 2001). 
Dopamine peak areas were quantified by comparison with a daily three-point standard 
curve defining the range of dopamine values. Dopamine, DOPAC, and NE levels in 
epileptic hippocampi were normalized as a percent of the average control hippocampi 
dopamine, DOPAC, and NE content.  
 
2.8 STATISTICAL ANALYSIS 
Electrophysiological data was analyzed using pClamp10 (Molecular Devices, 
Sunnyvale, CA) and Origin7.5 (OriginLab, Northampton, MA). Data collected from 




(National Institute or Health, USA) or cell counts. Data depicting changes in DAR, DAT, 
and COMT protein expression were obtained by averaging data collected from a 
minimum of two separate western blots. 
All cell counts, electrophysiological data, and immunoblot data were analyzed 
using independent samples Student’s t-test for significant main effects. All values are 










Kainate receptors (KARs) are ionotropic glutamate receptors composed of 
tetrameric assemblies of GluK1-5 subunits (Pinheiro and Mulle, 2006). GluK2, GluK4, 
and GluK5 are thought to compose postsynaptic KARs at mossy fiber (MF) to CA3 
pyramidal cell synapses (mossy fiber-CA3 synapses) (Mulle et al., 1998; Contractor et 
al., 2003; Fernandes et al., 2009), where they contribute with small amplitude, slowly 
decaying currents (Castillo et al., 1997; Vignes and Collingridge, 1997). Despite their 
small amplitude, KAR-excitatory postsynaptic currents (EPSCs) were hypothesized to be 
important for the integration of information because they summate temporally (Frerking 
and Ohliger-Frerking, 2002). Furthermore, kainate receptors are composed of subunits 
that demonstrate distinct pharmacology, kinetics, and localization, thus, providing a 
higher level of complexity to deciphering the role of kainate receptor subunits in the 
brain. Although we know that each subunit can bind to glutamate and open the receptor, 
we do not know whether each subunit contributes equally to receptor activation, 




 The lack of pharmacological tools that selectively block KAR subunits known to 
be located on CA3 pyramidal cells hampers clarifying the physiological relevance of 
postsynaptic KARs at mf-CA3 synapses. Recently, an intense effort was made to 
synthesize and characterize subunit-selective KAR antagonists, mainly against GluK1 
(Jane et al., 2009). However, no selective antagonist of GluK5 or GluK4 subunits yet 
exists, although they likely represent a major population of KARs in the brain (Wenthold 
et al., 1994). Previous papers hint at how other GluK1 antagonists can be promiscuous in 
also inhibiting heteromeric GluK2/K5 receptors (Pinheiro et al., 2013). The implication 
of KAR-EPSCs at hippocampal MF synapses has only been addressed by comparing 
wild-type and GluK2
-/-
 mice, which display loss of postsynaptic KARs (Mulle et al., 
1998; Sachidhanandam et al., 2009). This was followed by demonstrations showing that 
KAR-EPSCs are eliminated when GluK4 and GluK5 subunits are knocked out 
(Fernandes et al., 2009). Thus, these two experiments can be explained by the latter, 
suggesting that GluK2 is necessary for integration of GluK4 and GluK5 into the synapse. 
However, it is the GluK2/GluK4 and/or the GluK2/GluK5 heteromers that are necessary 
for KAR-EPSCs at the MF-CA3 synapses. Interestingly, the GluK4
-/-
 demonstrated the 
most diminished KAR-EPSCs at MF-CA3 synapses compared with the GluK5
-/-
(Contractor et al., 2003; Fernandes et al., 2009). However, these results are not 
conclusive that the GluK4 subunit is more important for postsynaptic KAR transmission 
than the GluK5 subunit, because receptor compensation from congenital knockouts 
cannot be ruled out. In addition to the previous research demonstrating a need for the 
GluK4 and GluK5 subunits to produce postsynaptic KAR current, new research has 




synapse and altering the properties KAR postsynaptic current at mf-CA3 synapses 
(Copits et al., 2011; Straub et al., 2011a). 
 In search for antagonists of KARs at mf-CA3 synapses, we reevaluated the 
efficacy of willardiine derivatives (Jane et al., 2009) on native KARs. ACET was 
originally developed as a GluK1 selective antagonist (Dolman et al., 2007). We found 
that ACET blocks postsynaptic KARs at mf-CA3 synapses. We further show that ACET 
is also an antagonist of recombinant GluK5 and GluK4 subunits, the subunits required for 
postsynaptic KAR current. Using this tool and the drug kynurenate, which was previously 
demonstrated to antagonize the GluK2 subunit, we directly investigated the relative 
contribution of the GluK2 and GluK5 subunits to KAR current in recombinant cells and 
the brain. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 CULTURE AND TRANSFECTION OF HEK-293T CELLS 
HEK-293T cells (GenHunter, Nashville, TN, USA) were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 
IU ml
-1
 penicillin and 100 µg ml
-1
 streptomycin. Cells were passaged with a 0.025% 
trypsin/0.01% EDTA solution in phosphate-buffered saline (10 mM Na2HPO4, 150 mM 
NaCl, pH 7.3). Full-length cDNAs for the GluK or Neto1 subunits in mammalian 




previously described (Mott et al. 2010). Plasmids encoding rat GluK2 (Q), GluK4 or 
GluK5 were provided by S. Heinemann (Salk Institute, San Diego, CA, USA). Human 
Neto1 was provided by S. Tomita (Yale University, New Haven, CN, USA). Plasmids 
were transfected at ratios of 1:3:4 (GluK2: GluK4 – GluK5: Neto1), previously shown to 
optimize formation of heteromeric receptors (Barberis et al. 2008) and Neto1 assembly 
with KARs (Fisher & Mott, 2012). To identify transfected cells, we co-transfected 1 µg 
of a cDNA encoding a single-chain antibody recognizing the hapten 4-ethoxymethylene-
2-phenyl-2-oxazoline-5-one (phOx; Chesnut et al. 1996). Positively transfected cells 
were isolated using phOx-coated beads 18 – 28 hr after transfection and plated onto glass 
coverslips treated with poly-L-lysine and collagen.  
 
3.2.2 WHOLE-CELL RECORDING 
 Whole-cell recordings were performed on isolated HEK-293T cells 40 – 52 h 
after transfection under voltage-clamp conditions. Patch pipettes were pulled from 
borosilicate glass with an internal filament (World Precision Instruments, Sarasota, FL, 
USA) on a two-stage puller (Narishige, Japan) to a resistance of 5 – 10 MΩ and filled 
with a solution containing (in mM): 130 CsGluconate, 5 CsCl, 10 Hepes, 5 CsBAPTA, 2 
MgCl2, 2 MgATP, 0.3 NaGTP (pH 7.3, 290-300 mosmol l
-1
). Cells were continually 
perfused with an external solution containing (in mM): 150 NaCl, 3 KCL, 10 Hepes, 1 
CaCl2, 0.4 MgCl2 (pH 7.4, 295-305 mosmol l
-1
). For whole-cell recordings glutamate and 
antagonists (ACET and kynurenate) were applied to cells using a stepper solution 




application was <50 ms in the whole-cell recording configuration as determined using a 
diluted external solution applied to the electrode. Rise times (10 – 90%) of the junction 
potential at the open tip were consistently faster than 400 µs and were tested using a 
diluted external solution. All antagonists were applied to cells before glutamate per 
sweep. Current recordings were amplified (Axopatch 200B; Molecular Devices, Foster 
City, CA, USA), filtered (1kHz) and digitized at 10 kHz using a Digidata 1320 analog to 
digital board (Molecular Devices) and stored on a computer hard drive for off-line 
analysis.  
 
3.2.3 ANALYSIS OF WHOLE-CELL CURRENTS 
 Whole-cell currents were analyzed using the programs Clampfit (pClamp9.2 
suite, Molecular Devices, Foster City, CA, USA) and Origin (MicroCal, Northampton, 
MA, USA). Concentration-response data were fit with a four-parameter logistic equation: 
Current = [Minimum current + (Maximum current – Minimum current)]/1 + (10^(log 
EC50 – log [Glutamate]) x n), where n represents the Hill number. All fits were made to 
normalized data with current expressed as a percentage of the maximum response to 
glutamate for each cell. Peak currents and log EC50 values were compared using unpaired 









3.3.1 ACET INHIBITION OF HETEROMERIC KAINATE RECEPTORS 
ACET is a williardine compound previously described to be a GluK1 antagonist 
(Dargan et al., 2009; Jane et al., 2009). Studies have confirmed that ACET does not 
inhibit the activation of GluK2 homomeric currents (Dargan et al., 2009). However, 
doubts about the specificity of ACET to inhibit only GluK1 receptors were raised when it 
was demonstrated that ACET could inhibit KAR currents at mossy fiber-CA3 synapses 
(Dargan et al., 2009), a synapse in which few if any postsynaptic GluK1 receptors are 
located (Paternain et al., 2003). To examine the selectivity of ACET, we transfected 
HEK-293T cells with heteromeric and homomeric kainate receptors known to be 
predominantly expressed on CA3 pyramidal cells (GluK2, GluK2/K4 and GluK2/K5) 
and evaluated the efficacy of ACET to inhibit their glutamate-induced current. 
Using whole cell patch-clamping electrophysiology, we gained access to the 
internal milieu of the cell and clamped the voltage inside the cell at -70 mV. An EC50 
glutamate dose was applied to each cell as a reference for maximum current activation. 
Glutamate was applied at the beginning and end of each experiment to 1) receive a 
reference for maximum current activation, and 2) as a way to determine receptor 
rundown throughout the experiment. In cells transfected with GluK2/K4 KAR subtypes, 
a 5 sec application of 30 µM glutamate produced a rapid on and fast desensitizing current 
(Figure 3.1A). These receptor kinetics are similar to those reported in other papers (Fisher 




the peak current amplitude by 54 ± 6.3% (Figure 3.1A). In cells transfected with 
GluK2/K5 KAR subtypes, an EC50 glutamate dose of 10 µM produced a rapidly activated 
but slowly desensitizing current (Figure 3.1A). This receptor kinetic was similar to those 
reported in other papers (Fisher and Mott, 2011; Fisher and Fisher, 2014). Co-application 
of 1 µM ACET with 10 µM glutamate reliably reduced the peak current by 92 ± 0.85% 
(Figure 3.1A). However, in cell transfected with GluK2 KAR subtypes, and EC50 
glutamate dose of 300 µM glutamate produced a rapidly activating and desensitizing 
current (Figure 3.1B). Co-application of 1 µM ACET with 300 µM glutamate did not 
inhibit the peak current amplitude (Figure 3.1B).  
Interestingly, our results demonstrate that 1µM ACET is not sufficient to inhibit 
GluK2 when expressed alone. However, 1 µM ACET is sufficient to inhibit peak currents 
when GluK2 is expressed with either GluK4 or GluK5 subunits. Thus, we designed 
further experiments to test whether the GluK4 or GluK5 subunits contribute to the 
appearance of ACET inhibition. To test whether GluK4 or GluK5 subunits contribute to 
ACET inhibition of heteromeric KAR currents, we co-transfected GluK4 or GluK5 
subunits with a mutated GluK2, in which the 738
th
 glutamate (E) amino acid was 
replaced with a aspartate (D) amino acid. This mutation reduces the GluK2 subunit 
sensitivity to glutamate 1,000 fold (Fisher and Mott, 2011), resulting in the lack of GluK2 
activation at glutamate concentrations less than 1 mM. Now, when GluK4 and GluK5 is 
expressed with the mutated GluK2 subunit (GluK2E738D), the receptor kinetics change 
from a rapid on and desensitizing current to a non-desensitizing current. This was 
reported and elucidated in other papers, where they described this phenomenon was due 




Desensitization requires that activation of at least three or more subunits. By removing 
the sensitivity of the GluK2 subunit to glutamate, only the GluK4 or GluK5 subunits in 
the tetramer can bind to glutamate, and thus produces a non-desensitizing current. 
Application of 1 µM ACET was sufficient to block activation induced by EC50 dose of 
glutamate (Figure 3.1B)  
 
Figure 3.1 ACET inhibits current at GluK2/4 and GluK2/5 heteromers by 
antagonizing the GluK4 and GluK5 subunit, respectively. 
A. Sample waveforms showing the effect of ACET (1 µM, red trace) compared to 
glutamate alone (black trace). ACET inhibits the glutamate-induced current in 
HEK-293T cell transfected with wildtype GluK2/K4 or GluK2/K5 kainate 
receptors.  
B. Sample waveforms showing the effect of ACET (1 µM, red trace) compared to 
glutamate alone (black trace). Similarly to previously reported, ACET did not 
inhibit current at cells transfected with wildtype GluK2 homomeric KAR 
receptors. However, in cells transfected with heteromeric KARs in which the 
GluK2 subunit was mutated so that it was 1,000 fold less sensitive to glutamate 
(GluK2(E738D)/K4 and GluK2(E738D)/K5), ACET almost completely inhibits 






















































































































Desensitization requires that activation of at least three or more subunits. By 
removing the sensitivity of the GluK2 subunit to glutamate, only the GluK4 or GluK5 
subunits in the tetramer can bind to glutamate, and thus produces a non-desensitizing 
current. Application of 1 µM ACET was sufficient to block activation induced by EC50 
dose of glutamate (Figure 3.1B)  
 
3.3.2 ACET SIMILAR INHIBITS THE GLUK4 AND GLUK5 SUBUNITS 
 The GluK4 and GluK5 subunits can have drastically different pharmacology from 
the other KAR subtypes. They can be activated by ligands, such as AMPA, that GluK1 – 
GluK3 subunits cannot bind (Alt et al., 2004). Also, GluK4 and GluK5 are more sensitive 
to glutamate, given them the name of ‘high affinity’ KAR subunits (Heckmann et al., 
1996; Paternain et al., 1998; Barberis et al., 2008; Fisher and Mott, 2011, 2013). Thus, 
their incorporation into KAR subtypes can have drastic effects on the pharmacology of 
the whole KAR receptor. We previously, demonstrated that 1 µM of ACET was 
sufficient to reduce EC50 glutamate activation of GluK2-containing heteromers, although 
the inhibition of GluK2/K5 wildtype KARs current was more than in GluK2/K4 KARs. 
This difference in current inhibition in GluK4 versus K5 KARs was occluded when co-
expressed with a mutant GluK2, which lacked sensitivity to the EC50 glutamate dose. 
Next, we sought to determine whether the sensitivity of the GluK4- and GluK5-
containing KARs to ACET was similar. To test this, we conducted an ACET 
concentration curve, where increasing concentration of ACET were co-applied with an 




concentration in each cell. All data was normalized to the EC50 glutamate concentration 
alone. Results are reported as a measure of how much a particular drug (ACET or 
kynurenate) is needed to inhibit current amplitude by half (IC50). Analyses of wildtype 
GluK2, GluK2/4 and GluK2/5 receptors demonstrated that the IC50 of ACET was very 
different across the KAR subtypes (GluK2, IC50 = 126 ± 3 nM, n = 4; GluK2/K4, IC50 = 
71 ± 5 nM, n = 8; and GluK2/K5, IC50 = 29 ± 7 nM, n = 10, respectively) (Figure 3.2A). 
As shown above, wildtype GluK2/K5 heteromers have the highest sensitivity to ACET 
inhibition, followed by wildtype GluK2/K4 heteromers. As expected, GluK2 homomers 
were non-responsive to ACET inhibition until concentrations exceeding 1 µM. It is also 
important to note that ACET inhibition of the GluK2/K4 peak current plateaued at ~45% 
of the maximum glutamate response irrespective of increased ACET concentrations 
(Figure 3.2A). Thus, the difference in wildtypes GluK2/K4 and GluK2/5 sensitivity to 
ACET inhibition is more pronounced with higher concentrations of ACET (Figure 3.2A).  
Interestingly, the difference between GluK2/K4 and GluK2/K5 sensitivity to 
ACET inhibition was abolished when co-expressed with the mutated GluK2 subunit 
(GluK2(E738D)). ACET concentration-response curves for GluK2(E738D)/K4 and 
GluK2(E738D)/K5 were not statistically different. This was also supported by the 
similarities of their ACET IC50s: GluK2(E738D)/K4, IC50 = 112 ± 1 nM, n = 6; 
GluK2(E738D)/K5, IC50 = 64 ± 1 nM, n = 7 (Figure 3.2C). 
Steady-state current is achieved when there is equilibrium between the amount of 
receptors in the desensitized state and the open state. Thus, the amount of current remains 
constant in the presence of glutamate. ACET did not inhibit the steady-state current in 




current in GluK2(E738D)-containing heteromers was sensitive to ACET inhibition 
(Figure 3.1B).   
GluK2 homomeric KARs with a glutamine (Q) residue in the pore domain are 
subject to voltage dependent block by intracellular polyamines, which cause inward 
rectification of their current – voltage relationship. The ending result is that positive ions 
are hindered from leaving the cell even when the cell is depolarized to higher voltages. 
Cell that express heteromeric KARs do not experience inward rectification and allow ions 
to flow freely in or out of the cell in response to hyperpolarization or depolarization, 
respectively. To ensure that heteromeric receptors were expressed when we transfected 
with GluK2 and GluK4 or GluK5, we test for the lack of inward rectification. To test for 
the presence of rectification, we took the cell through a range of voltage steps (-90 mV - 
+70 mV) and measured the peak current in response to the EC50 glutamate. Results were 
plotted on a current (I) – volts (V) curve, where peak current for each step is averaged 
and normalized to the peak current at -90 mV. The presence of positive current indicates 
the lack of inward rectification and the successful expression of functional heteromeric 
KARs. In cell transfected with GluK2/K5 and GluK2/K4, we saw the presence of 
positive current when the cells were depolarized above 0 mV (Figure 3.2C). However, we 
saw a lack of positive current at higher voltage potential in cell transfected with GluK2 
homomers (Figure 3.2C).  
The glutamate EC50 for GluK2-containing homomers and heteromers and 
GluK2(E738D) have been previously described (Fisher and Fisher, 2014). Our glutamate 





Figure 3.2 The efficacy of ACET is similar at GluK4 and GluK5 KAR subunits. 
However this similarity is occluded when these subunits are incorporated with the GluK2 
subunit. 
A. Graph illustrating an ACET concentration curve. Peak amplitude of each current 
to concentration of ACET was normalized to the peak current response to 
glutamate application alone. The difference in ACET inhibition of wildtype 
GluK2/K4 to GluK2/K5 was abolished when the GluK2 subunit was mutated to 
be 1,000-fold less sensitive to glutamate.  
B. ACET (1 µM) does not inhibit steady state currents at wildtype GluK2/K4 or 
GluK2/K5 KAR receptors.  
C. Graph illustrating the I-V curve for cells transfected with GluK2 homomers and 
GluK2/K4 and GluK2/K5 heteromers. Cells transfected with heteromers 
GluK2/K4 and GluK2/K5 demonstrated reduced inward rectification compared to 
GluK2 homomers, and thus, confirms expression of heteromeric receptors.  
D. Glutamate EC50s are 330 µM (GluK2) and 8 µM (GluK2/K5). GluK2(E738D) is 






















































































































3.3.3 NETO1 ALTERS ACET INHIBITION  
Neto1 is an auxiliary protein to KARs. Neto1 alters the kinetics of GluK2-
containing receptors (Copits et al., 2011; Straub et al., 2011a; Fisher and Mott, 2013). As 
previously described, co-expressing Neto1 with GluK2/K5 KARs removes 
desensitization of the glutamate-induced current (Figure 3.3A). Co-application of ACET 

















































Figure 3.3 Neto1 enhances ACET inhibition of steady state GluK2/K5 currents 
A. Sample waveforms demonstrating that ACET (1 µM) inhibits steady state current 
at GluK2/K5 receptors only when Neto1 is present. 
B. Averaged data demonstrating that co-transfecting with Neto1 enhances ACET 
inhibition of steady state, but not peak current at GluK2/K5 receptors. We suggest 
that the steady state current remaining in the presence of ACET is mediated by 
activated GluK2 subunits. 
 
not expressing Neto1. Alternatively, we previously demonstrated that ACET did not 
inhibit the steady-state current in cells not expressing Neto1. However, when Neto1 is co-
expressed with GluK2/K5 receptors, ACET now inhibits the steady-state current (Figure 
3.3A, B). 
 
3.3.4 KYNURENATE INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS 
Kynurenate (KYN) is a non-selective glutamate antagonist. Among GluK2-
containing KARs, kynurenate preferentially inhibits the GluK2 subunit (Fisher and Mott, 
2011). Thus, when co-expressed with GluK2/K5 kainate receptors, coapplication of 
kynurenate with an EC50 concentration of glutamate yielded a non-desensitizing current. 
Representative waveforms illustrate that KYN dose-dependently inhibits the peak current 
amplitude of GluK2, GluK2/K4, and GluK2/K5 KARs induced by an EC50 dose of 
glutamate. In GluK2 homomers, the rapidly activating and desensitizing current is 
progressively inhibited by increasing concentrations of KYN (Figure 3.4A). GluK2/K4 
currents, although desensitizing slight slower, responded to KYN inhibition similarly to 





Figure 3.4 Kynurenate has distinct effects on GluK2/K4 and GluK2/K5 receptors 
A. Sample waveforms demonstrating that with increasing kynurenate (KYN) 
concentration, glutamate-activated current at GluK2 homomeric receptors is 
progressively inhibited. Increasing concentrations of kynurenate had a similar 
effect on GluK2/K4 receptors. Alternatively, at GluK2/K5 receptors, kynurenate 
inhibits peak current and strongly removes desensitization. 
B. Reduced inward rectification in IV-curves confirms expression of heteromeric 
GluK2/K4 and GluK2/K5 receptors. 
C. Graph illustrating a kynurenate concentration curve. Kynurenate inhibition of 
glutamate-induced currents was normalized to the peak current amplitude of 
glutamate application alone. Peak glutamate current at GluK2/K5 receptors is less 




























































concentrations, GluK2/K4 currents adopted a non-desensitizing receptor kinetic (Figure 
3.4A). KYN application had a distinguishing different effect on GluK2/K5 KAR kinetics. 
Increasing concentrations of KYN did inhibit the peak current amplitude, however, it 
more so removed desensitization (Figure 3.4A). A KYN concentration-curve, further 
demonstrates that GluK2 (IC50 = 345 ± 50 µM, n = 8) and GluK2/K4 (IC50 = 162 ± 15 
µM, n = 5) have similar sensitivities to KYN inhibition (Figure 3.4C). However, 
GluK2/K5 KARs (IC50 = 3857 ± 163 µM, n = 9) were less sensitive to KYN inhibition 
than the other GluK2-containing KARs (Figure 3.4C). These results agree with 
previously published data (Fisher and Mott, 2011). Additionally, the presence of 
heteromers in GluK2/K4 and GluK2/K5 transfected cells was confirmed by the lack of 
inward rectification (Figure 3.4B). 
 
3.3.5 NETO1 ALTERS KYNURENATE INHIBITION 
As described previously, incorporation of Neto1 into GluK2/K5 preparations 
removes desensitization of the glutamate-induced current. In wildtype GluK2/K5 
receptors, coapplication of 1 mM KYN with an EC50 dose of glutamate moderately 
suppresses the peak current amplitude (Figure 3.5A, B). However, the steady-state current 
is significantly increased (Figure 3.5A, C). When Neto1 is expressed with GluK2/K5 
KARs, KYN inhibits the peak current amplitude similarly to preparations without Neto1 
(Figure 3.5A, B). However, the steady-state current is now inhibited by 3 mM KYN. 
Thus, KYN reduces desensitization of GluK2/K5 receptors not expressed with Neto1 and 




KYN does not alter this steady-state/peak amplitude ratio when applied to GluK2/K5 
receptors with coexpressed Neto1 (Figure 3.5A, C).  
 
Figure 3.5 Neto1 occludes the effect of kynurenate on desensitization, but not 
inhibition 
A. Representative traces illustrating that co-transfected cells containing GluK2/K5 
with Neto1 occludes kynurenate removal of desensitization and allows inhibition 
of the steady-state current. 
B. Concentration curve comparing the relative kynurenate inhibition of GluK2/K5 ± 
Neto1 peak current amplitude. Co-transfection with Neto1 does not alter 
inhibition of GluK2/K5 peak current by kynurenate. 
C. Concentration curve illustrating the relative inhibition of GluK2/K5 ± Neto1 
steady state current. Co-transfection with Neto1 prevents inhibition of GluK2/K5 












































































3.3.6 USING ACET AND KYNURENATE AS PHARMACOLOGICAL TOOLS 
In the previous sections, we demonstrated that ACET inhibits the GluK5 and 
GluK4 KAR subunits in heteromers. Additionally, we confirmed that KYN preferentially 
does not inhibit the GluK5 KAR subunit in heteromers. Thus, we can use these drugs as 
pharmacologic tools to selectively activate or inhibit specific receptors subunits in the 
GluK2/K5 heteromer. To test the effectiveness of these tools, we sought to verify the 
receptor occupancy model for KARs. The receptor occupancy model states that 
desensitization occurs when three or more subunits are activated. If only two or less 
KARs are activated, the receptor can open, but will not desensitize (Fisher and Mott, 
2011; Fisher and Fisher, 2014; Reiner and Isacoff, 2014). Application of an EC50 
glutamate dose allowed GluK2/K5 receptors to rapidly open and desensitize, as 
illustrated previously. Co-application with 3 mM kynurenate, preferentially inhibits the 
GluK2 subunits, leaving the GluK5 subunits to open the receptor to a non-desensitizing 
current. Consecutively, co-applying 1 µM ACET inhibited the remaining predominately 
GluK5-mediated current (Figure 3.6A). Steady-state was measured across conditions (10 
µM glutamate alone, 3 mM KYN, and 3 mM KYN + 1 µM ACET) and normalized to the 
condition with the maximum steady-state current (KYN). Averaged data demonstrates 
that the steady-state current was significant reduced in the glutamate alone (26 ± 1%, n = 
5) and KYN + ACET (1 µM: 23 ± 4.5%, n = 5; 10 µM: 8.3 ± 1.7%, n = 5; p < 0.05) 
condition compared to the KYN condition.  
 We determined that activation of the GluK5 subunit is sufficient to open the 
receptor. Next, we wanted to determine whether activation of the GluK2 subunit is 





Figure 3.6 Occupancy of either the GluK2 or GluK5 subunits can activate 
GluK2/K5 receptors 
A. Sample waveforms (left) and bar graph (right) illustrating that kynurenate (3 mM) 
removed desensitization at GluK2/K5 receptors, and consequently enhances the 
steady state current. ACET (1 µM) inhibits this steady state current. Bar graph 
(right) illustrates the amplitude of the steady state current for each condition 
normalized to the condition with the maximum steady state amplitude (3mM 
kynurenate alone). 
B. Sample waveform (left) and bar graph (right) illustrating that co-application of 
ACET (10 µM) with glutamate (300 µM) enhances the steady state current and 
the addition of KYN (3 mM) inhibits this steady state current. Bar graph (right) 
illustrates the steady state current amplitude for each condition normalized to the 
condition with the maximum steady state current (10μM ACET). 
 
µM) to ensure sufficient activation of the GluK2 subunits. The GluK2 subunit is less 
sensitive to glutamate activation than the GluK2/K5 subunit. Thus, more glutamate is 
needed to ensure sufficient binding of the GluK2 subunit. Perfusion of 300 µM glutamate 
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dose chosen to maximally inhibit the GluK5 subunits with minimal inhibition of the 
GluK2 subunits), open the GluK2/K5 KAR to a non-desensitizing current. Consecutive 
application of 3 mM KYN with 10 µM ACET completely inhibited GluK2/K5 current. 
The steady-state current was significantly reduced in the 300 µM glutamate alone (14 ± 
7%, n = 5, p < 0.05) and 10 µM ACET + 3 mM KYN condition (26 ± 1%, n = 5, p < 
0.05) compared to the ACET condition.   
3.3.7 ACET INHIBITS KAINATE – MEDIATED SYNAPTIC TRANSMISSION  
 The GluK4 and GluK5 subunits are necessary for kainate receptor synaptic 
transmission at the mossy fiber – CA3 synapse (Fernandes et al., 2009). Thus, we 
hypothesized that ACET will inhibit kainate receptor fEPSPs at this synapse. Field 
EPSPs were evoked by stimulating mossy fibers extending from the dentate gyrus 
pyramidal cell layer and recording synaptic field potentials in CA3 stratum lucidum. The 
KAR component of the fEPSP was isolated with an antagonist cocktail: 50 µM GYKI 
53655, 10 µM MK801, 50 µM picrotoxin, and 1 µM CGP 5585, and resembled the slow 
fEPSPs as previously described (Castillo et al., 1997) (black trace, Figure 3.7A,B). 
Concurrent perfusion of 1 µM ACET significantly and completely blocked the KAR 
fEPSP (red trace, 6.6 ± 4.8%, n = 8 p < 0.05), Figure 3.7A,B). Averaged data was 
represented as a bar graph, where the peak amplitude was normalized to the fEPSPs 






Figure 3.7 ACET blocks kainate receptor synaptic transmission at mossy fiber – 
CA3 synapses. 
A. Sample waveform of KAR fEPSPs (black trace) isolated by perfusing an 
antagonist cocktail (50 µM GYKI 53655, 10 µM MK801, 50 µM picrotoxin, and 
1 µM CGP 55845). Adding 1 µM ACET to the perfusing antagonist cocktail 
completely inhibited the KAR EPSPs.  
B. Bar graph of averaged data normalized to the KAR fEPSPs. ACET significantly 





In the present study, we used whole cell electrophysiology on cells transfected 
with various GluK2-containing KARs to determine whether ACET and/or kynurenate can 
be used as pharmacological tools to delineate specific subunit contribution to KAR 




GluK4 and GluK5 subunits, and KYN preferentially does not inhibit the GluK5 subunit. 
Furthermore, we demonstrated that ACET inhibits KAR – mediated synaptic current in 
the brain, specifically the mossy fiber – CA3 synapse. These drugs can be used as 
pharmacological tools to distinguish GluK2 subunit contribution from KAR current from 
the GluK5 subunit.   
 
3.4.1 INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS BY ACET 
ACET is a willidarine compound originally characterized as a GluK1 antagonist 
(Jane et al., 2009). However, doubts about ACET being a selective drug for GluK1 has 
surfaced. One reason for recent suspicion is that other compounds within the ACET 
family and with a similar structure, have demonstrated a more promiscuous ligand 
affinity than for the GluK1 subunit alone. One such compound was the drug UBP310 
(Pinheiro et al., 2013). Pinheiro et al., described quite convincingly that UBP310 can 
inhibit current at GluK2/K5 currents in cultured cells and acute brain slices (Pinheiro et 
al., 2013). Here we describe that ACET, similar to UBP310, also has a more promiscuous 
ligand affinity than previously thought and inhibits glutamate current at GluK2/K5 
receptors. We took it a step further and characterized another GluK2-containing 
heteromer, GluK2/K4. Our results demonstrated that not only is the GluK2/K5 receptor 
sensitive to ACET inhibition, but also GluK2/K4 receptors. Furthermore, by mutating the 
GluK2 subunit, we determined that ACET inhibition of GluK2-containing heteromers 




Interestingly, ACET inhibition at GluK2/K4 wildtype receptors plateaued around 
45% of the maximum glutamate response, such that higher concentrations of ACET did 
not produce additional inhibition of the GluK2/K4 current. The reason for the plateau 
could be that the GluK4 is fully inhibited (as indicated by the GluK2(E738D)/K4 
concentration-curve), however the remaining current is mediated by the GluK2 subunit. 
An alternative explanation is that ACET may act as a partial agonist. Partial agonists 
have partial efficacy at the receptor relative to a full agonist. They are often confused 
with competitive antagonists because partial agonists can compete with full agonists for 
receptor binding sites and produce a net reduction in receptor activation. Future studies 
are needed to determine whether ACET is in fact a partial agonist. Our results suggest 
that ACET is not a specific GluK1 antagonist, but should be considered more of an 
inhibitor of most KARs (there is no data available on ACET inhibition of GluK3 KARs) 
except at GluK2 subunits. 
We also examine the impact of the auxiliary subunit Neto1 on the ACET 
inhibition of GluK2/K5 current. Neto1 is an auxiliary protein known to bind to KARs in 
the brain and recombinant cells (Tang et al., 2011). Neto1 has a role in incorporation of 
KARs to the synapse and alters for KAR synaptic transmission (Copits et al., 2011; 
Straub et al., 2011a). In recombinant cells, Neto1 has little impact on surface expression 
of recombinant KARs. However, Neto1 does change receptor kinetics (Fisher and Mott, 
2012, 2013). Co-expression of Neto1 shifts the concentration dependent for the onset of 
desensitization towards higher levels of glutamate, but does not change the glutamate 
EC50 for GluK5-containng subunits (Fisher and Mott, 2013). Thus, at the glutamate EC50 




rapidly desensitizing current to a non-desensitizing current, as previously reported (Fisher 
and Mott, 2013). In the present study, we demonstrate that the presence of Neto1 does not 
significantly change ACET inhibition of GluK2/K5 peak current. However, the presence 
of Neto1 did alter how ACET inhibited the heteromeric current. ACET did not inhibit the 
remaining steady-state current in the absence of Neto1. However, in the presence of 
Neto1, ACET inhibited the steady-state current. It is our suggestion that ACET does not 
bind to the desensitized conformation of GluK2/K5 heteromeric receptor. Thus, in 
preparations when Neto1 is absent and the GluK2/K5 receptors are allowed to undergo a 
desensitized conformation, ACET will inhibit the GluK2/K5 peak current when the 
receptors are predominantly in an open/activated conformation. However, ACET did not 
inhibit the steady state GluK2/K5 current when majority of the GluK2/K5 receptors are 
in the desensitized conformation. Alternatively, when Neto1 is co-expressed with 
GluK2/K5 receptors, the GluK2/K5 receptor is prevented from undertaking a 
desensitized conformation, and now ACET can inhibit both the peak and steady state 
current. These results suggest that ACET may have bias towards the physical 
conformation of GluK5-containing kainate receptors.  
Another cause for suspicion on the subunit selectivity of ACET, is that ACET 
produced inhibition of kainate mediated mossy fiber – CA3 EPSPs (Dargan et al., 2009). 
Interestingly, GluK1 is not expressed at detectably levels on CA3 pyramidal cells, and 
thus, does not contribute to kainate mediated mossy fiber – CA3 EPSPs (Bahn et al., 
1994; Bureau et al., 1999; Paternain et al., 2000). These results produced confusion about 
the function of KARs in the brain. We submit that the previous confusion was stemmed 




recombinant cells demonstrate that ACET inhibits current at heteromeric receptors 
containing either GluK4 or GluK5 subunits. Both GluK4 and GluK5 subunits are 
expressed at high level postsynaptically on CA3 pyramidal cells (Bahn et al., 1994), and 
they are required for kainate-mediate current at that synapse (Fernandes et al., 2009). 
Thus, our results provide further reasoning that postsynaptic KARs located on CA3 
pyramidal neurons are composed of GluK4 and GluK5 subunits.  
Additionally, we discovered in our own hands that ACET completely blocks 
kainate mediated EPSPs at mossy fiber – CA3 synapses. This was quite interesting to us, 
because although we expected ACET to reduce KAR EPSPs at this synapse, we did not 
expect a complete blockage of this KAR EPSPs. Glutamate released from presynaptic 
terminals can reach concentrations of ~ 1mM before rapidly declining (Clements et al., 
1992; Clements, 1996; Diamond and Jahr, 1997). Majority of our data in this paper used 
the EC50 dose of 10 µM glutamate. This concentration is sufficient to activate the GluK5 
subunits; however, it is 30 fold less than the EC50 glutamate concentration for the GluK2 
subunit. Thus, most of the current is produced as a result of glutamate binding to the 
GluK5 subunit, in which 1 µM ACET produced a pronounced inhibition of the current. 
However, when glutamate concentration was increased (300 µM glutamate) equivalent to 
the EC50 for the GluK2 subunit and allowing sufficient activation of the GluK2 subunit, 1 
µM ACET produced much less inhibition of the peak GluK2/K5 current (Figure 3.6B).  
We suggest that these seemingly contradictory data between ACET inhibition of the 
recombinant and brain slice KAR responses is an extension of ACET bias for the 
open/activation confirmation over the desensitized conformation. At the synapse, 




desensitized conformation (deactivation). However, in our preparations the onset and 
duration (5 seconds) of applied glutamate is slow compared to the synapse, and allows 
sufficient time for KAR desensitization. Indeed, other studies have demonstrated with 
similar antagonist to ACET (UBP310), that rapidly applying glutamate allows UBP310 to 
inhibit the GluK2/K5 response significantly more than with prolonged application of 
glutamate (Pinheiro et al., 2013). Another potential explanation is that higher-affinity 
GluK5 subunits contribute to the rapid activation of GluK2/K5 heteromeric receptors 
even at high glutamate concentrations, while during prolonged glutamate application the 
binding of lower-affinity GluK2 subunits (which are insensitive to ACET and UBP310) 
to glutamate contributes more to the GluK2/K5 heteromeric current. 
 
3.4.2 INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS BY KYNURENATE 
Kynurenate is a nonselective competitive antagonist of glutamate receptors. 
Previous studies have reported that kynurenate has a substantially higher affinity for 
GluK2 than GluK5 subunits (Fisher and Mott, 2011). However, it is not known whether 
kynurenate can inhibit currents at GluK2/K4 heteromers nor whether the presence of 
Neto1 alters kynurenate inhibition of KAR current. At a concentration that blocked 
current at GluK2 homomers, our findings demonstrate that kynurenate produced little 
inhibition of peak current and removed desensitization from GluK2/K5 receptors. These 
results are consistent with previously reported data (Fisher and Mott, 2011). We further 
characterized kynurenate inhibition of GluK2/K4 receptors. Kynurenate dose 




receptors, kynurenate did not substantially increase the steady-state current. The resulting 
kinetics of kynurenate inhibition resembled kynurenate inhibition of GluK2 homomers. 
We do not know why there is such qualitative difference in receptor kinetics between the 
GluK2/K4 and GluK2/K5 receptors when kynurenate is applied. One suggestion is that 
the GluK4 subunit appears to make greater contribution to desensitization (Mott et al., 
2010), and can desensitize to glutamate activation in and of itself (Fisher and Fisher, 
2014).  
We also examined whether co-expression with Neto1 alters kynurenate inhibition 
of KAR current. Similarly to our previous data with ACET, the presence of Neto1 did not 
alter GluK2/K5 sensitivity to kynurenate inhibition. However, it did alter the kinetics of 
the receptor once kynurenate was applied. As reported earlier, kynurenate potentiated the 
GluK2/K5 steady-state current (Fisher and Mott, 2011). Co-expression of Neto1 removed 
desensitization and allowed kynurenate to inhibit the steady-state current.  
 
3.4.3 FUNCTIONAL SIGNIFICANCE OF PHARMACOLOGICAL TOOLS FOR KAINATE 
RECEPTORS 
 KARs contribute to synaptic integration at glutamate synapses (Frerking and 
Ohliger-Frerking, 2002).  Specifically, GluK2/K5 receptors are known to constitute a 
major population of KARs in the brain: both subunits are abundantly co-expressed in the 
cerebellum, neocortex, striatum, amygdala, and hippocampus, at higher levels than other 
KAR subunits (Bureau et al., 1999). The lack of pharmacological tools has hindered our 




knockout animals, have shown that GluK5 subunits are required for proper function of 
synaptic KARs and contribute to their slow kinetics (Contractor et al., 2003; Barberis et 
al., 2008; Fernandes et al., 2009). However, congenital knockouts are not site or region 
specific and remove presynaptic KARs. Additionally, congenital knockouts may undergo 
receptor compensation and not represent KAR function in the normal brain. It would 
therefore be of great value to be able to directly test the implication of KARs in synaptic 
integration and information transfer in CA3 pyramidal cells.  
Based on our results we identified ACET and kynurenate as potential 
pharmacological tools to elucidate the relative function of GluK2 and GluK5 receptors at 
GluK2/K5 heteromers. Previous studies observed that glutamate binding of GluK5 
subunits activated GluK2/K5 channels and subsequent activation of the GluK2 subunit 
desensitizes the receptor (Fisher and Mott, 2011). They concluded that the GluK2 subunit 
intrinsically desensitized the receptor. However, it is not known whether the GluK2 
subunit can open the GluK2/K5 receptor to a non-desensitizing current. We identified 
ACET as a drug selective for the GluK4 and GluK5 subunits in GluK2-containing 
heteromers. Additionally, we identified kynurenate as a glutamate antagonist that 
preferentially inhibits the GluK2 subunits. Thus, we used both ACET and kynurenate to 
determine whether the GluK2 or the GluK5 subunits are intrinsically unique in their 
functional role in desensitizing the receptor. Applying 10 µM ACET inhibited glutamate 
binding to the GluK5 subunits, and thus glutamate binding to only the GluK2 subunits 
was sufficient to open the heteromeric receptor to a non-desensitizing current. The 
remaining current was sensitive to 3 mM kynurenate inhibition, suggesting the remaining 




Furthermore, applying 3 mM kynurenate to GluK2/K5 receptors exposed to 300 µM 
glutamate (an EC50 for the GluK2 subunit) produced a non-desensitizing current as 
previously described in this study and other publications (Fisher and Mott, 2011). 
Concurrent application of 1 µM ACET inhibited the remaining current, suggesting that 
the remaining current was mediated predominantly by glutamate binding to the GluK5 
subunit. Our results indicate that either GluK2 or GluK5 subunits can open the KAR 
channel, while binding of the other can initiate desensitization. Thus, we propose that 
KAR desensitization requires three or more subunits to bind to glutamate regardless of 
the subunits activated. Additionally, we observed that glutamate binding to either the 
GluK2 or the GluK5 subunits is sufficient to open KAR receptors. Thus, ACET and 
kynurenate can be used as pharmacological tool to differentiate subunit contribution to 





MUSCARINIC AND DOPAMINERGIC RECEPTOR REGULATION OF KAINATE 




 Muscarinic acetylcholine receptors (mAChRs) play a critical role in synaptic 
plasticity and neuronal excitability (Dodd et al., 1981). In the hippocampus, they are 
important for modulating learning and memory in the hippocampus (Power et al., 2003). 
There are five types of mAChR, M1 – M5 (Bonner, 1989), all of which, except M5 
mAChRs, can be found at different levels of expression in area CA3 in the hippocampus 
(Volpicelli and Levey, 2004) where they are co-expressed with kainate receptors. One 
way mAChRs influence the synaptic network is by modulating the function of glutamate 
receptors. Both NMDA and AMPA receptors have been shown to be susceptible to 
mAChR modulation (Marino et al., 1998; Lu et al., 1999; Grishin et al., 2005; Dickinson 
et al., 2009; Nomura et al., 2012). Specifically, NMDA receptor currents in CA3 
pyramidal neurons are reduced by activation of M1 mAChRs through a mechanism 
proposed to involve a calmodulin-activated tyrosine phosphatase (Grishin et al., 2005). 
Additionally, M1 mAChRs induce long-term depression of hippocampal AMPA receptor 
activity through protein kinase C (PKC) mediated phosphorylation of specific AMPAR 




localization protein) and subsequent removal of AMPARs from the synapse (Dickinson 
et al., 2009). Although we know that NMDAR and AMPARs can be modulated by M1 
mAChRs, it is not known whether M1 mAChRs can alter KAR activity in the brain.  
 There are several lines of evidence to suggest that M1 mAChRs can modulate 
KAR activity in the brain. Dysfunctional interactions between KARs and mAChRs have 
been demonstrated in a number of neurological diseases, including temporal lobe 
epilepsy (Frucht et al., 2000). For example, injection of a mAChR agonist (pilocarpine) 
in rodents induces prolonged seizures and epilepsy (Cavalheiro et al., 1991), which can 
be blocked by a KAR antagonist (Smolders et al., 2002). Also, previous studies have 
reported that M1 mAChRs can increase KAR current in recombinant cells (Benveniste et 
al., 2010). Although these studies were not conducted in brain tissue, it does validate the 
potential for KAR and M1 mAChR interaction. As stated earlier, M1 mAChRs are 
GPCRs and elicits modulatory effects through phosphorylation cascades and second 
messenger systems (Felder, 1995). KAR subunits can be phosphorylated, which can 
affect both KAR channel conductance and KAR trafficking to and away from the synapse 
(Cho et al., 2003; Park et al., 2006; Selak et al., 2009; Rojas et al., 2013). 
Phosphorylation sites for PKC have been found on the GluK2 and GluK5 subunits (Rojas 
et al., 2013). However, it remains unclear whether M1 mAChRs can alter KAR activity in 
the hippocampus or whether this can be mediated through a PKC phosphorylation-
signaling cascade.  
 In this study we sought to determine whether M1 mAChRs alters KAR activity in 
the hippocampus. We evaluated this question at the mossy fiber – CA3 synapse because 




that, similarly to NMDAR at the same synapse, activation of M1 mAChRs will depress 
KARs at the mossy fiber – CA3 synapse. Furthermore, we suspect this M1 mAChR 
mediated depression will be mediated through a PKC phosphorylation signaling cascade.   
 
4.2 MATERIALS AND METHODS 
 
4.2.1 BRAIN SLICES PREPARATION 
Hippocampal slices were made from postnatal day (P) 21 – P28 and P45 – P60 
Sprague-Dawley rats as described previously (Iyengar and Mott, 2008). Briefly, animals 
were deeply anesthetized with isoflurane and decapitated with a guillotine. The brain was 
removed under ice-cold (4ºC), sucrose-based ‘cutting’ artificial cerebrospinal fluid 
(aCSF) that contained (in mM): 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 248 
sucrose, 0.5 CaCl2, and 5 MgSO4 (350mOsm). The use of this solution during the cutting 
process enhances neuronal survival by limiting excessive excitation. Transverse slices 
were made with a vibratome (Leica VT1000S, Nussloch, Germany) at 500 µM and 
incubated for at least one hour at room temperature in aCSF containing (in mM): 125 
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2, 5 MgSO4, 20 µM D-
AP-5, and 1 mM kynurenate (305 mOsm; pH=7.4). Both the sucrose-based and standard 






4.2.2 FIELD POTENTIAL ELECTROPHYSIOLOGY 
 After 1 hour, individual slices were transferred to a submersion chamber 
maintained at 32 – 34 ºC, held in place by a bent piece of platinum wire resting on the 
surface of the slice, and perfused continuously at 3 – 4 ml/min with recording aCSF 
containing (in mM): 125 NaCl, 2.01 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 2 
CaCl2, 1 MgSO4. Glass electrodes were pulled from borosilicate glass to achieve 2 – 3 
MΩ and filled with recording aCSF. Extracellular dendritic field potentials recording 
were made from the stratum lucidum of the CA3 region of the hippocampus, which was 
visually identified with a light microscope. Synaptic currents were evoked with a 
monopolar platinum-iridium glass electrode positioned in the stratum lucidum. For 
AMPA-fEPSPs recordings, we recorded composite MF-fEPSPs, which were primarily 
composed of AMPA-fEPSPs (~ 93%) (Contractor et al., 2003), with aCSF containing 10 
µM MK-801, 50 µM picrotoxin, and 1 µM CGP 55845 to block NMDA, GABAA, and 
GABAB receptors, respectively. We defined synaptic currents as MF-fEPSPs if they 
showed characteristically large paired-pulse facilitation (Salin et al., 1996), had a rapid 
rise time and short latency, and were inhibited by >70% by the group II-selective 
metabotropic glutamate receptor (mGluR) agonist (2S,2’R,3’R)-2-(2’3’-
Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM), which was bath applied at the end of 
some experiments. To isolate KA-fEPSPs recordings, we recorded from CA3 pyramidal 
cells in the presence of the aCSF containing the AMPA antagonist GYKI53655 (50 µM) 
in addition to the GABAA, GABAB and NMDA receptor antagonist cocktail. Once KAR-
fEPSPs were isolated, a four pulse train stimuli (100 Hz, 0.1 ms/stumulus, cathodal, 




monopolar, platinum-iridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced 
to the bath ground. KAR-fEPSPs were stable for a minimum of 20 min. prior to 
pilocarpine (300 nM) perfusion onto the slice for 10 – 15 min. to activate predominately 
M1 mAChRs. In experiments were M1 mAChRs or PKC were inhibited, telenzepine 
(100 nM) or chelerythrine (5 µM) respectively were applied concurrently with AMPA, 
GABAA, GABAB, and NMDA antagonists. To resolve small KAR-fEPSPs that were 
obscured by stimulation artifacts, we digitally subtracted a “template” stimulation trace 
that was acquired after application of an AMPA/KAR antagonist (CNQX, 50 µM) at the 




4.3.1 KAINATE RECEPTOR SYNAPTIC TRANSMISSION IS DEPRESSED BY MACHR 
ACTIVATION 
 Muscarinic receptors have been shown to affect the function of AMPA and 
NMDA glutamate receptors. However, it is not known whether muscarinic receptors can 
regulate the function of kainate receptors. To test this question, we used the drug 
pilocarpine. Pilocarpine is a M1 preferring mAChR agonist. Previous studies have 
demonstrated that mAChR activation with pilocarpine can alter KAR currents in oocytes 
and KAR-dependent excitability in mossy fibers (Benveniste et al., 2010). Here, we 




agonist that preferentially binds to M1 mAChRs, produced a depression in KAR fEPSPs 
at the mossy fiber – CA3 synapse (Pilo: 63.6 ± 6.9% of baseline fEPSP amplitude, n = 8, 
p < 0.05) (Figure 4.1A). We previously demonstrated that ACET (1 μM), a previously 
characterized GluK1 KAR subunit – selective antagonist, inhibits current at heteromeric 
receptors containing either the GluK4 or GluK5 subunits (Chapter 3). Additionally, we 
demonstrated that ACET (1 μM) was sufficient at completely inhibiting KAR current at 
the mossy fiber – CA3 synapse (Chapter 3). Thus, we applied ACET (1 μM) after each 
experiment as a control to verify that we were measuring the KAR fEPSP. Any further 
depression induced by ACET application indicated the remaining KAR fEPSPs. After 
pilocarpine administration, ACET (1 μM) application completely blocked the KAR 
fEPSP, such that a competitive AMPA/KAR antagonist (CNQX, 50 μM) did not produce 
any additional inhibition of the KAR fEPSP current (Figure 4.1A). Thus, by using both 
controls (ACET and CNQX) we are confident that we measured the KAR fEPSP in its 
entirety.  
 There a several ways mAChRs can modulate KAR fEPSPs. Muscarinic 
acetylcholine receptors, specifically M1, co-localize with KARs on CA3 pyramidal 
neurons. There are two potential ways these receptors can interact. Activation of 
mAChRs can either 1) initiate a G-protein to begin a signaling cascade that would 
eventually cause phosphorylation of the KARs, or 2) directly binding to KARs. Both of 
these scenarios are a direct postsynaptic mechanism and require mAChRs and KARs to 
be co-localized. Alternatively, mAChRs could affect KAR fEPSPs by affecting the 
amount of glutamate released from presynaptic terminals. If activation of mAChRs 




reduced because less glutamate is binding to KARs postsynaptically. This scenario does 
not require mAChRs to be co-localized with KARs, and thus, is an indirect presynaptic 
mechanism by which activation of mAChRs can affect KAR fEPSPs. To determine 






Figure 4.1 mAChR activation depresses kainate, but not AMPAR-mediated fEPSPs 
A. A graph illustrating the peak amplitude of KAR fEPSP as it changes over time as 
a result of drug application. Trains were evoked by stimulation of the mossy fiber 
– CA3 pathway. Application of pilocarpine (300 nM) depresses the kainate 
fEPSP. ACET (1 µM), a drug we previously characterized as an antagonist at 
GluK4 and GluK5 receptors, completely inhibited the KAR-fEPSP, as verified by 
an AMPA/KAR antagonist (CNQX, 50 µM)  
B. Pilocarpine (300 nM) does not depress the AMPA fEPSP. Subsequent application 
of CNQX (50 μM) completely block synaptic transmission, confirming the 
presence of AMPA receptors.  
C. Bar graph illustrating peak amplitude for KAR and AMPA fEPSP normalized to 
the peak amplitude recorded during baseline. Pilocarpine significantly depresses 
the kainate, but not the AMPA fEPSP measured after 10 min. of pilocarpine 
application.  
 
or presynaptic, we tested whether the AMPA fEPSP is also affected by mAChR 
activation. To isolate the AMPA fEPSPs, we perfused an antagonist cocktail (same as 
Chapter 3) to block NMDA, GABAA, GABAB, and KAR synaptic transmission 
throughout the experiment (Figure 4.1B). Application of pilocarpine (300 nM) did not 
inhibit the AMPA fEPSP (Pilo: 100.9 ± 9.7% of baseline fEPSP amplitude, n = 7, p < 
0.05). Subsequent application of CNQX (50 μM) served as a control and completely 
inhibited the AMPA fEPSP. The inhibition of KAR fEPSPs by pilocarpine (300 nM) was 
significantly more than AMPA fEPSPs. 
 
4.3.2 MACHR DEPRESSION OF KARS IS A FORM OF SHORT-TERM PLASTICITY 
 Next we wanted to determine whether this mAChR – induced depression of KAR 





Figure 4.2 mAChR depression of KAR is short term 
A. Pilocarpine (300 nM) transiently depresses the kainate fEPSP. 
B. Pilocarpine (300 nM) significantly depresses the kainate fEPSP, but not 45 
minutes after pilocarpine is washed out. 
 
in the way one neuron communicates with another neuron. This change in 
communication can persist longer than 1 hour (long-term plasticity) or less than 1hour 
(short-term plasticity). Both forms of plasticity have important implication in the brain 




hippocampus causes significant deficits in learning and memory (Morris et al., 1986; 
Silva et al., 1996). To test which form of synaptic plasticity is exemplified, we applied 
pilocarpine (300 nM) as previously described. Then, we washed out the pilocarpine for 
45 minutes and recorded the KAR fEPSP amplitude as a percent to the baseline 
amplitude (Figure 4.2A). Pilocarpine (300 nM) produced a similar depression to KAR 
fEPSPs as we reported previously (Pilo: 60.0 ± 4.3% of baseline fEPSP amplitude, n = 5, 
p < 0.05). However, this depression went away as pilocarpine (300 nM) was washed out 
(Washout: 108.7 ± 5.5% of baseline fEPSP amplitude, n = 5, p < 0.05). Thus, the 
mAChR depression of the KAR fEPSP did not last longer than 1hour, and resembles a 
short-term plasticity. Subsequent application of ACET (1 µM) and CNQX (50 µM) 
produced complete inhibition of the measured KAR fEPSP. As stated previously, 
pilocarpine (300 nM) induced a significant depression of KAR fEPSPs. However, the 
KAR fEPSP amplitude was not significantly different from baseline 45 min. after 
pilocarpine (300 nM) application (washout) (Figure 4.2B). 
 
4.3.3 ACTIVATION M1 MACHRS DEPRESS KAR FEPSPS AT MOSSY FIBER – CA3 
SYNAPSES 
 Our previous data demonstrated that activation of mAChRs transiently depresses 
KAR fEPSP at mossy fiber – CA3 synapses through a direct postsynaptic mechanism. 
The next step in elucidating this mechanism is to determine the mAChR necessary for 
KAR fEPSP depression. Pilocarpine at low concentrations is considered an M1 preferring 




pyramidal neurons (Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al., 
1997; Scarr et al., 2007). Thus, we sought to determine whether M1 mAChRs are  
 
Figure 4.3 M1 mAChRs mediate the pilocarpine-induced depression of KAR 
fEPSPs 
A. Telenzepine (100 nM), an M1 mAChR antagonist, prevents pilocarpine-induced 
depression of KAR fEPSPs at mossy fiber – CA3 synapses. 
B. There is no significant difference in KAR fEPSP amplitude in the presence of 
telenzepine (100 nM) with or without pilocarpine (300 nM) co-application.  
 
responsible for the pilocarpine – induced depression of KAR fEPSPs. To test this, we 




antagonist (telenzepine, 100 nM) for a minimum of 15 min before administering 
pilocarpine (300 nM). In the presence of telenzepine (100 nM), pilocarpine (300 nM) 
failed to depress the KAR fEPSP (Figure 4.3A). The presence of a KAR fEPSP was 
verified by complete inhibition of synaptic transmission by subsequent applications of 
ACET (1 µM) and CNQX (100 µM). A bar graph illustrates that neither application of 
telenzepine (100 nM) nor co-application of telenzepine (100 nM) and pilocarpine (300 
nM) produced significant inhibition of the KAR fEPSP amplitude as compared to 
baseline KAR fEPSP amplitude prior to telenzepine (100 nM) application (97.9 ± 4.7%, n 
= 7) (Figure 4.3B).  
 
4.3.4 PKC PHOSPHORYLATION IS NOT REQUIRED FOR MACHR – INDUCED 
DEPRESSION OF KAR FEPSPS 
 We discovered earlier that M1 mAChRs depresses KAR fEPSPs more than likely 
through a postsynaptic mechanism. One potential mechanism is by M1 mAChRs eliciting 
a G-protein mediated second messenger signaling cascade resulting in the 
phosphorylation of KARs. M1 mAChRs can coupled to Gαq and are thought to initiate a 
second messenger cascade involving protein kinase C (PKC). To test whether PKC 
phosphorylation is necessary for M1 mAChR – induced depression of the KAR fEPSPs, 
we bath applied a PKC inhibitor (chelerythrine. 5 µM) at least 15 min. prior to and during 
pilocarpine (300 nM) application (Figure 4.4 A,B). In the presence of chelethryine (5 
µM), pilocarpine still depressed the average KAR fEPSP amplitude to levels similar to 
that of pilocarpine application alone (67.9 ± 13.7%, n = 6). However, the depression in 




KARs may not be fully responsible for M1 mAChR depression of KAR fEPSPs. 
Subsequent bath application of ACET (1 µM) and CNQX (100 µM) verified the presence 
of KAR fEPSPs.  
 
 
Figure 4.4 mAChRs depression of KARs is not mediated through PKC 
A. Chelerythrine (5 μM), a PKC inhibitor, does not prevent pilocarpine-induced 
depression of KAR fEPSPs at mossy fiber – CA3 synapses.  
B. Pilocarpine (300 nM) depression of KAR fEPSPs is not significant in the presence 







4.3.5 M1 MACHR DEPRESSION OF KAR FEPSP IS DEVELOPMENTALLY REGULATED 
Kainate receptor expression and function is fundamentally different in the 
adolescent brain than the adult brain (Bahn et al., 1994). All data collected previously 
was using adolescent aged rats (P21 – P28). However, it is not known whether this 
regulation changes during further development. Thus, we examined whether this same 
phenomenon (M1 mAChR activation depresses KAR fEPSP) happens in an ‘adult’ aged 
brain. In this experiment, we used rats aged P65 – P80. The experimental set up was  
 
Figure 4.5 mAChR depression of KARs is developmentally regulated 
A. Pilocarpine (300 nM) fails to depress the kainate fEPSP in 65 days old rats. 
B. Pilocarpine (300 nM) significantly suppresses kainate fEPSP in 22 days old rats, 






identical to previous experiments by isolating the KAR fEPSP with an antagonist 
cocktail. Then, we recorded a minimum of 20 min. of stable baseline (Figure 4.5A). Bath 
application of pilocarpine (300 nM) did not depress the KAR fEPSP. Subsequent bath 
application of ACET (1 µM) and CNQX (100 µM) confirmed the presence of KAR 
synaptic transmission. A bar graph illustrates that pilocarpine (300 nM) application 
significantly depressed the KAR fEPSPs in “adolescent” rat brains (22 days); however, 
pilocarpine (300 nM) failed to produce a significant depression of KAR fEPSPs in the 
“adult” rat brain (65 days) (87.6 ± 5.3%, n = 5).  
 
4.3.6 D1-LIKE DOPAMINE RECEPTORS DO NOT ALTER KAR FEPSP AT THE MOSSY 
FIBER – CA3 SYNAPSE 
 
 Dopamine receptors (DARs) are another GPCR with important modulatory 
affects in the brain (Ehringer and Hornykiewicz, 1960; Robinson and Berridge, 1993; 
Goto and Grace, 2007; Del Campo et al., 2011; Lodge and Grace, 2011). DARs are 
separated into two groups based upon the G protein in which they associate: D1 and D5 
DARs (D1-like) couple to Gs proteins and stimulate adenylate cyclase activity, leading to 
PKA phosphorylation, while D2, D3, and D4 DARs (D2-like) couple to Gq proteins and 
inhibit adenylate cyclase activity. Specifically, the D1 DARs in the hippocampus are 
necessary for learning and memory (Huang and Kandel, 1995; Lemon and Manahan-
Vaughan, 2006; Bethus et al., 2010; Clausen et al., 2011; da Silva et al., 2012). Previous 





Figure 4.6 Activation of D1-like dopamine receptors did not alter KAR fEPSP 
Activation of D1-like (D1 and D5) dopamine receptors (SKF38393, 50 µM) did 
not alter KAR fEPSPs at the mossy fiber – CA3 synapse. Subsequent bath 
application of ACET (1 µM) and then CNQX (100 µM) verified the presence of 
KAR potentials and the lack of AMPAR potentials.  
 
such as NMDAR and AMPAR, through either a classical PKA-mediated second 
messenger signaling pathway or a direct protein-protein interaction (Price et al., 1999; 
Lee et al., 2002b; Hallett et al., 2006; Paoletti et al., 2008). However, it is not known 
whether KAR activity is mediated by dopamine receptors. Recombinant data demonstrate 



























that KARs can be phosphorylated by PKA, yielding an increase in KAR current 
(Raymond et al., 1993; Wang et al., 1993; Kornreich et al., 2007). There is no data to 
demonstrate whether this can happen in the brain.  
 In this experiment, we sought to determine whether D1 dopamine receptors 
modulate KAR function in the brain. As previously described, we isolated KAR fEPSPs 
at the mossy fiber – CA3 synapse by stimulating the hilus of the dentate gyrus and 
recording in CA3 stratum lucidum in the presence of an antagonist cocktail to block 
AMPA, NMDA, GABAA, and GABAB synaptic potentials. After recording a stable 
baseline for a minimum of 20 min., we bath applied a selective D1-like DAR agonist 
(SKF38393, 50 μM) (Figure 4.6). Activation of D1-like DARs did not significantly alter 
the KAR fEPSP (101.9 ± 16.3, n = 4). To verify the presence of a KAR fEPSP, we 
subsequently bath applied the selective KAR antagonist, ACET (1 μM). Furthermore, to 
ensure that we did not inadvertently measure AMPAR fEPSPs, we bath applied an 
AMPAR/KAR antagonist, CNQX (100 μM), which did not produce any further reduction 
of the measured KAR fEPSP. These data demonstrate a lack of D1 DAR modulation of 




The major findings of our study are that M1 mAChRs, but not D1-like dopamine 
receptors, activation depresses KAR fEPSPs. This effect is likely through a postsynaptic 
mechanism, because the AMPAR fEPSP was unaffected by M1 mAChR activation by 




(Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al., 1997; Scarr et al., 
2007). It binds to the Gαq protein to signal PKC phosphorylation. Inhibition of PKC 
phosphorylation prevented the significant depression of KAR fEPSPs by pilocarpine. 
However, a depression in the KAR fEPSP did occur. This suggests that PKC 
phosphorylation has some affect on the magnitude of the depression. Interestingly, this 
depression of KAR fEPSPs by M1 mAChRs is developmentally regulated and goes away 
with age (‘adult’ P65 – P80).  
 
4.4.1 M1 MACHRS DEPRESS KAR, BUT NOT AMPAR, AT MOSSY FIBER – CA3 
SYNAPSES 
This report is the first demonstration that M1 mAChRs can alter KARs activity in 
the brain. We demonstrated that pilocarpine, an M1 preferring agonist, depresses KAR 
fEPSPs at the mossy – fiber CA3 synapse. This depression was completely blocked by an 
M1 antagonist. In other studies, it was reported in a recombinant receptor that muscarinic 
activation by pilocarpine potentiated GluK2 containing heteromeric, but not homomeric, 
KARs, suggesting that potentiation of KARs by mACh receptors also requires the high-
affinity KAR subunits (Benveniste et al., 2010). The difference in M1 mAChRs 
potentiating instead of inhibiting KAR activity, as in what we saw in our studies, could 
result from the experimental model being used. It is possible that the mACh receptors 
could increase channel conductance and receptor trafficking simultaneously. 
Recombinant experimental models are more sensitive to changes in channel conductance 




those experiments would not undergo changes in receptor trafficking that would resemble 
that in the actual brain slice. In the brain, it is possible that the amount of receptor 
trafficking away from the synapse could outperform the increase in channel conductance. 
Indeed, M1 mAChRs have been shown to alter NMDAR and AMPAR synaptic 
transmission primarily through trafficking of the receptors in or out of the synapse 
(Zheng et al., 1998; Dickinson et al., 2009; Nomura et al., 2012).  
Although my research has yielded several interesting results, there are several 
questions that must be addressed. It was interesting to us that activation of M1 mAChRs 
can produced a significant depression of postsynaptic KAR fEPSPs but not AMPAR 
fEPSPs located in the same cell populations and synapses. Even more interesting is that 
both KARs and AMPARs can be phosphorylated by mAChRs and specifically M1 
mAChRs. Thus, it seems interesting how there is a significant effect on KARs but not 
AMPARs. Further looking in the literature reveals that we are not the only laboratory to 
find such interesting divergence in the effect of muscarinic activation on glutamate 
receptors. Grishin et al. demonstrated that M1 mAChR activation depressed NMDAR 
currents on postsynaptic CA3 pyramidal neurons, but did not affect AMPAR currents at 
the same synapse (Grishin et al., 2005). Alternatively, other studies have shown that the 
same signaling cascade can elicit different effects on KARs and AMPARs due to the 
receptor association with the PDZ domain – interacting proteins PICK1 and GRIP 
(Hirbec et al., 2003). Dissociation of PICK1 with KARs caused a loss of KAR synaptic 






4.4.2 M1 MACHR DEPRESSION OF KAR ACTIVITY IS A FORM OF SHORT-TERM 
PLASTICITY 
Another interesting result that deserves some explanation is that M1 mAChR 
depression of KAR fEPSP was a form of short-term plasticity. Short-term plasticity, as 
opposed to long-term plasticity, lasts for less than 1 hour after the initial stimulus. This 
form of plasticity is thought to be important for the dynamic regulation of synaptic 
function (Silva et al., 1996). Other studies have suggested that the determinate factor 
between a short-term versus long-term plasticity phenotype is the association with a 
second messenger system. Previous studies have reported that PICK1 plays an important 
role in the expression of long-term depression, and disruption of glutamate receptor 
interaction with PICK1 turns long-term plasticity into short-term plasticity (Xue et al., 
2010). Thus, one mechanism that might explain the short-term effect is a dissociation of 
KARs with a PICK1 complex (Xue et al., 2010).  
 
4.4.3 M1 MACHR DEPRESSION OF KAR ACTIVITY IS NOT MEDIATED BY PKC 
PHOSPHORYLATION 
Another interesting result was that M1 mAChR depression of KAR fEPSPs at the 
mossy fiber – CA3 synapse was not prevented by application of the PKC inhibitor, 
chelethryine. M1 mAChRs couple to Gq proteins and are primarily thought to regulate 
other proteins, including glutamate receptors, through a PKC-dependent signaling 
cascade. We found this not to be true for M1 mAChR depression of KARs fEPSPs at the 




M1 mAChRs postsynpatically depressed NMDAR, but not AMPAR, current at CA3 
pyramidal neurons (Grishin et al., 2005). This depression was mediated not through PKC 
phosphorylation but was dependent upon protein tyrosine phosphatases. Thus it is 
possible that our M1 mAChR depression of KARs located also on CA3 pyramidal 
neurons is mediated through protein tyrosine phosphatases.  
An alternative explanation for the inability of chelethryine to inhibit the 
pilocarpine-induced depression of KAR fEPSPs at the mossy fiber – CA3 synapse is that 
chelethryine did not block PKC activity. Unlike the other drugs used in this chapter 
whose ligand binding sites are extracellular, chelethryine must maneuver inside the cell 
to inhibit PKC activity. We did not incorporate a positive control into our experiments to 
verify the inhibition of PKC activity by chelethryine. 
 
4.4.4 M1 MACHR DEPRESSION OF KAR ACTIVITY IS DEVELOPMENTALLY 
REGULATED 
We also discovered that M1 mAChR – induced depression of KAR fEPSPs was 
developmentally regulated. In rats around adolescent age (P21 – P28), the KAR fEPSP 
depression was robust; however, in rats around adult age (P65 – P80) we no longer saw a 
M1 mAChR depression of KAR fEPSP. Although we did not directly test the reason for 
this development ‘switch’, there are several possible mechanisms that we can speculate to 
be responsible. One such mechanism is the age-dependent change in mAChR expression. 
Previous studies have demonstrated that although mRNA expression of mAChRs does 




downregulated in the hippocampus (Lee et al., 1994; Narang, 1995; Tice et al., 1996). 
Specifically, M1 mAChRs expression in the CA3 field of the hippocampus is 
significantly reduced in the aged rat brain compared to the young rat brain. A reduction in 
the expression of M1 mAChRs in the adult rat brain would occlude the M1 –dependent 
depression KAR fEPSPs.  
Another possible explanation is the expression level of KARs. KARs are 
necessary for the correct integration of mossy fiber – CA3 synapse (Tashiro et al., 2003; 
Lanore et al., 2012). Early in development KARs expression is high, peaking at P9 (Bahn 
et al., 1994). After P9 the expression of KARs steadily declines. In the transition from 
adolescent to adulthood, the ratio of GluK2 expression to GluK4 and GluK5 become 
higher (Bahn et al., 1994). Thus, it may be possible that the relative concentration of 
ACET-sensitive KAR responses decline with aging. However, the persistence of an 
ACET-sensitive KAR response in the adult mossy fiber – CA3 synapse verifies that the 
KARs necessary for mAChR regulation is present. 
Lastly, another possible difference is the relative expression of proteins associated 
with translocation of KARs to the synapse, such as GRIP and PICK1. GRIP association 
has been shown to increase more than 100% from P7 to P11, while PICK1 remains 
unchanged (Xue et al., 2010). An age - induced increase in GRIP expression relative to 
PICK1 expression was demonstrated to cause a switch from a depressive plasticity to 
facilitation plasticity at the same synapse (Xue et al., 2010). If this trend continues 
through adulthood, we can contend that our M1 mAChR – induced depression of KAR 




These data demonstrate that muscarinic cholinergic receptors can modulate KARs 
in the brain. Acetylcholine is released in the brain, specifically in the hippocampus, 
during different brain states, such as during exercise (Nakajima et al., 2003; Uchida et al., 
2006) and just before a seizure (Hillert et al., 2014). Understanding what happens to the 
glutamate receptors, especially KARs, during these brain states can provide a better 
understanding for how the brain functions to improve cognition while exercising, and it 
will allow us to elucidate critical mechanism involved in the genesis of a seizure, which 
will lead to potential therapies.  
 
4.4.5 KAINATE RECEPTOR ACTIVITY IN THE MOSSY FIBER – CA3 SYNAPSE IS NOT 
MEDIATED BY D1-LIKE DOPAMINE RECEPTORS 
 In contrast to our M1 mAChR data, we found that D1-like dopamine receptors did 
not alter KAR activity in the mossy fiber – CA3 synapse. D1-like dopamine receptors 
couple to Gs proteins to stimulate adenylate cyclase activity and PKA mediated 
phosphorylation pathways. Thus, these data suggest that KAR activity is more sensitive 
to M1 mAChR regulation than D1-like DAR mediated regulation. Indeed, there are few 
PKA phosphorylation sites on the C-terminus domain of KARs (GluK2, S856 and S868) 
(Rojas and Dingledine, 2013). These PKA phosphorylation at residues S856 and S868 
have only been shown to potentiate kainate-evoked currents of recombinant receptor 
(Raymond et al., 1993; Wang et al., 1993). There is no evidence demonstrating that PKA 










Dopamine receptors in the hippocampus are important for modulating learning 
and memory (Packard and White, 1991; Gasbarri et al., 1996; Bernabeu et al., 1997; 
O’Carroll et al., 2006). The hippocampus receives dense dopaminergic innervation from 
the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) (Simon et 
al., 1979; Scatton et al., 1980; Swanson, 1982), where dopamine is synthesized through 
the rate-limiting enzyme, tyrosine hydroxylase (TH). Dopamine released from these 
neurons can bind to two main types of dopamine receptors: D1-like (D1 and D5) and D2-
like (D2L/S, D3, and D4), which are categorized based on pharmacological agonists and 
second messenger coupling. Particularly D1-like receptors have been shown to be 
important in learning and memory consolidation (Frey et al., 1990, 1991; Huang and 
Kandel, 1995; Otmakhova and Lisman, 1996, 1998; Navakkode et al., 2007; Granado et 
al., 2008; Ortiz et al., 2010). Pharmacological blockage of D1-like receptors prevents 
early and late phase long-term potentiation, a cellular model of learning, and blocks long-
term memory storage (Frey et al., 1990, 1991). Additionally, D1 knockouts and adult rats 




significant decline in spatial learning, fear learning, classical conditioning of the eyelid 
response, as well as the associated activity-dependent synaptic plasticity in the 
hippocampal CA1-CA3 synapse (Ortiz et al., 2010). These studies provided compelling 
evidence that a reduction in D1-like receptors in the hippocampus is correlated with 
deficits learning and memory. 
In temporal lobe epilepsy, D1-like receptors are also implicated in seizure 
generation, as previous studies have shown that a D1-like receptor agonist can elicit 
seizures in and of itself (O’Sullivan et al., 2008). Furthermore, a D1-like antagonist can 
prevent seizures (al-Tajir et al., 1990a, 1990b; Barone et al., 1990; Turski et al., 1990; 
DeNinno et al., 1991; Starr, 1996).  To date, it is unknown whether temporal lobe 
epilepsy alters D1 and D5 dopamine receptor protein expression in the hippocampus. The 
chronic epilepsy model we use is clinically relevant as rats experience chronic 
spontaneous seizures with comorbid cognitive decline (Rice et al., 1998). However, it is 
not known whether dopamine receptors in this model have been pathologically altered.  
One potential mechanism by which D1-like dopamine receptors mediate learning 
and memory and temporal lobe epilepsy is by altering ionotropic glutamate receptor 
function. D1-like dopamine receptors can alter both AMPAR and NMDAR function 
through either a phosphorylation-signaling cascade or direct protein-protein 
heterodimerization (Price et al., 1999; Snyder et al., 2000; Lee et al., 2002b; Dunah et al., 
2004; Gao et al., 2006; Hallett et al., 2006). Although we previously did not see an 
interaction between D1-like dopamine receptor activation and KAR receptor – mediated 
synaptic transmission at the mossy fiber – CA3 synapse (Figure 4.6), evidence exists for 




dopamine receptor antagonist can reduce the severity of seizures initiated by kainate 
receptor agonists (Bourne et al., 2001). Before we can investigate whether D1-like 
dopamine receptors regulate KAR function in the epileptic hippocampus, we must first 
determine how D1-like dopamine receptors are altered in the epileptic hippocampus.  
The goal of this study was to compare and contrast the dopaminergic system 
between the normal and chronically epileptic brain. We were particularly interested in 
evaluating differences known to regulate learning and memory. Thus, we evaluated the 
effects of chronic epilepsy on D1 and D5 dopamine protein expression, dopamine 
concentration, dopamine metabolites, and dopamine transporter protein expression in the 
hippocampus.  Our study provides further detail for one mechanism that may explain the 
cognitive decline commonly experienced by TLE patients.  
 
5.2 MATERIALS AND METHODS 
 
5.2.1 ANIMALS 
 Adult male Sprague Dawley rats (40-45 days old; 200-250 gm) were purchased 
from Harlan and were housed two-three per cage. Rats were kept in a temperature-
controlled facility with access to food and water ad libitum. All experimental procedures 
were approved by the University of South Carolina Animal Care and Use Committee in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. Every 





5.2.2 INDUCTION OF STATUS EPILEPTICUS (SE) 
 The pilocarpine model of TLE is widely used in rodents (Cavalheiro, 1990) and 
reproduces the human condition closely (Curia et al., 2008). Specifically, rodents treated 
with pilocarpine exhibit spontaneous generalized and partial seizures, behavioral 
abnormalities, as well as the pathologic and histological signs commonly observed in 
human patients with TLE (Goffin et al., 2007). The mechanism by which pilocarpine 
administration causes spontaneous recurrent seizures and epilepsy is fairly well 
understood (Hamilton et al., 1997) and the stereotypic set of behavior produced by this 
cholinergic agonist is well characterized (Goffin et al., 2007).  
 For detailed methods on the pilocarpine model of induced status epilepticus, 
please see section 2.4.2.  
 
5.2.3. IMMUNOHISTOCHEMISTRY 
 For detailed immunohistochemistry methods, please see section 2.6.  
 
5.2.4. CELL COUNTS 
 Sections containing dorsal hippocampus (approximately 3.14-3.6 mm caudal to 
bregma; Paxinos and Watson, 1998) were selected for manual cell counts of GAD-67-
positive somata. An area was selected encompassing all regions (stratum oriens [SO], 
stratum pyramidale [SP], and striatum radiatum [SR]) of CA1 at 2X magnification, and 




with Neurolucida software (v.9, MicroBrightField, Inc., Williston, VT, USA) at 20X 
magnification. For all counts, no hemispheric differences were noted in either sham or 
epileptic tissue in any neuronal marker, cells or terminals. Therefore, we unilaterally 
counted and averaged across two sections for each animal.  
 
5.2.5. IMMUNOBLOT ANALYSIS 
Please see section 2.5 for detailed immunoblot analysis methods.  
 
5.2.6. SPECIFICITY OF THE ANTISERA 
The D1 dopamine receptor antibody used in this study (#D2944, Sigma, St. Louis, 
MO, USA) is a rat monoclonal (clone 1-1-F11 s.E6) which recognizes the C-terminal 97 
amino acid of D1 dopamine receptor. The immunogen was affinity purified. The 
specificity of this antibody, which does not cross-react with fusion proteins derived from 
the same regions of D2, D3, D4, D5 receptors, has been well documented (Levey et al., 
1993). 
The polyclonal D5 receptor antiserum (#SC-1441, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA) was raised in goat and is a widely used antiserum to D5 
receptors. Previous absorption studies demonstrate that it recognizes D5 dopamine 






5.2.7. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 Please see section 2.7 for a detailed description of the high performance liquid 
chromatography methods.  
 
5.2.8. STATISTICAL ANALYSES 
 Data are presented as mean ± standard error. Student’s t-test for independent 
samples was used to compare the difference between means. Two sample sets were 
considered significantly different when p < 0.05. All statistical data were analyzed and 
graphical representations made in Origin version 7.5 software (OriginLab Corp, 




5.3.1 D1 DOPAMINE RECEPTORS ARE LOCALIZED DISTINCTLY IN INTERNEURONS, 
AND LESS APPARENT IN PYRAMIDAL NEURONS 
To determine how D1-like dopamine receptors are altered in the chronic epileptic 
CA1 region of the hippocampus, we first sought to determine the localization of both D1 
and D5 dopamine receptors in the control ‘naïve’ brain. A previous study identifies D1 
dopamine receptor localization primarily in non-parvalbumin GABAergic interneurons 
(Gangarossa et al., 2012). Indeed, our immunostaining for D1 dopamine receptor clearly 




radiatum) of hippocampal area CA1 (Fig. 5.1, B-D). Less distinct labeling was seen in the 
pyramidal cell body layer and proximal dendrites. No staining was observed in the ‘no 
primary’ control (Fig. 5.1, A). 
 
Figure 5.1 D1 dopamine receptors are located primarily in interneurons and less 
apparently in pyramidal neurons. 
A. Representative normal CA1 demonstrating lack of immunostaining in the absence 
of primary antiserum. 
B. Representative D1 dopamine receptor labeled CA1 illustrating D1 labeling 
prominently in interneurons throughout the stratum oriens (S.O.), striatum 
pyramidale (S.P.), and striatum radiatum (S.R.). Faint labeling was observed 




5.3.2. D5 DOPAMINE RECEPTORS ARE LOCALIZED PREDOMINANTLY IN PYRAMIDAL 
NEURONS 
 
D5 dopamine receptor pattern of labeling was substantially different from D1 
dopamine receptors. Previous studies report D5 labeling in pyramidal cell bodies and 
apical dendrites (Khan et al., 2000). Indeed, our D5 labeling was almost exclusive to 
pyramidal neurons (Fig. 5.2, B-D). Labeling extended from the pyramidal cell soma 
surface down the length of the dendrites into the stratum lacunocum-molecularis (Fig. 
5.2, B-D). This resulting pattern of labeling suggests that D5 DARs may elicit its 
functional effects predominantly through excitatory inputs.  
 
5.3.3. REMAINING INTERNEURONS CONTAIN MORE D1 DOPAMINE RECEPTORS 
 
 To investigate whether D1-like receptor protein expression and/or localization are 
altered in the chronically TLE CA1 region of the hippocampus, we performed western 
blots from microdissected CA1 and immunohistochemistry from sham-treated and 
epileptic animals. Immunoblot analysis revealed that D1 protein expression in the 
epileptic CA1 (113.326 ± 6.832%, n = 8) was not significantly different from sham-
treated animals (Fig. 5.3, D). This result was particularly interesting based on previous 
reports that interneurons are selectively susceptible to neuron loss in epilepsy (Houser 
and Esclapez, 1996; Morin et al., 1998; André et al., 2001; Cossart et al., 2001; Dinocourt 
et al., 2003). Immunostaining with D1 receptor antibody revealed no change in labeling 




labeled interneurons appeared more intensely stained in the epileptic condition than 
sham-treated (Fig. 5.3, A-C). These results suggest that the remaining interneurons are 
more tightly regulated by D1 dopamine receptors.  
 
Figure 5.2 D5 dopamine receptors are located primarily on pyramidal neuron soma 
surface and dendrites. 
A. Representative CA1 from a naïve rat demonstrating lack of immunostaining in the 
absence of D5 primary antiserum. 
B. Representative D5 dopamine receptor labeled CA1 illustrating D5 labeling 
exclusively to pyramidal neuron soma surface and dendrites that extend 
throughout stratum radiatum (S.R.) and terminate in the stratum lacunosum 






Figure 5.3 D1 dopamine receptor expression does not change in epilepsy CA1, but 
the intensity of interneuron labeling increases.  
A. Immunohistochemistry for D1 dopamine receptor labeling in area CA1 of sham-
treated rats.  
B. Immunohistochemistry for D1 dopamine receptor labeling in area CA1 of 
epileptic rats reveal no difference in labeling pattern. 
C. However, closer analysis suggests that D1 dopamine receptor labeling in 
interneurons are more intense in the epileptic CA1 area than sham-treated. 
D. Western blot analysis demonstrated no significant change in total D1 dopamine 





5.3.4 DOPAMINE D5 RECEPTORS ARE REDUCED IN EPILEPSY 
We then sought to determine whether the localization and/or protein expression of 
D5 dopamine receptors were altered in the chronically epileptic CA1 region of the 
hippocampus. Immunoblot analysis of D5 protein expression in microdissected CA1 
revealed a 72% significant reduction in epilepsy (27.701 ± 4.574%, n = 10, p < 0.0001) 
compared to sham-treated animals (Fig. 5.4, E). This result was reproduced by an 
unbiased colleague. Immunostaining also confirmed the immunoblot analysis. D5 
labeling in the epileptic condition was visibly reduced predominately in the pyramidal 
dendrites (Fig. 5.4, A-D). Instead of dense D5 dopamine receptor labeling extending 
down into the stratum lacunocum-molecularis as in the sham condition (Fig. 5.4, A,C), in 
the epileptic conditions D5 labeled staining was less dense and remained proximal to the 
pyramidal cell body layer (Fig. 5.4, B,D). 
 
5.3.5 INTERNEURONS IN STRATUM ORIENS ARE SELECTIVELY LOSS IN EPILEPSY 
To ensure that GABAergic interneurons are selectively lost in our chronic TLE model, 
we completed immunostaining for GAD67 and counted the positively labeled neurons. 
Results were normalized to sham-treated animals. As previously reported, we observed a 
significant reduction in GAD67 positively labeled interneurons, particularly in stratum 
oriens, in epilepsy (27.19 ± 0.809%, n = 5) when compared to sham. No significant 
difference was observed in the epileptic stratum pyramidale (82.895 ± 6.644%, n = 5) or 
stratum radiatum (82.915 ± 8.814%, n = 5) when compared to sham-treated animals (Fig. 




(Houser and Esclapez, 1996; Morin et al., 1998; André et al., 2001; Cossart et al., 2001; 
Dinocourt et al., 2003). Thus, knowing that D1 expression in located primarily in 
interneurons and interneurons are selective loss in epilepsy, demonstrating that total D1 
expression does not change suggests that D1 expression in remaining interneurons may 
have increased. 
 
Figure 5.4 D5 dopamine receptor expression is reduced in the epileptic CA1 
A. Immunohistochemistry for D5 dopamine receptor labeling in area CA1 of sham-
treated rats 
B. Immunohistochemistry for D5 dopamine receptor labeling in area CA1 of 
epileptic rats revealed a substantial decrease in immunostaining in the pyramidal 
neuron soma and dendrites.  
C. Higher magnification of D5 dopamine receptors labeled dendrites in striatum 




D. Higher magnification of D5 dopamine receptors labeled dendrites in striatum 
radiatum in epileptic rats. 
E. Western blot analysis confirmed immunohistochemistry results, revealing a 
significantly reduction in D5 expression in microdissected CA1 area. 
 
 
Figure 5.5 Epilepsy reduces the number of GABAergic interneurons in CA1. 
A. Immunohistochemistry for glutamate decarboxylase (GAD)-67 labeling in area 
CA1 of sham-treated rats. 
B. Immunohistochemistry for glutamate decarboxylase (GAD)-67 labeling in area 
CA1 of epileptic rats revealed seizure-related decreases in inhibitory neurons in 
stratum oriens (S.O.). 
C. Higher magnification of GABAergic labeling CA1 interneurons in sham treated 
rats. 
D. Higher magnification of GABAergic labeling CA1 interneurons in epileptic rats. 
E. Epilepsy was associated with a significant decrease in the number of GAD-67 




5.3.6 LOCALIZATION OF D1 DOPAMINE RECEPTORS IS UNCHANGED IN THE EPILEPTIC 
DENTATE GYRUS 
 
D1 dopamine receptors are expressed more abundantly in the dentate gyrus than 
any other region in the hippocampus (Gangarossa et al., 2012), where they impact neuron 
excitability and learning and memory. Indeed, D1-like dopamine receptors activate 
during a “novel” or “rewarding” signal in freely moving animals, and consequentially 
increases DG excitability (Hamilton et al., 2010). Furthermore, inhibition of D1-like 
dopamine receptors inhibits LTP in the DG (Yanagihashi and Ishikawa, 1992; Kusuki et 
al., 1997; Swanson-Park et al., 1999). Thus, we investigated whether D1 dopamine 
receptor expression is altered in the epileptic dentate gyrus. In agreement with previous 
studies, D1 dopamine receptors demonstrated diffused labeling throughout the molecular 
layer (MOL) and hilus (H) of the dentate gyrus (Figure 5.6A). We also observed abundant 
D1 dopamine receptor labeling in the stratum lucidum. Notably, D1 dopamine receptor 
labeling was absent from granule cell layer (GCL). This pattern of labeling suggests that 
D1 dopamine receptors are expressed on dentate granule cell dendrites and axons (mossy 
fibers), but absent from dentate granule cell soma.  
D1 dopamine receptor expression in the epileptic dentate gyrus demonstrated no 
observable difference in D1 dopamine receptor labeling pattern or strength in labeling 
signaling (Figure 5.6B). Thus, these results illustrate that D1 dopamine receptor 







Figure 5.6 D1 dopamine receptor expression in the dentate gyrus does not change in 
epilepsy. 
A. Immunohistochemistry for D1 dopamine receptor labeling in the dentate gyrus of 
sham-treated rats. D1 dopamine receptors are localized throughout the molecular 
layer (MOL) and hilus (H) of the dentate gyrus but absent from the granule cell 
layer (GCL).  
B. Immunohistochemistry for D1 dopamine receptor labeling in the dentate gyrus of 
epileptic rats revealed a similar labeling pattern to sham-treated controls.  
 
5.3.7 LOCALIZATION OF D1 DOPAMINE RECEPTORS IS UNCHANGED IN THE EPILEPTIC 
CA3 REGION 
 
In the CA3 region, previous studies have demonstrated spare localization of D1 
dopamine receptors on GABAergic interneurons (Gangarossa et al., 2012). In this study, 
we also found that D1 dopamine receptors are scattered on interneurons (Figure 5.7A, B). 
However, in addition to D1 labeled interneurons, we also saw prominent labeling in the 










Mossy fiber sprouting and hyperexcitability is a hallmark symptom of chronic 
epilepsy (Tauck and Nadler, 1985; Sutula et al., 1988, 1989; Houser et al., 1990; Babb et 
al., 1991; Cronin et al., 1992). Thus, we investigated whether D1 dopamine receptor 
expression is altered in the epileptic CA3 region compared to sham-treated controls 
(Figure 5.7C, D). Our immunostaining demonstrated no observable differences in D1 
dopamine receptor labeling in the epileptic CA3 region (Figure 5.7C) when compared to 



























Figure 5.7 D1 dopamine receptor expression does not change in the epileptic CA3 
region.  
A. Representative normal hippocampus illustrating the CA1, CA3, and dentate gyrus 
(DG) regions. The black box indicates the CA3 region.  
B. Magnification of the CA3 region from a naïve rat. D1 dopamine receptor 
immunobloting prominently labeled mossy fiber axons in the stratum lucidum 
(S.L.). D1 dopamine receptors were also expressed on spare interneurons 
throughout the stratum oriens (S.O.), stratum radiatum (S.R.), stratum pyramidale 
(S.P.), and stratum lucidum (S.L.). 
C. Immunohistochemistry for D1 dopamine receptor labeling in the CA3 region of 
sham-treated rats. 
D. Immunohistochemistry for D1 dopamine receptor labeling in the CA3 region of 
chronically epileptic rats demonstrates similar labeling pattern and intensity to the 
sham-treated rats.  
 
5.3.8 TOTAL DOPAMINE AND DOPAMINE METABOLITE LEVELS REMAIN UNCHANGED 
IN TLE HIPPOCAMPUS 
We next sought to better understand how changes in the D1-like receptor 
expression and localization might alter overall dopaminergic function. Our leading 
hypothesis was overall D1-like receptor expression in the TLE hippocampal was 
suppressed due to homeostatic compensation for upregulated dopamine. Thus, we used 
HPLC to measure dopamine, dopamine metabolites, and norepinephrine concentration in 
whole TLE hippocampus and sham-treated controls. Several experimental controls were 
applied to ensure we identified the correct peak as dopamine. In addition to running 
standard controls at various concentrations, sample from a sham-treated hippocampus 
was also spiked with DA standard. The solemn differentiating peak was considered 
dopamine (Fig. 5.6, C).  
Total dopamine (DA), dopamine metabolites (DOPAC), and norepinephrine (NE) 





Figure 5.8 Total dopamine and dopamine metabolite levels remain unchanged in the 
TLE hippocampus. 
A. High performance liquid chromatography (HPLC) chromatorgrams for sham-
treated (black line) superimposed with epileptic (gray line) illustrated no change 
in total hippocampus concentration of dopamine (DA), dopamine metabolite (3,4-
dihydroxyphenylacetic acid (DOPAC)), or norepinephrine (NE, downstream 
synthesized catecholamine).  
B. Chromatographs of a combination standard (100 nM of NE, DOPAC, and DA; 
black dash line), sham-treated sample (black solid line), and sham-treated sample 
“spiked” with 100 nM combination standard (gray line) superimposed to 
demonstrate correct identification of each monoamine.  
C. Quantification of DA, DOPAC, dopamine utilization (DOPAC/DA, a measure of 
released dopamine), and NE revealed no significant differences in monoamine 




were reported as a percentage of Sham-treated controls. Total levels of DA in epileptic 
animals were 86.376 ± 8.114% of that in sham-treated animals (n = 4 sham-treated, n = 7 
epileptic) (Fig. 5.6, A-B,D). Total DOPAC levels in epileptic animals were 105.466 ± 
23.817% of that in sham-treated animals. Total NE levels in epileptic animals were 
100.609 ± 3.115% of that in sham-treated animals. Dopamine utilization was calculated 
by dividing total DOPAC by DA concentration as a measure of released dopamine. No 
difference was observed in the epileptic hippocampus (125.133 ± 27.885%) from sham-
treated animals. Thus, the amount of dopamine produced is not different between the 
sham and epileptic hippocampus. These results suggest that changes in dopamine 
receptor expression are more significant. 
 
5.3.9. REDUCED DOPAMINE CLEARANCE IN THE EPILEPTIC HIPPOCAMPAL CA1 
REGION 
After observing that dopamine concentration did not change in epilepsy, we then 
evaluated whether dopamine clearance is altered in the chronically epileptic 
hippocampus. Western blots for COMT in microdissected CA1 from epileptic and sham-
treated animals displayed two bands (35kD and 25kD) (Fig. 7, B). Immunoblot analysis 
revealed no significant difference at either protein size (35kD, 109.921 ± 10.073%; 25kD, 
98.658 ± 12.286%; n = 11) when compared to sham-treated animals (Fig. 7, B).  
Immunoblots for DAT also displayed a band at two protein sizes (80kD and 
55kD) (Fig. 7, A). Epilepsy demonstrated a significant reduction in DAT protein 




55kD protein size (84.534 ± 8.287%, n = 11), when compared to sham-treated animals 
(Fig. 7, A). Thus, we observed reduced dopamine clearance in the epileptic hippocampal 
CA1 region.  
 
 
Figure 5.9 Reduced dopamine clearance in the epileptic hippocampal CA1 region. 
A. Antigen for DAT recognized bands at 80 kilodaltons (kD) and 55 kD. Western 
blot analysis revealed a significant reduction in dopamine transporter (DAT) 
protein expression in the epileptic CA1 area only at 80 kD when compared to 
sham-treated rats. 
B. Antigen for COMT recognized bands at 35 kD and 25 kD. Western blot analysis 
revealed no difference in catechol-O-methyl transferase (COMT) protein 
expression in the epileptic CA1 area when compared to sham-treated rats. 





5.3.10 NO CHANGE IN DOPAMINERGIC FIBER EXPRESSION IN THE EPILEPTIC 
HIPPOCAMPAL CA1 REGION 
To determine whether dopaminergic fibers expression and/or localization were 
altered in the epileptic condition, we performed immunoblots with microdissected 
hippocampal CA1 and immunohistochemistry with epileptic and sham-treated animals. 
Immunoblot analysis revealed no significant change in epileptic tyrosine hydroxide (TH) 
expression (97.047 ± 15.919%, n = 8) from sham-treated animals (Fig. 8, C). This result 
was confirmed by immunostaining. TH labeled catecholamine fibers that dispersed 
randomly throughout all CA1 layers (Fig. 7, A-B). Thus, no change was observed in the 




Figure 5.10 No change in dopaminergic fiber expression in the epileptic 
hippocampal CA1 region. 
A. Immunohistochemistry for tyrosine hydroxylase (TH) labeling in area CA1 of 
sham-treated rats. 
B. Immunohistochemistry for tyrosine hydroxylase (TH) labeling in area CA1 of 
epileptic rats revealed no difference in dopaminergic fiber innervation. 
C. Western blots confirmed immunostaining results, demonstrating no difference in 
TH protein expression when comparing epileptic to sham-treated CA1. TH 





The principal finding of this study is that the dopaminergic system is altered in a 
chronic model of temporal lobe epilepsy. In our study we have identified differential 
patterns of labeling between D1 and D5 receptors. D1 DARs were located primarily on 
interneurons, diffused throughout the molecular layer of the dentate gyrus, and on mossy 
fiber axons, while D5 receptors were located predominately in pyramidal neurons 
dendrites. D5 DAR protein expression was significantly reduced in proximal dendrites of 
the epileptic hippocampal CA1 area. No change in protein expression was seen in D1 
DARs; however we did observe a possible increase in interneuron D1 DAR expression in 
the epileptic CA1. These results were accompanied by a reduction in dopamine clearance, 
but no change in overall dopamine content.  
We identify that D5 dopamine receptors are significantly reduced in the epileptic 
hippocampus. This deficit in D1-like receptor may result in the cognitive decline 
associated with epilepsy. To date the role of D5 dopamine receptors are not well 




receptors in learning and memory. D5 dopamine receptors are particularly important in 
regulating plasticity of the medial perforant path onto dentate granule cells (Yang and 
Dani, 2014) Furthermore, a rat model of ADHD that demonstrates impaired learning also 
has significantly lower D5 dopamine receptor expression than healthy controls (Medin et 
al., 2013).  
Previous studies have identified D1 DARs primarily on interneurons (Mansour et 
al., 1990, 1991; Fremeau et al., 1991; O’Sullivan et al., 2008; Gangarossa et al., 2012). 
However, other studies suggest that D1 DARs are predominately in pyramidal neurons 
(Bergson et al., 1995). We identify D1 DARs to be predominately located on 
interneurons, with diffuse labeling throughout the stratum pyramidal cell body layer and 
dendrites. In our hands, we identified no change in D1 DAR expression. This was of 
particular interest to us because we identified D1 DARs to be primarily located on 
interneurons. It has been widely demonstrated in previous literature and also replicated in 
this study that interneurons, particularly in the stratum oriens, are susceptible to cell death 
in epilepsy (Dinocourt et al., 2003). Thus, no change in D1 DAR expression may indicate 
that the remaining interneurons have upregulated D1 DAR expression.  
There is not a consensus on how the dopaminergic system is altered in epilepsy. 
Some studies indicated that dopamine concentration increases (Cavalheiro et al., 1994), 
while others indicate no change dopamine content but an increase in dopamine 
metabolites (Freitas et al., 2004). We identified no significant change in dopamine 
concentration. We went to great lengths to identify the correct peak for each monoamine 
measured. Not only were various concentration of each monoamine standard used to 




but a hippocampus sample was “spiked” with a combination of each monoamine 
standard. The spiked sample, original hippocampus sample, and the monoamine standard 
were all superimposed onto each other, and the peaks in common were identified as the 
respective monoamine.  
We demonstrated a significant reduction of dopamine clearance in the epileptic 
hippocampal CA1 region. This reduction in dopamine clearance suggests that even 
though dopamine concentration is unchanged in the epileptic hippocampus, the dopamine 
may be allowed to diffuse further away for the synapse. This would allow dopamine to 
bind to receptors it would not normally interact with, in effect, increasing its sphere of 
influence. Immunoblots for both COMT and DAT produced two bands. COMT 
immunoblots produced bands at 35kD and 25kD. The 35kD band represents the 
phosphorylated form of COMT, which is transported to the cell surface where it can be 
more active. The 25kD COMT band represents the non-phosphorylated from of COMT, 
which is left in the cytoplasm and is considered the less active form. DAT immunoblots 
demonstrated bands at 80kD and 55kD. The 80kD band represents the glycosylated, 
mature form of DAT, which is packaged and transported to the cell membrane. The 55kD 
band is thought to be the non-glycosylated, immature form of DAT, which is left in the 
endoplasmic reticulum.  
Based on our findings, we suggest that dopamine D1-like receptor expression is 
differentially regulated in the epileptic hippocampus. A decrease in D5 dopamine 
receptors located in CA1 hippocampus pyramidal neurons and reduction in dopamine 






GENERAL DISCUSSION AND SIGNIFICANCE
 
6.1 FINDINGS OF THE STUDY 
 
1. ACET selectively inhibits the GluK4 and GluK5 subunits in GluK2/K4 and GluK2/K5 
heteromeric receptor. Kynurenate selectively inhibits the GluK2 subunits. We used both 
drugs to determine that glutamate binding to either the “high-affinity” subunits (GluK4 or 
GluK5) or the GluK2 subunit is sufficient to activate the heteromeric receptor. However, 
desensitization occurred only when three or more subunits are bound to glutamate. 
Furthermore, we demonstrated that perfusing ACET onto brain slices inhibits kainate 
receptor synaptic transmission at the mossy fiber – CA3 synapse. See Figure 6.1 for an 
illustration of these conclusions. 
 
2. Activation of M1 mAChRs, but not D1 dopamine receptors, depressed KAR synaptic 
transmission at the mossy fiber – CA3 synapse. This effect is mediated through co-
localized M1 and KARs on the postsynaptic CA3 neuron. However, PKC 
phosphorylation does not explain this depression. Furthermore, M1 mAChR depression 
of KAR synaptic transmission goes away in adulthood. See Figure 6.2 for an illustration 




3. Dopamine D5 receptor is significantly reduced in the epileptic CA3 region of the 
hippocampus, while D1 dopamine receptor expression in remaining interneurons is 
upregulated. Additionally, dopamine transporter and COMT were significantly reduced 
although tyrosine hydroxylase and dopamine content were unchanged. Thus, total 
dopamine in the epileptic hippocampus is unchanged but dopamine clearance is reduced. 
This suggests that more dopamine is floating in the extrasynaptic space. See figure 6.3 for 
an illustration of these conclusions. 
 
6.2 MUSCARINIC MODULATION OF KAINATE RECEPTORS: IMPLICATIONS FOR 
EXERCISE AND EPILEPSY 
 
Exercise alters the cholinergic system in healthy and diseased brains. Particularly, 
in the hippocampus, exercise has been shown to double acetylcholine release during 
moderate intensity exercise (Nakajima et al., 2003; Uchida et al., 2006), while inhibiting 
acetylcholine degradation by inhibiting acetylcholinesterase (Tsakiris et al., 2006). Thus, 
more acetylcholine is released and remains in the extrasynaptic space in the exercising 
brain. This increase in acetylcholine content would increase binding and activation of 
acetylcholine receptors, including abundantly expressed M1 muscarinic acetylcholine 
receptors (Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al., 1997; Scarr et 
al., 2007). In the CA3 region, we proved that M1 mAChR activation depressed KAR-
mediated synaptic transmission, where they are co-localized on CA3 pyramidal neurons 
(Chapter 4). Thus, an exercise-induced increase in acetylcholine in the hippocampus 








Figure 6.1 Illustration of the receptor occupancy model for KAR activation and desensitization. When no glutamate is 
present, the kainate receptor is closed and no current is produced. If either GluK2 or the GLuK5 subunits in the GluK2/K5 
heteromeric tetramer are bound to glutamate, the receptor opens to a non-desensitzing current. However, when three or more 









Figure 6.2 Illustration of M1 mAChR depression of kainite receptor EPSPs. During normal synaptic 
transmission, depolarization of mossy fibers causes release of glutamate from mossy fiber terminals. This released 
glutamate binds to GluK2/K4 and/or GluK2/K5 receptors located postsynaptically on CA3 pyramidal neurons and 
produces a KAR EPSP. Bath application of pilocarpine activates M1 mAChRs located on CA3 pyramidal neurons, 
which elicits a signaling cascade that either phosphorylates or dephosphorylates GluK2/K4 and GluK2/K5 






Figure 6.3 Illustration of dopaminergic system alteration in the epileptic CA1 
compared to the normal brain. We discovered that D5 dopamine receptors and 
dopamine clearance is reduced in the epileptic hippocampus, while dopamine 
concentration and the amount of dopaminergic fiber is unchanged. Thus, we reasoned 
that released dopamine remains in the extrasynaptic space longer in the epileptic brain 






increased M1 mAChR activation would subsequently depress KAR synaptic 
transmission.  
Overactivation of KARs have been implicated in epilepsy (Ben-Ari and Cossart, 
2000; Vincent and Mulle, 2009; Contractor et al., 2011; Lerma and Marques, 2013). 
First, due to their slow deactivation kinetics, KARs facilitate temporal summation of 
postsynaptic excitatory potentials and epileptiform bursting (Castillo et al., 1997; Vignes 
and Collingridge, 1997; Frerking et al., 1998; Kidd and Isaac, 2008). Secondly, 
postsynaptic KARs elicits a metabotropic function that reduces the slow 
afterhyperpolarization, causing an increase in spike firing and neuronal excitability 
(Melyan et al., 2002, 2004). Furthermore, a hallmark symptom of chronic epilepsy in 
both human and animal models is mossy fiber sprouting, where mossy fibers in the CA3 
make aberrant synaptic connections onto dentate granule cell neurons (Buckmaster et al., 
2002). This sprouting creates an excitatory feed forward circuit that is susceptible to 
epileptiform bursting. KARs also located on these sprouted mossy fibers and can respond 
to glutamate (Epsztein et al., 2005). Lastly, KARs are also located presynaptically on 
principal and interneurons where they facilitate glutamate release and inhibit GABA 
release (Contractor et al., 2011; Carta et al., 2014). Overactivation of presynaptic KARs 
would tilt the excitatory/inhibitory brain balance to being more excitatory. Thus, an 
exercised-induced suppression of KARs activity on CA3 pyramidal neurons would be 
beneficial for patients with epilepsy. Indeed, humans and animals with a chronic model 
of temporal lobe epilepsy have demonstrated reduced seizure frequency and susceptibility 
to developing seizures when engaged in exercise training (Westerberg et al., 1984; Arida 





et al., 2013). Acutely, seizures susceptibility is higher during rest than during or 
immediately after bouts of physical activity, which has been shown to silence 
epileptiform discharges (Camilo et al., 2009; Vancini et al., 2010; de Lima et al., 2011). 
 
6.3 ALTERATIONS IN THE DOPAMINERGIC SYSTEM IN TEMPORAL LOBE 
EPILEPSY: IMPLICATIONS FOR EXERCISE 
 
Forty years ago, epilepsy was thought to be a disease of dopaminergic 
hypoactivity versus schizophrenia (Lamprecht, 1977; Starr, 1996), which is thought to be 
a disease of dopaminergic hyperactivity. This theory was conceived as a result of studies 
demonstrating that application of a general dopamine receptor agonist reduces seizure 
susceptibility (Lamprecht, 1977; Lal, 1988), whereas blockage of dopamine receptors 
induced seizures (Laird et al., 1984; Jann et al., 1993). We now known that there are two 
subtypes of dopamine receptors: D1-like and D2-like. These dopamine receptors have 
opposite effects on seizure susceptibility. D1-like dopamine receptor activation 
precipitates seizures (Starr et al., 1987; al-Tajir et al., 1990a, 1990b), while D2-like 
dopamine receptors reduce seizure susceptibility (al-Tajir et al., 1990a; Al-Tajir and 
Starr, 1991).  
In the chronically epileptic brain, we found that D5 dopamine receptor expression 
is reduced in CA1, while total D1 dopamine receptor expression is unchanged but likely 
upregulated in remaining interneurons in CA1. Additionally, we discovered that total 
dopamine concentration remains unchanged, while dopamine clearance is reduced in the 





remaining in the extrasynaptic space. An increase in extrasynaptic dopamine would allow 
more dopamine binding to both D1-like and D2-like dopamine receptors. In theory, these 
anatomical changes of increased extrasynaptic dopamine and reduced D1-like dopamine 
receptor expression are beneficial for the epileptic condition.  
Interestingly, these changes mimic exercise’s effects on the dopaminergic system. 
Briefly, exercise also increased dopamine concentration in the brain while reducing D1 
DA receptor density (de Castro and Duncan, 1985; MacRae et al., 1987; Greenwood et 
al., 2011). Exercise also decreases dopamine turnover (a ratio of dopamine metabolites to 
dopamine concentration) in Parkinson patients (Aguiar et al., 2015), suggesting that a 
higher percentage of released dopamine remains in the extrasynaptic space. Also, 
exercise has been shown to increase the sensitivity of dopamine receptors to dopamine 
(Zigmond et al., 2012). As stated in the previous section, exercise is beneficial for people 
with epilepsy and can be used as an alternative therapy in conjunction with 
pharmaceutical therapies to help patients manage their seizures. 
 
6.4 FUTURE DIRECTIONS 
 
1.  We used ACET and kynurenate to discover that binding to either the GluK2 or 
GluK5 subunit is sufficient to activate the receptors, and that binding or both are required 
for desensitization. However, we did not investigate the subunit contribution to 
deactivation, which is fundamentally different mechanism than desensitization. Also, 





use the pharmaceutical tools, ACET and kynurenate, to delineate the function roles of 
GluK2 and GluK5 to deactivation.  
 
2. We found that M1 mAChRs depresses postsynaptic KAR-mediated synaptic 
transmission at the mossy fiber – CA3 synapse. Epilepsy has been shown to modulate 
both the cholingeric system and kainate receptor expression. Thus, it would be important 
to determine whether a chronic model of epilepsy alters this M1 mAChR-mediated 
depression of KARs. 
 
3. The dopaminergic system is altered in a chronic model of temporal lobe epilepsy. 
Exercise is a potent therapy demonstrated to both reduce seizure frequency and alter the 
dopaminergic system. Thus, it would be important to evaluate the anatomical and 
functional differences between the dopaminergic system in a chronically epileptic rat and 
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